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ABSTRACT 
 
The  human  mitochondrial  pyruvate  dehydrogenase  complex  (PDC)  is  a  vital 
metabolic  assembly  that  controls  the  key  committed  step  in  aerobic  carbohydrate 
utilisation  and  energy  production  and  as  such  is  responsible  for  overall  glucose 
homeostasis in man. PDC, particularly  from prokaryotic sources, has  been widely 
studied  as  a  model  system  for  investigating  the  molecular  basis  of  cooperativity 
between physically and functionally linked enzymes in a metabolic pathway and the 
catalytic  and  regulatory  advantages  conferred  by  their  organisation  into  precisely-
engineered ‘molecular-machines’. Defects in human PDC have been implicated in a 
wide variety of genetic, metabolic and autoimmune disorders. Over 200 PDC-linked 
mutations  have  been  reported  to  date  in  the  human  population  leading  to  clinical 
symptoms of various magnitudes and manifestations, mostly in the X-linked gene for 
the α subunit of the E1 component. 
PDC is a vast molecular machine (Mr, 9-10 MDa) composed of multiple copies of 3 
distinct enzymes: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase 
(E2),  dihydrolipoamide  dehydrogenase  (E3)  and  an  additional  structural  protein 
known  as  E3-binding  protein  (E3BP).  Central  to  its  structural,  morphological  and 
mechanistic framework is its large oligomeric ‘core’ comprising 60 E2 and 12 E3BP 
polypeptide chains, arranged as pentagonal dodecahedron, to which up to 30 α2β2 E1 
enzymes and 6-12 homodimeric E3 enzymes are tethered tightly, but non-covalently, 
at  maximal  occupancy.  More  recently  a  substitutional  model  of  PDC  has  been 
proposed  where  the  core  is  formed  by  48  E2  and  12  E3BP  with  the  12  E3BP 
polypeptides  replacing  an  equivalent  number  of  E2s.  The  N-termini  of  the  E2 
enzyme(s) each contain two peripherally-extended lipoyl domains that exhibit great 
mobility and in effect, act as ‘swinging arms’ since their attached lipoic acid cofactors 
must visit the active sites of all the three enzymes in strict rotation during the catalytic 
cycle.  Similarly, E3BP is a distinct E2-related polypeptide that is primarily involved 
in E3 integration but also displays overlapping functions with E2 as it contains a 
single, highly-flexible lipoyl domain that can participate in catalysis. 
In this study, a model recombinant human PDC has been reconstituted from its E1, 
E2:E3BP and E3 components that  were all overexpressed in and purified from E. coli   v 
in high yield prior to assembling spontaneously into fully-active complex in vitro. The 
wild-type  recombinant  PDC  displayed  similar  enzymatic  activity  to  the  native 
complex purified from human heart. As a prelude to examining 3 novel naturally- 
occurring, E2-linked mutations, the recombinant PDC model was validated initially 
by  examining the effects of  alterations in its lipoylation status on its activity and 
overall properties and secondly by assessing the characteristics of recombinant PDC 
lacking  the  E3BP  subunit.    A  possible  enzymatic  role  for  E3BP  in  promoting 
formation of an S
6, S
8-diacetylated dihydrolipoamide intermediate on E2 and E3BP 
was also investigated.  
In the first analysis a series of mutant E2:E3BP cores were created containing all 
possible  combinations  of  active  and  inactive  lipoyl  domains.  These  possible 
combinations were ++/+, -+/+, +-/+, --/+, ++/ -, -+/-, +-/- and --/-, where ‘+’ is a 
lipoylated and ‘-’ is a non lipoylated outer, inner or E3BP domain in the E2:E3BP 
cores.  Eight  recombinant  PDC  models  were  successfully  reconstituted  from  these 
cores and analysed for their effects on PDC activity compared to wild-type complex.  
The data indicate that mutation of the outer or inner lipoyl domain of E2 by replacing 
the lipoylatable lysine by glutamine leads to a 25-35% decrease in activity; moreover 
the  presence  of  an  active  or  inactive  lipoyl  domain  on  E3BP  had  no  detectable 
influence  on  PDC  function.  However,  PDC,  in  which  only  active  E3BP  lipoyl 
domains  were  present,  retained  15%  of  wild-type  activity.  These  data  confirm 
previous reports on the functional redundancy of lipoyl domains observed in bacterial, 
yeast and mammalian PDCs and suggest that the E2 lipoyl domains and the lipoyl 
domain of E3BP can act independently as effective substrates for E1, E2 and E3. 
A  parallel  study  on  recombinant  PDC  lacking  E3BP,  was  also  consistent  with 
previous studies in showing that it retained partial activity in the complete absence of 
this subunit. E3BP-deficient patients retain relatively high levels of PDC activity (15-
20%) as compared to the 3-8% observed using stoichiometric amounts of E3 in our in 
vitro assay. However, our data also suggested that 40-50% PDC activity could be 
achieved in the presence of a 100-200 fold excess of E3 that may account for slightly 
higher activity in the patients. Interestingly, wild-type PDC activity declined by 10-
30% in the presence of a large E3 excess in agreement with the idea that the E1 
binding site on E2 retains a residual affinity for E3 and is able to partially displace the 
rate-limiting E1 enzyme when present in high amounts.     vi 
The main objective of the thesis was to apply our recombinant PDC model to conduct 
a detailed investigation of the molecular defects underlying three novel E2 mutations/ 
deletions identified at the genetic level by Dr. Garry Brown, University of Oxford in 
PDC-deficient  patients  under  his  care.  These  were  two  separate  ‘in  frame’  3-bp 
deletions  encoding  glutamate-35  and  valine-455  in  the  mature  E2  protein  and  a 
phenylalanine-490 to leucine (F490L) substitution located near the active site of the 
enzyme. Full length copies of these mutant enzymes were generated by site-directed 
mutagenesis as well an outer lipoyl domain-GST construct housing the D35E deletion. 
In  the  case  of  D35E  mutant,  our  data  from  lipoylation  assays,  circular  dichroism, 
tryptophan  fluorescence,  non-denaturing  gel  electrophoresis,  size  exclusion 
chromatography and cross-linking analyses indicate that the mutant lipoyl domain is 
misfolded  and  displays  a  pronounced  tendency  to  form  dimers  or  higher  order 
aggregates,  presumably  via  inappropriate  exposure  of  hydrophobic  surfaces.  As  a 
result, the bulk of the E2:E3BP core does not assemble properly as evidenced by its 
unusual subunit composition and the presence of several abnormal species including 
non-specific  aggregates  detected  by  analytical  ultracentrifugation.  Mutant  E2, 
E2:E3BP core and reconstituted PDC showed low activity (10-20%) as compared to 
wild-type controls, indicating a small proportion of active core can still form under 
these conditions. In this study, replacement of glu-35 by aspartate or glutamine had 
only  minor/negligible  effects  on  E2:E3BP  core  assembly  and  reconstituted  PDC 
activity indicating that the size or charge of amino acid at this position is not critical 
for normal folding and assembly.  
In  the  valine-455  deletion  study,  the  patient  was  reported  to  contain  no 
immunologically-detectable E3BP, despite the apparent absence of any mutation in 
the  PDX1  gene.  Therefore,  in  this  study,  it  was  hypothesised  that  this  E2-based 
mutation might be responsible for preventing integration of E3BP into the E2 core 
assembly, thereby promoting its rapid degradation. Although, this deletion resulted in 
reduced E2 and PDC activity (50%), it was not found to prevent E3BP integration 
when the mutant core was produced at either 30 °C or 37 °C. As this patient has no 
detectable levels of E3BP protein despite the presence of mRNA for this component 
as detected by RT-PCR studies in Oxford, the precise molecular basis for this defect 
remains unclear at present. The patient is currently undergoing a complete medical 
and clinical re-evaluation.    vii 
Recombinant  mutant  PDC  containing  the  F490L  mutation  also  loses  about  50% 
enzymatic activity as compared to the normal or wild-type PDC confirming the role 
of this mutation in PDC deficiency in this patient. This phenylalanine located near to 
the catalytic site of E2 has been found to be responsible for substrate specificity and 
its substitution could be directly responsible for decreased enzymatic activity in this 
case.  No major structural changes were observed in this mutant core.  
In summary, our recombinant PDC model has proved to be of considerable benefit in 
enabling  us  to  gain  a  more  informed  insight  into  the  molecular  mechanisms  of 
pathogenesis underlying these rare E2-linked mutations, particularly in the case of the 
DE35-E2  mutant.  In  the  absence  of  the  recombinant  model,  such  detailed 
investigations would have proved impossible owing to the lack of access to human 
tissue from individual patients. 
As a corollary to the main aim of the thesis, a preliminary attempt was made to create 
an equivalent recombinant OGDC model. OGDC is also a mitochondrial assembly 
that is involved in the TCA cycle and is increasingly implicated in the aetiology of 
various neurodegenerative diseases linked to oxidative stress including Alzheimer’s 
and Parkinson’s disease.   
The basic organisation of the OGDC is directed by the self-assembly of 24 copies of 
dihydrolipoyl succinyltransferase (E2o) to form a cubic core, to which multiple copies 
of  2-oxoglutarate  dehydrogenase  (E1o)  and  dihydrolipoamide  dehydrogenase  (E3) 
bind non-covalently. The mammalian E2o is unusual in lacking any obvious E3 or 
E1o binding domain. In this study, E2o and E3 were successfully overexpressed and 
purified.  Initially it was confirmed that E2o and E3 do not interact with each other on 
gel filtration although stable association of all 3 constituent enzymes occurs in the 
native complex.  Full-length E1o  was  also cloned successfully  although it proved 
impossible to achieve detectable expression in our E. coli BL21 host system.  
Previous studies employing subunit-specific proteolysis have identified the extreme 
N-terminal segment of E1o as a key region involved in the maintenance of complex 
stability and integrity and is required for E2 and E3 binding. To investigate this region 
in  more  detail,  three  N-terminal  E1o  fragments  of  decreasing  size  were   viii 
overexpressed, one in His-tag form (193 amino acids) and two as E1o-GST fusion 
proteins (166 and 83 amino acids). In co-expression, purification and gel filtration 
studies, it was found that all these N-terminal truncates of E1o appeared capable of 
interacting with E2o although problems were encountered with rapid degradation and 
unambiguous  identification  in  some  cases.  However,  Western  blotting  revealed 
conclusively that even the shortest N-terminal E1o fragment (83 amino acids) was 
able  to  enter  into  a  stable  association  with  E2o.  Owing  to  time  constraints  and 
difficulties with rapid degradation and/or solubility of the E1o truncates, it remains to 
be determined whether this N-terminal region of E1o can also interact with E2o in a 
post-translational fashion and whether it is directly involved in mediating E3 binding. 
However, this type of approach should continue to provide additional insights in the 
unique subunit organisation of OGDC and is an important step towards creating a 
recombinant  model  of  OGDC.  This  will  be  invaluable  for  future  studies  on  an 
important  metabolic  assembly  that  has  been  increasingly  implicated  in  disorders 
linked to oxidative stress and neurodegeneration.  
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Introduction to pyruvate dehydrogenase 
and 2-oxoglutarate dehydrogenase 
complexes  
 
1.1 Multienzyme complexes  
 
Multienzyme  complexes  are  organised  assemblies  in  which  the  individual  components 
function in a cooperative manner by catalysing consecutive reactions linked by common 
metabolic  intermediates.  They  may  provide  the  means  to  attain  high  local  substrate 
concentrations,  regulate  competition  amongst  competing  pathways,  coordinate  the 
activities  of  interdependent  pathways,  and/or  sequester  toxic  and  labile  intermediates 
within cells. Two or more enzymes associating in this way allow the substrates to travel 
efficiently between the active sites. This process, known as ‘channelling’, can in certain 
cases  be  kinetically  advantageous.  Thus  multienzyme  complexes  optimise  the  catalytic 
activity and ensure the regulated activity of a metabolic pathway. Chapter 1  
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The most prominent examples of multienzyme complexes are the family of stable 2-oxo 
acid  dehydrogenase  complexes,  that  include  the  pyruvate  dehydrogenase  (PDC),  2-
oxoglutarate  dehydrogenase  (OGDC)  and  branched-chain  2-oxoacid  dehydrogenase 
(BCOADC) complexes. PDC links glycolysis to the tricarboxylic acid (TCA) cycle and 
fatty  acid  synthesis  by  catalysing  the  oxidative  decarboxylation  of  pyruvate  with  the 
concomitant production of acetyl-CoA and NADH. OGDC, in contrast, controls a major 
regulatory step in the TCA cycle and decarboxylates its substrate, 2-oxoglutarate to form 
succinyl-CoA (Sheu and Blass, 1999). Finally, the BCOADC oxidatively decarboxylates 
the branched chain 2-oxoacids derived by transamination of valine, leucine and isoleucine 
in addition to methionine and threonine (Jones and Yeaman, 1986) (Fig. 1.1). 
The molecular understanding of the 2-oxoacid dehydrogenases began in 1950s with the 
isolation  of  lipoic  acid.  The  years  from  1960-80  involved  mainly  the  application  of 
standard  protein-chemical  and  enzymatic  techniques  for  isolation,  characterisation  and 
determination of the catalytic and regulatory functions of these complexes. This has been 
supplemented  in  recent  years  by  the  increasing  application  of  recombinant  DNA, 
biophysical techniques and refined structural and functional approaches. The pioneering 
studies on these complexes were undertaken on the microbial multienzyme complexes that 
have paved the way for advances and new insights into the organisation of these complexes 
in other species. Interestingly, there are considerable differences in the structure, function 
and regulation of these multienzyme complexes across plant, bacterial and animal species 
as elucidated by various recent studies. Human pyruvate dehydrogenase complex (PDC), 
the most prominent member of the mammalian 2-oxoacid dehydrogenase complex family 
is an excellent example of a multienzyme assembly and a major focus of research. PDC 
plays an important role in many metabolic disorders, one of which is congenital childhood 
lactic  acidaemia,  that  is  a  poorly  understood  group  of  genetic  diseases  (Robinson  and 
Sherwood, 1984). The most common cause of this inherited defect is a deficiency of the 
pyruvate  dehydrogenase  complex.  It  has  also  been  described  in  patients  with 
subacute/chronic neurodegenerative disease without significant metabolic acidosis (Dahl et 
al.,  1992).  Two  clinical  forms  of  lactic  acidaemia  related  to  PDC  deficiency  are 
recognized,  neonatal  and  juvenile.  The  neonatal  form  is  a  relatively  common  cause  of 
lactic acidosis in the first weeks of life and may also feature an erythematous rash. The 
juvenile  form  presents  with  lactic  acidosis,  alopecia,  intermittent  ataxia,  seizures  and 
erythematous rash. Chapter 1  
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Figure 1.1: Schematic representation of involvement of 2-oxoacid dehydrogenases in 
cellular metabolism 
 
Multienzyme complexes are shown in blue and their products in green. Chapter 1  
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1.2 Subunit organisation of the pyruvate dehydrogenase 
complex 
 
PDC  in  mammalian  systems  is  composed  of  multiple  copies  of  three  main  enzymes  - 
pyruvate  dehydrogenase  (E1),  dihydrolipoamide  acetyltransferase  (E2)  and 
dihydrolipoamide  dehydrogenase  (E3).  In  addition  to  these  enzymes,  there  are  two 
regulatory components, namely a tightly bound, tissue specific E1-kinase and a phospho-
E1-phosphatase. Specific PDC phosphatases involved in the activation of the complex and 
are loosely bound to it (Teague et al., 1982). Mammalian PDC also contains an accessory 
protein,  formerly  known  as  protein  X,  now  referred  to  as  E3-binding  protein  (E3BP) 
(Behal et al., 1993).  
In mammals the basic framework of the complex is provided by a central core composed 
primarily of E2 subunits. Sixty copies of E2 and/or E3BP are arranged in a pentagonal 
dodecahedron displaying 532 symmetry (Yeaman et al., 1978) (Fig. 1.2 A). However, the 
E2  core  in  the  PDC  of  Gram  negative  bacteria  and  in  all  the  known  OGDCs  and 
BCOADCs, exists as a 24-meric cubic structure with octahedral (432) symmetry (Fig.1.2 
B). The E1 enzyme of PDC in mammals exists as an α2β2 heterotetramer with up to thirty 
E1s  arranged  around  the  E2  core  (Reed,  1974).  E3  is  a  ubiquitous  flavin-containing 
dehydrogenase  and  is  present  as  a  homodimer  with  6-12  copies  occupying  the  12 
pentagonal faces of the E2 core (Yeaman et al., 1978). Twelve copies of E3BP are tightly 
associated with E2 where, it mediates E3 binding to the complex (Gopalakrishnan et al., 
1989; Lawson et al., 1991). Other studies have also suggested that one E3BP molecule 
binds to each of the 12 faces of the E2 core while 6-12 E3 homodimers are attached to the 
complex  via  E3BP  (Sanderson  et  al.,  1996b).  Recently  another  model  of  PDC  core 
organisation has been suggested based on sedimentation equilibrium and small angle x-ray 
scattering data. According to this substitution model, the core comprises 48:12 E2:E3BP 
instead of 60:12 to which 12 E3 are bound in 1:1 stoichiometric relationship with E3BP 
(Hiromasa et al., 2004).  Chapter 1  
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It has been shown that E2 and E3BP must be co-expressed to promote their co-integration 
into a native oligomeric core. E3BP is thought to have its C-terminal region embedded in 
the core structure while the rest of the molecule extends outwards. Until recently, it was 
generally accepted that the PDC comprises at maximum occupancy 60 E2 monomers, 30 
E1 heterotetramers, 12 E3BP monomers and 6-12 E3 dimers. Recent isothermal titration 
calorimetry studies, however, have suggested that one E3 dimer binds two E3BPs implying 
that  each  E3  is  capable  of  forming  cross  bridges  with  the  12  E3BPs  across  adjacent 
pentagonal  faces  of  the  E2  core  assembly  assuming  60:12  meric  E2:E3BP  core 
organisation (Fig.1.3 A). In a similar way, it has been suggested that the E1 tetramers may 
also form crossbridges between pairs of E2 monomers along the 30 edges of the E2 core 
assembly (Fig.1.3 B). However, this study is in conflict with recent X-ray structures for the 
human E3 in association with E3BP where 1:1 binding of the E3BP didomain (lipoyl and 
E3-binding domains) and E3 has been shown (Ciszak et al., 2006).  
 
1.3 Catalytic mechanism  
 
PDC is responsible for controlling a key committed step in carbohydrate utilisation by 
catalysing the oxidative decarboxylation of pyruvate to yield acetyl CoA, CO2 and NADH 
(Patel  and  Roche,  1990).  This  is  a  multi-step  reaction  involving  a  high  degree  of 
cooperation among the constituent enzymes of this multienzyme complex (Fig. 1.4). As no 
net production of carbohydrate is possible from its acetyl CoA product, PDC is the main 
regulator of glucose homeostasis in mammals (Sugden and Holness, 2003). E1 catalyses a 
two-step  reaction,  that  is  the  first  and  the  rate-limiting  step  in  the  overall  catalytic 
mechanism. Active E1 has an absolute requirement for the cofactor thiamine diphosphate 
(ThDP) and Mg
2+ ions. Pyruvate forms an adduct with the thiazole ring of ThDP and this 
undergoes decarboxylation to produce a 2 (1-hydroxyethylidene) ThDP intermediate that 
undergoes  oxidation  while  the  dithiolane  ring  of  the  lipoyl  moiety  on  E2  becomes 
reductively  acetylated.  This  reductive  acetylation  step  supplies  the  acetyl  group  and 
electrons that are transferred, via E2 and E3 respectively, to CoA and NAD
+. Both of these 
initial partial reactions are catalysed by E1. E2 then mediates the transfer of the acetyl 
group from its S
8-acetyldihyrolipoamide intermediate to free CoA, thus forming acetyl Chapter 1  
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CoA. E3 reoxidises the reduced lipoyl moiety of E2 regenerating the disulphide bridge in 
the lipoyl group with NAD
+ acting as the final electron acceptor. 
 
1.4 Pyruvate dehydrogenase (E1) 
 
Mature E1 in mammalian systems exists as a heterotetramer composed of two copies each 
of  E1a  and  E1b  subunits  (Barrera  et  al.,  1972).  The  E1  component  is  a  thiamine 
diphosphate dependent (ThDP) enzyme that catalyses the decarboxylation of pyruvate to 
CO2 to form the intermediate compound 2(1-hydroxyethylidene) ThDP and the reductive 
acetylation of the lipoyl groups of the E2 as shown in Fig. 1.4. The enzymatic reaction also 
requires Mg
2+, that interacts with the pyrophosphate linkage of ThDP to facilitate binding 
(Walsh  et  al.,  1976).  The  crystal  structure  of  human  E1  PDC  has  been  resolved  at  a 
resolution of 1.95 Å (Ciszak et al., 2003) providing detailed insights into the catalytic 
mechanism and interaction between the two active sites. ThDP is found at the end of a 20 
Å long hydrophobic channel that is capable of accommodating the lipoyl-lysine swinging 
arms. Although both active sites are chemically equivalent, their dynamic non-equivalence 
has been established indicating that one active-site catalyses the decarboxylation step while 
the  other  concurrently  reductively  acetylates  E2-bound  lipoamide.  Similarly,  access  to 
ThDP  is  granted  to  either  pyruvate  or  the  lipoyl–lysine  moiety  at  any  given  moment, 
resulting in flip-flop mechanism (Ciszak et al., 2003). There is a 20 Å tunnel that acts as a 
proton wire and is lined with acidic residues connecting the two active sites. Mutagenesis 
of these acidic residues greatly reduced the rate of E1-mediated decarboxylation (Frank et 
al., 2004). Chemical modification had previously identified cysteine-62 of the α subunit 
and tryptophan-135 of the β subunit (Ali et al., 1995) as being involved in the active site of  
mammalian  E1.  The  amino  acid  sequences  surrounding  this  tryptophan  residue  are 
conserved  in  E1b  from  several  species,  suggesting  that  this  region  may  constitute  a 
structurally and/or functionally essential part of the enzyme. Site-directed mutagenesis of 
these two residues has indicated that they are involved in coenzyme binding and could also 
be important for the stability of the E1 heterotetramer. Chapter 1  
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Figure 1.2: Structures of the octahedral and icosahedral E2 inner cores 
(acetyltransferase domains) of PDC 
 
(A) Octahedral E2 core of the A. vinelandii PDC; left to right, twofold, threefold, and 
fourfold  views.  (B)  Icosahedral  core  of  the  B.  stearothermophilus  PDC;  left  to  right, 
twofold, threefold, and fivefold views. In both instances, the three different subunits of a 
single trimer are in different colours, most readily seen on the threefold views (Fussey et 
al., 1991). Chapter 1  
 
8 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1.3: Schematic representation of possible subunit organisation of E1 and E3 on 
the surface of the E2:E3BP core assembly 
 
Putative  crossbridges  between  E3  dimer  and  two  E3BPs  of  PDC  (A).  Cross  bridges 
between  E1  tetramers  and  pairs  of  E2  monomers  of  PDC  (B).  SBD  (subunit  binding 
domain), LI & L2 (outer and inner lipoyl domains). 
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Figure 1.4: Reaction mechanism for pyruvate dehydrogenase complex 
 
The reactions catalysed by E1 are shown in red, the reaction catalysed by E2 is in green, 
and that catalysed by E3 is indicated in yellow. R represents CH3. Adapted from Perham 
(2000). Chapter 1  
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1.5 Dihydrolipoamide acetyltransferase (E2) 
 
E2 is the central, structural and functional component of all the known PDCs as it forms a 
core about which the other components are tethered tightly but non-covalently. It catalyses 
the transfer of acetyl groups from S
8-acetyl dihydrolipoamide to CoA (Butterworth et al., 
1975).  The  E2  subunit  associates  as  trimers  initially  before  assembling  into  a  larger 
multimeric structure (Hendle et al., 1995). Mammalian E2-PDC has two highly conserved 
lipoyl domains at its N-terminus called outer and inner lipoyl domains, respectively. These 
are followed by a small subunit-binding domain consisting of 30-40 amino acids. At the C-
terminus a large catalytic inner domain is present known as the catalytic domain that is 
also  responsible  for  E2  self-assembly  and  integration  of  E3BP  (Fig.  1.5).  Individual 
domains are connected to each other by well-defined linker regions rich in alanine, proline 
and acidic amino acids. 
1.5.1 Linker regions of E2 
Linker regions of E2 comprise segments of polypeptide chains approximately 20-30 amino 
acids in length. These linker regions are rich in alanine and proline and charged amino 
acids. NMR studies have shown that these linker regions are very flexible but also have a 
degree  of  rigidity,  providing  the  mobility  needed  to  allow  the  lipoyl  domains  and  the 
lipoamide prosthetic group to migrate between the catalytically active sites of the three 
constituent enzymes (Fussey et al., 1991). When deletions were made in the linker region 
that  separates  the  lipoyl  domain  from  the  dihydrolipoamide  dehydrogenase-binding 
domain in a genetically-modified E. coli E2 containing a single lipoyl domain, overall 
PDC activity was impaired without any effect on the reactions of the individual enzymes. 
Moreover, it was necessary to shorten the linker region sequence that separates the lipoyl 
domain from the peripheral-binding domain in the modified E2-PDC to approximately half 
of its original length before there was a pronounced effect on complex activity. Thus it was 
concluded  that  linker  should  be  at  least  13  amino  acids  long  for  maintenance  of  full 
activity (Miles et al., 1988).  Chapter 1  
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Figure 1.5: Schematic representation of the domain and linker regions of E2 and 
E3BP of PDC across various species  
 
The domains are separated by long, flexible but extended linker regions of polypeptide 
chain (indicated in light blue). Lipoylated domains are indicated by a star. Adapted from 
Perham (2000). Chapter 1  
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1.5.2 The lipoyl domains of E2 
 
The  lipoyl  domains  play  a  crucial  role  in  coupling  the  activities  of  the  three  enzyme 
components of PDC by providing ‘swinging arms’ that are mobile and responsible for 
efficient substrate product transfer among the three successive active sites (Fussey et al., 
1991; Yeaman et al., 1978). A specific lysine side chain of each lipoyl domain is modified 
with a lipoamide prosthetic group that is essential for transportation of acetyl groups from 
El to E2, and reducing equivalents from E2 to E3. Lipoic acid is 6, 8-thioctic acid or 1, 2 
dithiolane-3-pentanoic  acid  and  is  a  sulphur  containing  cofactor  (see  section  1.5.3  for 
details). A correctly-folded lipoyl domain is required for the efficient attachment of its 
lipoyl group and recognition by its cognate lipoyl-ligase and El component. The covalent 
attachment of the lipoic acid cofactor to apoprotein requires two enzymes in mammals. 
Firstly a lipoate activating enzyme promotes the formation of lipoyl AMP (Tsunoda and 
Yasunobu, 1967). Then a second enzyme, lipoyl AMP:N
e -lysine-lipoyltransferase, which 
depends on a structural cue rather than a specific amino acid motif, initiates lipoylation of 
the lysine residue (Fujiwara et al., 1994; Fujiwara et al., 1999). In contrast, in E. coli, 
lipoate-protein ligase A is responsible for cofactor attachment and catalyzes both lipoate-
activating and transferring reactions (Morris et al., 1994; Zhao et al., 2003).   
 
1.5.3 Structure of the E2 lipoyl domain  
 
The structure of the lipoyl domain from a number of prokaryotic sources has been solved 
by NMR spectroscopy. However, only one structure has been solved from a mammalian 
source (Howard et al., 1998). The overall backbone structure of the lipoyl domain is quite 
similar in all species examined so far. It comprises a b-barrel-sandwich hybrid that is now 
known to be typical for lipoyl domains (Fig.1.6). The domain is formed by two similar and 
almost parallel four-stranded antiparallel b-sheets connected by loops and turns. The b-
sheets each consist of three major and one minor strand, and are formed around a well-Chapter 1  
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defined  core  of  hydrophobic  residues.  The  lipoylatable  lysine  residue  is  located  on  an 
exposed  type-1  b  turn  in  one  of  the  b-sheets,  within  a  conserved  DKA  motif.  Highly 
conserved aspartic acid (D) and alanine (A) residues do not appear to be important for the 
recognition of the lipoylatable residue lysine, as determined by site-directed mutagenesis 
whereas the position of the lysine residue itself appears to be critical for lipoylation. When 
the  lysine  residue  was  mutated  to  alanine  or  moved  one  residue  in  either  direction, 
lipoylation  was  not  observed  as  determined  by  mass  spectrometry.  This  shows  that 
lipoylating enzymes require a precise structural cue in order to initiate lipoylation. In the B. 
stearothermophilus lipoyl domain of E2, the combined results of site-directed mutagenesis 
and  NMR  spectroscopy  pointed  to  the  surface  loop,  close  in  space  to  the  beta-turn 
containing the lipoyl-lysine residue, as a major determinant of the interaction of lipoyl 
domain with E1 (Wallis and Perham, 1994). In this study the mutant domain retained its 
overall  three  dimensional  structure  and  ability  to  become  lipoylated  but  could  not  be 
reductively acetylated by E1. Jones and co-workers (Jones et al., 2001) found that the 
lipoyl  domain  of  E2  undergoes  conformational  changes  when  interacting  with  their 
homologous  E1s  but  not  heterologous  E1s.  Gong  &  co-workers  (Gong  et  al.,  2000) 
determined the contribution of particular amino acids of the outer lipoyl domain of human 
PDC in E1 recognition and found that the specificity loop involves L140, S141, and T143. 
Other residues that markedly reduce activity of this enzyme on mutagenesis are E162, 
D172, A174, and E179 located close to the lipoylatable lysine residue (K173). They also 
found that influential residues are spread over more than 24 Å on one side of the outer 
lipoyl  domain,  suggesting  surface  residues  in  this  region  contribute  towards  substrate 
recognition 
At the far end of one of the sheets, the lipoyl-lysine residue is presented to the solvent in a 
beta-turn connecting two successive strands. The N-terminal and C-terminal ends of the 
folded domain meet on the exact opposite side of the domain in two adjacent beta-strands 
of the other sheet. Lipoyl domains display a remarkable internal symmetry that projects 
one b-sheet onto the other b-sheet after rotation of approximately 180° about a 2-fold 
rotational symmetry axis. 
In E. coli PDC it has been shown that there are three lipoyl domains per E2 chain although 
only the outermost domain needs to be lipoylated for optimal activity and growth (Fussey 
et al., 1988).  It was concluded that the reason for retaining three lipoyl domains is to 
extend the reach of the outermost lipoyl cofactor rather than to provide extra cofactors for 
catalysis.  Chapter 1  
 
14 
14 
Lipoic  acid  is  6,  8-thioctic  acid  or  1,  2  dithiolane-3-pentanoic  acid  and  functions  in 
transacylation,  redox  and  transport  reactions.  It  plays  a  central  role  in  oxidative 
decarboxylation where it is covalently attached  to a specific lysine side chain on each 
lipoyl domain to form a lipoamide prosthetic group. It is formed from octanoic acid via an 
enzymatic S insertion (Brody et al., 1997). Lipoic acid has a therapeutic role in many PDC 
deficiency symptoms. Clinical improvement has been achieved by oral administration of 
lipoic acid in a  young patient (Matalon et al., 1984). In addition, lipoic acid has been 
reported to prevent symptoms of vitamin E deficiency (Podda et al., 1994) and to protect 
against cerebral ischaemia perfusion in rodents (Cao and Phillis, 1995). Ziegler and co-
workers (Ziegler et al., 1997) evaluated the efficacy and safety of the oral treatment with 
the  antioxidant  lipoic  acid  in  non-insulin  dependent  diabetes  mellitus  patients  with 
autonomic neuropathy. Treatment with lipoic acid was well tolerated and slightly improved 
the patients with cardiovascular autonomic neuropathy symptoms. Chapter 1  
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Figure 1.6: Structure of the lipoyl domain of the E2-PDC from B. stearothermophilus  
 
The two sets of b-sheets are shown in light blue (strands 1, 3, 6, and 8) and dark blue 
(strands 2, 4, 5, and 7). The lysine residue that becomes lipoylated is in the loop between 
strands 4 and 5 (indicated in green), and the prominent surface loop between strands 1 and 
2  is  indicated  in  red.  The  orientation  of  the  side  chain  of  the  target  lysine  residue  is 
undetermined (Dardel et al., 1993). Chapter 1  
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1.5.4 Peripheral subunit binding domain of E2 
  
The primary function of this domain in human E2 is to bind E1 primarily through the E1β 
subunit (Lessard and Perham, 1995), but it may also retain a residual binding affinity for 
E3  (McCartney  et  al.,  1997).  The  three  dimensional  structure  of  this  domain  from  B. 
stearothermophilus PDC (Kalia et al., 1993) has been resolved and shown to comprise two 
a  helices  connected  by  a  loop.  It  is  about  43  amino  acids  in  length  with  33  of  these 
residues forming a structured core composed of two a helices connected by a loop that 
contains a short 3
10 helix. Two highly conserved hydrophilic residues, Asp34 and Thr24 
are  found  buried  in  the  structure  and  these  residues  are  thought  to  be  crucial  for  the 
stability of the domain (Spector et al., 1998). Sequence comparison of this domain from a 
variety of organisms has shown that they share a very similar structure (Russell and Guest, 
1991) and indeed is one of the most highly conserved regions of the E2 protein.  
 
1.5.5 The C-terminal acetyltransferase domain of E2 
 
The C-terminal domain of E2 forms the central core of PDC by associating into trimers 
that  are  located  on  each  vertex.  Eight  such  trimers  are  found  in  the  cubic  core  in  A. 
vinelandii (Mattevi et al., 1993b; Mattevi et al., 1992), while 20 each are found in the 
icosahedral core of B. stearothermophilus (Milne et al., 2002), yeast (Stoops et al., 1992; 
Stoops et al., 1997) and bovine PDC (Behal et al., 1994). The trimers are fairly loosely 
associated via bridges, 20 Å in length, along the two fold axes creating highly dynamic 
structures.  
The  C-terminal  domain  of  E2  is  responsible  for  the  acetyltransferase  activity  of  this 
enzyme and provides the binding sites involved in E2 self-assembly into the structural 
core. The active site is located in a 30 Å long channel at the C-terminal domain subunit 
interface and runs across trimers. A conserved sequence motif, DHRXXDG, is thought to Chapter 1  
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accommodate the histidine and aspartate necessary for catalysis (Radford et al., 1987). 
Two  substrates  for  transacetylation,  CoASH  and  the  acetylated  lipoyl  domain  have  to 
approach the E2 active site from opposite directions (Izard et al., 1999). CoASH binds to 
the inside of the E2 core, while the acetylated lipoyl domain interacts with the outside 
(Mattevi et al., 1993b; Mattevi et al., 1993c; Mattevi et al., 1992). Structural homology has 
been observed between the C-terminal domain of E. coli E2 and several chloramphenicol 
acetyltransferases (CATs) (Fussey et al., 1988). The comparison of this domain with CAT 
also shows two highly conserved residues, a histidine and an aspartic acid, thought to be 
involved in the catalytic mechanism of E2. This prediction was later confirmed when the  
crystal structure of the cubic E2 core from A. vinelandii was solved to 2.6Å resolution 
(Mattevi et al., 1993c; Mattevi et al., 1992). CAT is also organised as a tightly-associated 
trimer of identical chains with a catalytic centre, containing a 30 Å long channel, found at 
the interface between subunits and is structurally similar to E2  from A. vinelandii (Leslie, 
1990). 
 
1.6 E3 binding protein (E3BP)  
 
This subunit, also originally known as protein  X, has been found only in the PDC of 
mammals (De Marcucci and Lindsay, 1985), Ascaris suum (Klingbeil et al., 1996) and 
yeast (Behal et al., 1989). The presence of this subunit in PDC was not recognised for 
many years until 1985, because it was thought to be a degradation product of E2 as it 
contained a covalently-attached lipoyl group that can be reductively acetylated in a similar 
manner to the lipoyl domain of E2. It was found to be an individual component of PDC 
when anti-sera raised against other components of PDC failed to elicit a reaction against 
E3BP and vice-versa (De Marcucci and Lindsay, 1985; Jilka et al., 1986). Peptide mapping 
and radiolabelling studies further confirmed E3BP as a fourth separate component of PDC 
(De Marcucci et al., 1986; Hodgson et al., 1986; Jilka et al., 1986; Neagle et al., 1989). The 
main function of this protein is to bind E3 to the core structure; hence it was renamed E3 
binding protein (Lawson et al., 1991). Initially the precise role of the E3BP subunit was not 
known exactly because of its high affinity for the 60-meric E2 assembly from which it 
could only be dissociated under denaturing conditions. However, it was found that this 
subunit could be cleaved by selective proteolytic degradation employing arg C, releasing a  Chapter 1  
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15 kDa N-terminal fragment, whereas the 35 kDa C-terminal fragment was still bound to 
the high molecular weight core of the complex. Arg C cleavage of E3BP was prevented by 
the presence of E3; moreover the proteolytically-modified E2:E3BP was no longer able to 
bind E3 with high affinity (Sanderson et al., 1996a).   
 The human PDX1  gene encoding E3BP was cloned in 1997 (Harris et al., 1997)  and 
showed  high  similarity  to  that  of  E2-PDC.  It  consisted  of  a  lipoyl  domain,  a  subunit 
binding domain, a C-terminal domain and flexible linker regions (Fig. 1.5). The lipoyl 
domain of E3BP can be acetylated but no acetyltransferase activity or other catalytic role 
has been identified for E3BP. In the absence of E3BP, PDC sustains a low level of activity 
since the peripheral subunit-binding domain of the E2 displays residual affinity for E3 
(McCartney et al., 1997). Removal of E2 lipoyl domains by collagenase treatment of the 
complex results in retention of 15-20% of overall PDC activity as compared to wild-type 
complex,  suggesting  that  the  E3BP  lipoyl  domain  can  compensate  for  the  missing  E2 
lipoyl domains to some extent (Sanderson et al., 1996a).  
Recent studies with low resolution structure analyses indicate that there is 2:1 binding of 
E3BP  and  E3  forming  a  stable  complex.  One  lipoyl  domain  of  this  complex  may  be 
peripherally  extended  away  from  the
  E3  dimer,  whereas  the  second  lipoyl  domain  is 
docked into one
 of the E3 active sites that are located at the monomer-monomer
 interface  
in a dynamic state (Smolle et al., 2006) suggesting, as is the case for E1, that the two 
actively interact with their cognate substrate in a flip-flop mechanism.  
Complexes deficient in E3BP have been shown to retain partial PDC activity both in vivo 
and in vitro. Reconstitution studies have shown that bovine PDC lacking E3BP is able to 
retain residual activity in the presence of a molar excess of E3. However, in the presence of 
stoichiometric amounts of E3, little or no activity was apparent (McCartney et al., 1997). 
This is thought to be due to retention of a limited ability of mammalian E2 to bind to the 
E3 component, allowing E3 to bind specifically but with low affinity. 
This retention of residual binding activity is supported by studies on a group of patients 
who  have  no  immunologically-detectable  E3BP  but,  can  still  sustain  PDC  activity  at 
approximately 10-20% of wild-type levels (Geoffroy et al., 1996; Marsac et al., 1997). 
Such patients displayed symptoms that were indistinguishable from those associated with Chapter 1  
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classical PDC deficiency. Initially it was unclear if such patients produced low amounts of 
E3BP that might be compatible with the maintenance of life. However subsequent analysis 
of  E3BP  deficient  patients  indicated  that  they  carried  large  deletions  within  the  open 
reading frame of E3BP cDNA (Marsac et al., 1997). These large deletions occurred as a 
result of point mutations at intron-exon boundaries in genomic DNA leading to aberrant 
splicing and loss of an entire exon (Dey et al., 2002). 
 
1.7 Dihydrolipoamide dehydrogenase (E3) 
 
E3 is a member of the enzyme family known as the pyridine disulphide oxidoreductases 
involved  in  the  transfer  of  electrons  between  pyridine  nucleotides  and  disulphide 
compounds.  The  other  main  members  of  this  family  include  glutathione  reductase, 
thioredoxin reductase and NADH peroxidase.  
In  PDC,  E3  brings  about  reoxidation  of  the  reduced  lipoyl  moiety  on  E2  and  E3BP. 
Initially the dihydrolipoamide on E2 transfers its electrons to a reactive cysteine pair on 
E3, and then the electrons are passed via a tightly bound FAD cofactor before being finally 
transferred to NAD
+. The end result is the formation of NADH and an oxidised lipoamide 
moiety on E2 that is now ready for the next catalytic cycle.  
In the PDC, E3 exists as a dimer of two identical subunits. Each subunit contains a redox 
active disulphide, a non-covalently bound FAD molecule and NAD
+ binding site. Only the 
dimeric form of the enzyme is active and can interact correctly with E2 (Schulze et al., 
1991). The three dimensional structures of E3 from several different sources have been 
solved by x-ray crystallography the most recently from human (Brautigam et al., 2005). 
E3 also contains two active sites, each of which is formed by the flavin ring of FAD, two 
cysteine residues from one monomer and a histidine residue from the second monomer 
(Toyoda  et  al.,  1998).  Site-directed  mutagenesis  of  this  histidine  residue  (His-425)  in 
human E3 resulted in almost complete abolition of E3 activity and it was concluded that 
His-452, was the probable proton acceptor/donor critical to   E3 catalysis. In addition, the 
local  environment  around  His-452  and  Glu-457  is  important  in  the  binding  of Chapter 1  
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dihydrolipoamide to the enzyme (Kim and Patel, 1992). E3 is thought to be the identical 
gene  product  serving  all  three  2-oxoacid  dehydrogenase  multienzyme  complexes  in 
mammals.  
 
1.8 Regulation of PDC  
 
PDC is located at a significant branch-point in metabolism channelling intermediates into 
the  tricarboxylic  acid  cycle  (Fig.  1.1.).  Two  major  types  of  regulatory  mechanism  are 
present in PDC from higher organisms. One is the end product inhibition by NADH and 
acetyl  CoA  and  the  other  involves  covalent  modification  of  the  complex  by  a 
phosphorylation / dephosphorylation mechanism mediated by several protein kinases that 
are tightly bound to the complex and a specific phosphoprotein phosphatase that is more 
loosely associated (Behal et al., 1993) (Fig. 1.7).  
Stimulation of the pyruvate dehydrogenase kinase activity by acetyl-CoA and NADH is 
thought to occur due to changes in acetylation and reduction states, respectively of the 
transacetylase  lipoyl  moieties  (Yeaman  et  al.,  1978).  Four  isoenzymes  of  PDC  kinase 
namely PDK1, PDK2, PDK3 and PDK4 have been identified and characterised, PDK4 
being the most recent (Rowles et al., 1996). 
Initially PDC kinase (PDK) was thought to be organised as a heterodimer having an α 
subunit of molecular weight 48,000 and the β subunit of molecular weight 45,000 (Stepp et 
al., 1983). However, more recently it became apparent that there was a possibility of the 
individual isozymes of PDK forming homo- and heterodimers, which might differ with 
respect to their kinetic parameters and regulation in mammals. Indeed Boulatnikov and 
coworkers (Boulatnikov and Popov, 2003) have recently demonstrated heterodimerisation 
between PDK1 and PDK2.  
The kinase is present in very small quantities and is tightly bound to the complex. PDK 
catalyse the phosphorylation of three serine residues present on E1 α subunit. These are 
Ser-264,  Ser-271  and  Ser-203  in  human  PDC.  Phosphorylation  at  site  1  occurs 
independently. However, phosphorylation at site 2 (Ser-271) and site 3 (Ser–203) requires Chapter 1  
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the presence of E2 (Yeaman et al., 1978). Each of these isoenzymes exhibits tissue specific 
expression and acts at different preferential sites. PDK1 and 4 are mainly expressed in liver 
and muscle tissues, while PDK3 is present in the kidney, brain and testes. PDK2 is present 
in most tissues (Gudi et al., 1995). Site 1 seems to be preferentially phosphorylated by 
PDK2, site 2 by PDK3 while site 3 can only be phosphorylated by PDK1 (Korotchkina and 
Patel, 2001). PDK1-3 associate with the E2 inner lipoyl domain while PDK4 preferentially 
interacts with the  E3BP lipoyl domain (Yeaman et al., 1978). 
PDC kinase is a target protein in several drug development programmes since inhibitors of 
this enzyme should activate PDC, thereby increasing carbohydrate utilisation and is of 
particular interest in the treatment of diabetes.  
Pyruvate dehydrogenase is phosphorylated and inactivated by its specific, intrinsic, cAMP-
independent protein kinase, using Mg ATP as substrate (Cooper et al., 1974). Reactivation 
of the enzyme complex is accomplished by a Mg
2+ and Ca
2+ dependent phosphoprotein 
phosphatase, that removes the phosphoryl groups from phospho-E1. Huang and co-workers 
(Huang  et  al.,  1998)  showed  that  there  are  at  least  two  isoenzymes  of  pyruvate 
dehydrogenase phosphatase (PDP), designated as PDP1 & PDP2 in mammals, that are 
different with respect to tissue distribution and kinetic parameters and, therefore, are likely 
to be different functionally. These isoenzymes have tissue specific expression with PDP1 
located primarily in muscle whereas PDP2 is found in liver and adipose tissue (Huang et 
al., 1998). In contrast to PDK, PDP is loosely associated with PDC, although its catalytic 
activity is increased 7-16 fold by interaction with the E2 lipoyl domain (Chen et al., 1996).   
Like PDP1, PDP2 is a Mg
2+ dependent enzyme, but its sensitivity to Mg
2+ ions is almost 
ten-fold lower than that of PDP1. In contrast to PDP1, PDP2 is not regulated by Ca
2+ ions. 
Instead,  it  is  sensitive  to  the  polyamine  spermine,  which  in  turn  has  no  effect  on  the 
enzymatic activity of PDP1 (Huang et al., 1998).  
Another long term regulatory mechanism involves several hormones and nutritional factors 
that control the levels and activity of the PDC in several tissues. These factors have been 
studied, but to a lesser extent and probably affect the long term regulation of PDC through 
changes  in  the  levels  of  its  catalytic  and  regulatory  components  by  controlling  gene 
expression at the  transcriptional and translational level (Patel and Harris, 1995).  Chapter 1  
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Figure 1.7: Regulatory mechanism for PDC by feedback inhibition and covalent 
modification via protein kinase(s) and phosphoprotein phosphatase(s) 
 
Adapted from Behal et al. (1993). Chapter 1  
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1.9 Pyruvate dehydrogenase complex defects 
 
As human PDC
 is composed of several different gene products, a genetic defect
 involving 
any  one  of  them  can  lead  to  impairment
  in  its  function.  Deficiencies  of  the  pyruvate 
dehydrogenase complex are now well documented and mutations have been described in 
the genes PDHA1, PDHB, DLAT, DLD, PDX1 and PDP1 encoding the E1α, E1β, E2, E3, 
E3BP and PDP1 proteins, respectively (Brown, 1992; Brown et al., 2004; Lissens et al., 
2000; Seyda et al., 2000).  
Pyruvate dehydrogenase complex deficiency is one of the most common disorders leading 
to neurodegeneration associated with abnormal mitochondrial metabolism as the citric acid 
cycle is a major biochemical process  central to energy production and maintenance of 
intracellular  ATP  levels.  Malfunction  of  the  cycle  leads  to  abnormal  lactate  build-up 
resulting  in  non-specific  symptoms  (e.g.,  severe  lethargy,  poor  feeding,  tachypnea), 
especially  during  times  of  illness,  stress,  or  high  carbohydrate  intake.  Progressive 
neurological symptoms  usually start in infancy  but may  be evident at  birth or in later 
childhood. These symptoms may include developmental delay, intermittent ataxia, poor 
muscle tone, abnormal eye movements or seizures. 
The vast majority of these lesions reported to date are caused by mutations in the coding 
region of the gene responsible for E1α. About 80 point, insertion and deletion mutations 
have been reported in the E1α subunit causing a range of symptoms of varying degrees of 
severity in individual patients (Chun et al., 1993). The gene for E1α is localised on the X 
chromosome (Szabo et al., 1990) exposing it to a greater chance of mutation. In addition, 
location of the E1α gene on the X chromosome is responsible for variations in the clinical 
symptoms of E1a mutation between males and females, specifically the potential for the 
occurrence of mosaicism in heterozygous females. Complete PDC E1α deficiency
 has not 
been observed in males and is presumed to be lethal
 at an early stage of development. By 
contrast, mutations that
 abolish E1α protein synthesis are commonly found in heterozygous
 
female patients whose tissues are composed of two populations of cells
 as a consequence 
of X chromosome inactivation. In these females,
 some cells have completely normal PDC 
function whereas others
 are highly deficient (Dahl et al., 1992).  Chapter 1  
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The
 random pattern of X inactivation in different individuals,
 and in different tissues in the 
same individual, contributes
 significantly to the widely divergent clinical presentations
 in 
female patients. Although the majority of these heterozygous
 females present with obvious 
PDC deficiency, a small number
 of females carrying an E1α subunit mutation have mild 
symptoms
  or  no  symptoms  at  all,  presumably  because  of  an  X-inactivation
  pattern 
favouring expression of the normal X chromosome (Fujii et al., 1994; Matthews et al., 
1994). 
 There is a male preponderance amongst severely affected patients whereas females 
tend  to  have  milder  metabolic  and  neurological  dysfunction  (Brown  et  al.,  2004). 
Mutations affecting the PDHB gene encoding E1β have been identified in two patients 
only  so  far.  In  both  cases  a  single  amino  acid  substitution  destabilises  the  E1 
heterotetramer (Brown et al., 2004).  
Although not reported as frequently as E1 defects, abnormalities in E2, E3 and E3 binding 
protein have also been found producing a broad range of symptoms of varying severity 
(Chun et al., 1991; Dahl et al., 1992; Endo et al., 1991). Mutations in the PDX1 gene 
encoding E3BP have been reported in a dozen patients (Aral et al., 1997; Geoffroy et al., 
1996; Ling et al., 1998; Marsac et al., 1993; Ramadan et al., 2004). 
More than 20 cases of E3 deficiency have been reported due to different mutations in the 
DLD gene encoding the E3 enzyme, common to PDC, OGDC and BCOADC (Hong et al., 
1996; Robinson et al., 1989).  
Defects  in  the  E2  component  have  also  been  detected  in  patients  with  severe  lactic 
acidaemia  (Robinson  et  al.,  1990).  However  the  numbers  of  patients  encountered  with 
defects in the E2 are relatively few.  
PDC  deficiency  must  be  differentiated  from  other  disorders  causing  lactic  acidosis, 
particularly  defects  of  the  electron  transport  chain.  Although  electron  transport  chain 
defects  may  have  similar  neurological  manifestations  to  PDC  defects,  they  also  have 
systemic manifestations (skeletal and cardiac myopathies) not found in inborn errors of 
PDC.  Biochemically  these  two  entities  can  be  differentiated  because  electron  transport 
chain defects have an abnormally elevated lactate /pyruvate ratio and impaired fatty acid 
oxidation (Robinson et al., 1989). Further detailed information on this topic is provided in 
section 4.1, Chapter 4. Chapter 1  
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Another type of disease involving PDC subunits is primary biliary cirrhosis. This is an 
autoimmune disease characterised by the production of anti-mitochondrial auto-antibodies 
(AMA) against components of PDC although the major auto-antigen is the E2 component 
(Fussey et al., 1988; Gershwin et al., 1987). The primary epitope appears to be the inner 
lipoyl domain of E2 and involves the lipoamide prosthetic group. Since this domain is 
conserved in E3BP, it is also another major target of the autoimmune response (Surh et al., 
1989). Autoantibodies have also been reported against E2-OGDC (Fussey et al., 1988), 
BCOADC (Fussey et al., 1991) and the E1α protein (Fregeau et al., 1990). 
Defects in ThDP-containing enzymes such as pyruvate dehydrogenase have been reported 
in brain and peripheral tissues from patients suffering from Alzheimer’s disease (Gibson et 
al., 1988). A 50% decline in the activity of PDC, OGDC and cytochrome oxidase has also 
been shown in patients’ brains suffering from Alzheimer’s disease (Gibson et al., 1998). 
The exact molecular mechanism involved in linking PDC and OGDC to this disease is not 
known, however, possibilities are that free oxygen radicals and accompanying oxidative 
stress may cause damage to these enzymes (Shi et al., 2005). Defects in PDC may also 
reduce  acetyl-CoA  levels  leading  to  impaired  production  of  acetylcholine  that  is  an 
important  neurotransmitter in both the peripheral and central nervous systems (Szutowicz 
et al., 2006). Many patients suffering from systemic sclerosis, a multi-system connective 
tissue disorder, also produce antibodies to E1α (Fujimoto et al., 1995). Detailed enzymatic 
and genetic analysis of patients with such defects is very important in understanding the 
exact role of each component of PDC and also beneficial for clinical prenatal diagnosis, 
improved treatment regimens and potentially gene therapy in the future.  
The diagnosis of PDC deficiency has been enhanced by the availability of specific assays 
for PDC and its catalytic components. Immunological and molecular biological methods 
have facilitated characterisation of the genetic basis of specific PDC defects. Immunoblots 
and RNA blot analyses using specific antibodies and cDNA probes corresponding to all the 
catalytic  components  of  PDC  indicate  considerable  heterogeneity  in  PDC  deficiencies 
(Brown et al., 2004; Patel et al., 1992).  
As PDC is ultimately responsible for tailoring the appropriate usage of glucose in the body 
to  match  the  varying  energy  requirements  of  individual  tissues  on  a  minute-by-minute 
basis; therefore, PDK and its inhibitors are of great importance as therapeutics for diabetes, 
where glucose metabolism is impaired. Early interventions to treat PDC deficiency include Chapter 1  
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dietary manipulation and vitamin supplementation (Falk et al., 1976; Matalon et al., 1984). 
Ketogenic  diets  appear  to  lower  blood  lactate  levels,  but  do  not  significantly  improve 
neurological function in most cases. Another form of therapy includes the provision of 
thiamine and/or lipoic acids in an attempt to maximise residual PDC activity. Reduced 
lactic acidosis was observed in PDC deficient patients on treatment with dichloroacetate, 
which is an E1-kinase inhibitor (Berendzen et al., 2006; Stacpoole, 1989; Stacpoole et al., 
2006). 
Recently, a vector using recombinant adeno-associated virus (rAAV) that contained a full-
length E1a green fluorescent protein (GFP) construct was used to deliver wild type E1a 
into mitochondria after injection of the construct in vivo into the central nervous system of 
rats and in vitro into human cells. Transfection of cultured fibroblasts from a male patient 
with  E1a  deficiency  led  to  partial  restoration  of  PDC  activity,  as  determined  by 
decarboxylation of 
14C-pyruvate. These data indicate that at least partial correction of PDC 
defects may be feasible by gene transfer (Stacpoole et al., 2003). 
 
1.10 Biophysical tools in the study of PDC 
 
PDC is a highly important multienzyme complex central to the energy metabolism of an 
organism. Various researchers using a combination of molecular biological, biochemical 
and  biophysical  approaches  have  determined  the  structure,  function  and  modes  of 
interaction  of  various  components  of  PDC.  For  structural  determination,  the  choice  of 
biophysical techniques depends largely upon the physical and biochemical properties of 
the protein to be studied and also on the  advantages and limitations of the techniques 
employed.  For  example,  crystallography  gives  a  very  high  resolution  (up  to  0.1  nm) 
revealing  fine  details  of  atomic  structure  but  requires  the  production  of  high  quality 
crystals, which is always not feasible. The crystal structure of human E1-PDC has been 
resolved at a resolution of 1.95 Å (Ciszak et al., 2003) and the crystal structure of human 
E3 (Brautigam et al., 2005) and E3BP-subunit binding domain in association with E3 has 
been recently resolved at 2.6 Å (Ciszak et al., 2006). Chapter 1  
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NMR is another versatile tool for structural determination of macromolecules in solution 
giving  high  resolution  (0.2-0.3  nm),  information  about  the  flexibility  and  dynamics  of 
specific regions of polypeptides and providing a means for mapping sites of protein-protein 
interaction.  However,  this  approach  requires  concentrated  solutions  of  protein  and  is 
limited to the analysis of relatively small proteins (Mr, 30 kDa or less). The structure of the 
inner lipoyl domain of human PDC has been resolved through NMR (Howard et al., 1998). 
Similarly, the three-dimensional structure of the lipoyl domain (Dardel et al., 1993) and the 
peripheral subunit-binding domain of dihydrolipoamide acetyltransferase from the PDC of 
B. stearothermophilus has also been solved by this approach (Kalia et al., 1993). 
Small angle X-ray scattering (SAXS) is another biophysical tool that is often employed in 
combination  with  other  structural  and  biochemical  methods  and  is  an  important 
complementary  approach  to  generate  consistent  models  of  biological  macromolecules 
(Koch et al., 2003). SAXS not only provides low-resolution models of protein complexes 
in solution, but also in many cases delivers answers to significant functional questions. For 
example the structure of human E3 bound to subunit binding domain of E3BP has been 
resolved by SAXS and shows great asymmetry (Smolle et al., 2006). Most importantly, the 
method permits the study of native oligomeric protein complexes in near physiological 
state and the analysis of structural changes in response to variations in external conditions, 
thus yielding valuable information on the relationship between these structural changes and 
the operation of the proteins under investigation. In many cases solution structures differ 
significantly and are more open and extended than the equivalent crystal structures.  
Determination of the three-dimensional (3D) organization of PDC is key to understanding 
its highly regulated, multi-functional roles and underlying molecular mechanisms. While 
much progress has been made in the determination of 3D structures of the constituent 
enzymes of microbial and yeast PDCs through X-ray crystallography, NMR spectroscopy 
and  electron  cryomicroscopy  (cryo  EM),  3D  structural  studies  of  the  human  PDC 
complexes  have  been  hampered  both  by  sample  unavailability  and  by  the  increased 
complexity of additional regulatory  components. Construction of a recombinant human 
PDC  in  vitro  by  expressing  and  purifying  its  individual  enzymes  in  E.  coli  has  been 
achieved  in  this  laboratory  followed  by  their  spontaneous  reconstitution  into  active 
complex. This should facilitate detailed investigation of how the multiple components of 
human PDC and their cofactors interact with each other in normal as well as pathological 
states. Various biochemical, molecular as well as common biophysical techniques such as 
circular dichroism, size exclusion chromatography and analytical ultracentrifugation have Chapter 1  
 
28 
28 
been  used  in  this  study.  Analytical  ultracentrifugation  is  an  extremely  versatile  and 
powerful  technique  for  characterizing  the  solution-state  behaviour  of  macromolecules. 
When coupled with contemporary data analysis methods, experiments performed in the 
analytical  ultracentrifuge  are  capable  of  rigorously  determining  sample  purity, 
characterizing  assembly  and  disassembly  mechanisms  of  biomolecular  complexes, 
determining subunit stoichiometries and detecting and characterizing macromolecular and 
conformational changes.  
Circular  dichroism  (CD)  is  an  excellent  tool  for  rapid  determination  of  the  secondary 
structure and  folding properties of proteins that have been obtained using recombinant 
techniques or purified from tissues. The most widely used applications of protein circular 
dichroism are to determine whether an expressed, purified protein is folded correctly or if 
mutations affect its conformation or stability. CD is defined as the differential absorbance 
of left circularly polarized light (LCPL) and right circularly polarized light (RCPL): CD = 
Abs (LCPL) – Abs (RCPL). Ellipticity is the unit of circular dichroism and is defined as 
the tangent of the ratio of the minor to major elliptical axis. To be “CD active”, a molecule 
must be structurally asymmetric and exhibit absorbance in the uv region. Asymmetry can 
result  from  chiral  molecules  such  as  the  peptide  backbone  of  proteins,  a  non-chiral 
molecule covalently attached to a chiral molecule (aromatic amino acid side chains), or a 
non-chiral  molecule  in  an  asymmetric  environment  (e.g.  a  chromophore  bound  to  a 
protein). Increased relative absorption of left polarized light results in a positive CD signal, 
while a negative signal is the result of right polarized light being more highly absorbed. 
Proteins are CD active (all amino acids except glycine contain a chiral carbon), and the 
resulting CD signals are sensitive to protein secondary and tertiary structure.  
Three  common  secondary  structure  motifs  (alpha  helix,  beta  sheet,  and  random  coil) 
exhibit distinctive CD spectra in the far-ultraviolet region (170-260 nm). Alpha-helical 
proteins  have  negative  peaks  at  222  nm  and  208  nm  and  a  positive  peak  at  193  nm. 
Proteins with well-defined, antiparallel b-pleated sheets (b-helices) have a trough at 218 
nm and a peak at 195 nm, whereas disordered proteins have very low ellipticity above 210 
nm and negative bands near 195 nm (Greenfield and Fasman, 1969; Holzwarth and Doty, 
1965; Venyaminov et al., 1993). Secondary structure determination by CD is reported to 
achieve accuracies of 0.97 for helices, 0.75 for beta sheet, 0.50 for turns and 0.89 for other 
structure types (Manavalan and Johnson, 1987).  
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Using CD spectra, the secondary structure of proteins can be estimated using a variety of 
computer algorithms. The near ultraviolet region (320-260 nm) provides a fingerprint of 
the tertiary structure of proteins. Asymmetric environments of aromatic amino acids, that 
are sensitive to protein conformation in the local environment, provide the basis of the 
near-uv CD signal (Greenfield, 1975).  
Tryptophan fluorescence is another approach widely used in protein studies to determine 
structural changes in proteins. The major goal in the application of this tool is to interpret 
the fluorescence properties in terms of structural parameters and to predict the structural 
changes  in  the  protein.  Since  the  wavelength  and  intensity  of  tryptophan  fluorescence 
emission  spectra  is  sensitive  to  the  surrounding  environment  therefore,  it  is  regularly 
employed to monitor perturbation of the local tertiary structure.  
 
1.11 The 2-oxoglutarate dehydrogenase complex (OGDC) 
 
This  mitochondrial  enzyme  assembly  catalyses  the  oxidative  decarboxylation  of  2- 
oxoglutarate to succinyl CoA. E1o also utilizes thiamine diphosphate (ThDP) as a cofactor. 
The  ThDP  is  tightly  but  non-covalently  bound  to  E1,  which  catalyses  the  oxidative 
decarboxylation of 2-oxoglutarate and subsequent binding of the resultant succinyl moiety 
to a sulphur residue of E2 bound lipoic acid with concomitant regeneration of the ThDP. 
The core enzyme E2 catalyses succinyl group transfer to coenzyme A producing succinyl-
CoA. A multiple random coupling mechanism has been proposed for the E2 lipoyl domain 
in OGDC from E. coli (Hackert et al., 1983). E3 catalyses the two electron transfer of 
reducing equivalents from E2 to produce NADH and H
+
. 
The basic organisation of this complex is also believed to be similar to PDC with 24 copies 
of  dihydrolipoyl  succinyltransferase  (E2o)  forming  a  cubic  core  structure  displaying 
octahedral symmetry to which 12 copies of 2-oxoglutarate dehydrogenase (E1o) bind non-
covalently  (Yeaman  et  al.,  1978).  An  estimated  6  copies  of  dihydrolipoamide 
dehydrogenase  (E3)  are  attached  non-covalently  to  the  six  faces  of  this  complex.  In 
mammalian OGDC, some early studies suggested that E1o appears to bind more tightly to 
the E2o core than E3 (Yeaman et al., 1978). More recent reports indicate that single copies Chapter 1  
 
30 
30 
of E1o and E3 form a high-affinity subcomplex, with the homodimers binding to the E2o 
core through the N-terminal region of  E1o (McCartney et al., 1998). 
OGDC plays an important role in the regulation of 2-oxoglutarate concentration which is a 
key citric acid cycle intermediate and a common substrate for several enzymes. Regulation 
of OGDC is subject to feedback inhibition with its end products, NADH and succinyl CoA 
inhibiting the E1o component directly (Lawlis and Roche, 1981). Changes in both Ca
2+ 
and  Mg
2+  concentrations  can  also  control  OGDC  activity  and  along  with  ThDP  are 
required for maximal enzyme activity (Panov and Scarpa, 1996). Agonists that increase 
cytosolic  free Ca
2+ levels have been shown to  stimulate metabolic flux through the 2-
oxoglutarate  dehydrogenase  complex.  Another  study  indicated  that  physiological 
concentrations of inorganic Pi may exert significant activation of OGDC that could further 
be  potentiated  by  Mg
2+  (Chinopoulos  et  al.,  1999).  A  number  of  inhibitors  reduce  the 
activity of this complex including several reactive oxygen species and lipid peroxidation 
products such as 4-hydroxy-2-nonenal (Andersson et al., 1998; Chinopoulos et al., 1999; 
Humphries and Szweda, 1998; Park et al., 1999). Hydrogen peroxide interacts with nitric 
oxide (NO) to form peroxynitrite a reactive nitrogen species that is also reported to be an 
effective inhibitor of OGDC (Park et al., 1999). Hydroxynonenal and perhaps hydrogen 
peroxide  may  reduce  the  activity  of  OGDC  relatively  selectively  compared  to  other 
mitochondrial components of energy metabolism (Lucas and Szweda, 1999). Methotrexate 
and  some  other  environmental  toxins  can  also  inhibit  OGDC  function  (Caetano  et  al., 
1997).   
 
1.12 Dihydrolipoamide succinyltransferase (E2o) 
 
The  core  protein,  E2o  is  encoded  by  the  DLST  gene  that  in  humans  is  located  on 
chromosome 14q24.3. The human DLST gene and a pseudogene were first characterised in 
1994 (Nakano et al., 1994). The sequence of the human gene showed minor variations 
from  those  of  previously  published  cDNAs  (Ali  et  al.,  1994;  Nakano  et  al.,  1993). 
Determination of the entire sequence of the dihydrolipoamide succinyltransferase gene of 
human  OGDC  revealed  a  complete  absence  of  any  obvious  nucleotide  sequence 
corresponding to the E3-binding and/or E1-binding domain. It has been suggested that the Chapter 1  
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exon coding for the E3-binding and/or E1-binding domain may have been lost from the 
gene  during  evolution  (Nakano  et  al.,  1994).  Thus  human  dihydrolipoamide 
succinyltransferase possesses a unique structure consisting of only two domains in contrast 
to the dihydrolipoamide acyltransferases of the other 2-oxoacid dehydrogenase complexes. 
 
1.13 2-oxoglutarate dehydrogenase (E1o) 
 
E1o in humans is coded by the OGDH gene located on chromosome at position 7p13-p14 
and  the  gene  was  initially  characterised  in  1998  by  Koike  (Koike,  1998).  Although, 
thiamine diphosphate is a cofactor for this enzyme, its deficiency did not lower the levels 
of the mRNA for this component in several tissue culture systems (Pekovich et al., 1998). 
In the octahedral complex of OGDC, E1o exists as an a2 homodimer whereas E1 of PDC is 
a heterotetramer. Studies on mammalian OGDC employing specific proteolysis and N-
terminal sequence analysis, have identified
 a proteolytically sensitive region at the extreme 
N- terminus of the E1o component
 with significant sequence similarity to the E3BP and E2 
components
 of mammalian PDC (Rice et al., 1992). These similarities suggested that E1o 
 
may  perform  some  functions  normally  devolved  to  E2  in
  PDC  and  BCOADC.  Gel 
permeation
  of  the  E1o/E3  fraction  of  OGDC,  under  associative  conditions,  has 
demonstrated
  that  these  two  enzymes  interact  with  high  affinity  to  form  a  stable
 
subcomplex with an apparent Mr consistent with a 1:1 stoichiometry.
 These studies provide 
the first direct biochemical evidence that
 uniquely, in mammalian OGDC, its constituent 
E1O enzyme is responsible
 for binding the E3 component to the multi-enzyme complex 
(McCartney  et  al.,  1998),  a  function  similar  to  protein  E3BP  in  PDC.  Moreover, 
subsequent immunological analysis indicated that antiserum to E1o recognised antigenic 
epitopes in E3BP of PDC, whereas anti-E3BP-specific serum was also able to weakly 
recognise E1o (McCartney et al., 1998).  
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1.14 Dihydrolipoamide dehydrogenase (E3) 
 
Human dihydrolipoamide dehydrogenase (E3) is an enzymatic component common to the 
mitochondrial  2-oxoacid  dehydrogenase  and  glycine  decarboxylase  complexes  and  has 
been described earlier in section 1.7 in this chapter. It is encoded by the DLD gene which 
was first characterised in 1993 (Feigenbaum and Robinson, 1993).  
Site-directed  mutagenesis  of  human  E3  has  shown  that  lysine-54  is  necessary  for  the 
protein-FAD interaction and for the catalytic activity of this enzyme whereas, glutamate–
192 is involved in maintaining the appropriate orientation of lysine-54 during catalysis 
(Liu et al., 1999). The amount of E3 found in mitochondria typically exceeds the amount 
required for the maximal activation of OGDC, PDC and BCOADC. This finding has led to 
speculation that E3 may also have roles in the transfer of electrons between substrates 
within mitochondria including ascorbic acid (Xu and Wells, 1996).  
   
1.15 Role of OGDC in disease 
 
OGDC  deficiencies  have  been  associated  with  several  neurodegenerative  disorders 
including Alzheimer’s disease and Parkinson’s disease. It is also linked to primary biliary 
cirrhosis,  characterised  by  the  presence  of  anti-mitochondrial  antibodies  against  the 
subunits  of  the  2-oxoacid  dehydrogenase  complexes  including  E2o  (Kaplan  and 
Lundsgaarde, 1996). However, deficiency of OGDC is more characteristically associated 
with  neurological  syndromes.  This  association  is  not  surprising  because  of  the  acute 
dependence  of  the  integrity  of  the  nervous  system  on  oxidative  metabolism.  The 
neurological syndromes linked to OGDC deficiency vary from fatal disease of the neonates 
to chronic disease of the elderly. Infantile lactic acidosis with severe mental retardation is 
the characteristic symptom of OGDC deficiency (Hong et al., 1996; Munnich et al., 1982; Chapter 1  
 
33 
33 
Robinson et al., 1989; Shaag et al., 1999). Many symptoms of OGDC deficiency are a 
result of deficiency of E3, with accompanying deficiencies in PDC as well as BCOADC 
(Hong et al., 1996; Munnich et al., 1982; Robinson et al., 1989). The affected patients can 
be homozygous for mutations in DLD or can be compounded heterozygotes, inheriting 
different  defective  DLD  genes  from  each  of  their  parents  (Robinson  et  al.,  1989). 
Psychomotor  retardation  in  early  childhood  has  been  associated  with  somewhat  milder 
deficiency  of  OGDC  (Bonnefont  et  al.,  1992;  Guffon  et  al.,  1993).  Intermittent 
psychomotor symptoms occur in Ashkenazi Jews who generally have mild E3 deficiency 
(Shaag et al., 1999). For example, a group of these children have intermittent attention 
deficit disorder with mild ataxia, incoordination and hypotonic weakness linked to a single 
G229C mutation in the DLD gene. 
Friedreich’s  ataxia  (Wong  et  al.,  1999)  is  another  condition  associated  with  OGDC 
deficiency (Sheu and Blass, 1999). This condition was named after the German physician 
Nicholas Friedreich, who first described the condition in the 1860s. These patients develop 
ataxia and signs of damage to the long tracts of the spinal cord, with significant clinical 
manifestations  typically  beginning  in  adolescence  or  early  adult  life  (Sheu  and  Blass, 
1999).  The  primary  genetic  defect  is  in  the  FRDA  gene  (Wong  et  al.,  1999).  FRDA 
encodes  the  protein  frataxin  that  is  involved  in  free  radical  metabolism  within 
mitochondria.  The  Friedrich  mutations  can  lead  to  inactivation  of  a  number  of  key 
mitochondrial enzymes including aconitase (Rotig et al., 1997). E3 deficiency has been 
confirmed in the brain of Friedreich’s ataxia patients (Mastrogiacomo et al., 1996).  
Loss of mitochondrial enzyme activities including PDC and OGDC has been found in 
spinocerebellar  ataxia  also  (Sheu  and  Blass,  1999;  Sorbi  et  al.,  1989).  These  ataxias 
involve varying combinations of signs and symptoms associated with dysfunction of the 
spinal  cord  and  cerebellum  and  sometimes  other  parts  of  the  brain.  The  precise  gene 
product involved differs among the various types of spinocerebellar ataxias characterised 
so far (Pandolfo and Montermini, 1998).  
Another important association of OGDC is with Parkinson’s disease, a common disease of 
later life that impairs secondary motor function and often impairs intelligence as well. The 
best known defect in energy metabolism is in complex 1 of the electron transport chain, 
that may be caused in some Parkinson’s disease patients by a defect in mitochondrial DNA 
(Schapira et al., 1998). Deficiency of OGDC has been found in Japanese patients with 
Parkinson’s  disease,  based  on  immunocytochemical  studies  (Mizuno  et  al.,  1994).  A Chapter 1  
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genetic abnormality in the DLST gene, encoding E2o  has also been reported in Japanese 
patients  suffering  from  Parkinson’s  disease  (Kobayashi  et  al.,  1998).  The  Parkinson’s 
syndrome can be induced by poisoning with the compound MPTP (1-methyl 4-phenyl 1, 2, 
3,  6-tetrahydropyridine),  a  chemical  that  is  related  to  the  opioid  analgesic  drugs.  This 
chemical is converted in mitochondria to MPP
+. MPP
+ inhibits complex 1 of the electron 
transport chain but also inhibits OGDC. The reported activity of OGDC in human brain is 
about 10% of that of complex 1, suggesting that MPTP inhibition of OGDC might be 
functionally more important than inhibition of the electron transport chain per se (Sheu and 
Blass, 1999).  
Alzheimer’s disease (AD) accounts for over 80% of dementias in older people (Nolan et 
al., 1998). The classical pathological lesions visible under the light microscope are amyloid 
plaques  and  neurofibrillary  tangles  (Geddes  et  al.,  1997).  Among  the  characteristic 
biochemical  lesions  are  oxidative  stress  and  deficiency  of  OGDC  (Butterworth  and 
Besnard, 1990; Gibson et al., 1988; Mastrogiacomo et al., 1996; Terwel et al., 1998). At 
least two mechanisms may contribute to the reduction of OGDC activity in AD. A genetic 
component  is  implied  by  the  finding  that  OGDC  deficiency  persists  in  cultured  skin 
fibroblasts from many but not all patients with AD (Sheu and Blass, 1999). However, a 
plausible pathogenic mutation has not been defined as yet. Secondary damage to OGDC 
also appears to occur in AD due to other mutations and particularly as a result of oxidative 
stress. OGDC is particularly susceptible to oxidative stress (Sheu and Blass, 1999) which 
appears to be an important part of AD process and may be the main contributor to the 
reduction of OGDC activity in this disease. Thus genetic and non genetic mechanisms are 
not mutually exclusive and indeed polymorphisms (or mutations) in a gene encoding an 
OGDC component may sensitise OGDC to damage by free radicals.  
Human apolipoprotein E (APOE), a major component of lipoproteins, 
 plays a central role 
in the metabolism and redistribution of 
 lipids such as cholesterol and dysfunctional forms 
of APOE are associated with increased
 risk for AD (Corder et al., 1993; Farrer et al., 1997; 
Saunders et al., 1993; Strittmatter et al., 1993). Indeed, evidence indicates that DLST and a 
dysfunctional isoform of APOE, APOE4 may interact in the causation of AD (Sheu and 
Blass, 1999). In molecular genetics studies, the association of DLST with AD was found to 
be significant only in patients who were also positive for APOE4. The presence of this 
isoform has been proposed to be deleterious as a result of increased production of free 
radical evident from significantly enhanced lipid oxidation in brain cortex (Ramassamy et 
al., 1999) and such mechanisms can also affect OGDC.  Chapter 1  
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Amyloid aggregates of the amyloid-beta (Abeta) peptide are implicated in the pathology of 
AD.  Anti-Abeta  monoclonal  antibodies  (mAbs)  have  been  shown  to  reduce  amyloid 
plaques  in  vitro  and  in  animal  studies.  Consequently,  passive  immunization  is  being 
considered for treating AD and anti-Abeta mAbs are now in phase II trials (Gardberg et al., 
2007). 
OGDC defects have also been found associated with diabetes. Maturity-onset diabetes of 
the  young  (MODY)  is  a  rare  form  of  juvenile  diabetes  mellitus  that  presents  with 
hyperglycaemia  in  the  absence  of  ketosis.  Mutations  in  the  gene  encoding  hepatocyte 
nuclear factor-1α (HNF1α) are the cause of MODY3. Induction of HNF1-P291fsinsC the 
most common HNF1α mutation, is generated by a mutational hotspot in exon 4 occurring 
in unrelated families. This frameshift mutation, resulting from insertion of a C in a poly(C) 
tract  centred  around  codon  290,  encodes  a  truncated  protein  of  315  amino  acids.  This 
mutation has been reported to significantly inhibit expression of mitochondrial E1o mRNA 
and protein with a corresponding decrease in OGDC catalytic activity (Wang et al., 2000). 
 
1.16 Aims of this thesis 
 
The main aim of this thesis is to develop a recombinant model of human PDC for studying 
genetic mutations found in the human population. To achieve this, a recombinant model of 
PDC is created by overexpressing and purifying its various constituent enzymes before 
assembling  into  a  fully-active  complex.  Initially  reconstituted  PDC  is  evaluated  for  its 
functional  abilities  by  using  various  biochemical  and  molecular  biology  approaches  to 
study the effects of known mutations in PDC on lipoylation status and role of E3BP. Once 
the  usefulness  and  validity  of  this  novel  model  system  is  established  as  described  in 
Chapter 3, this model is used to study the role of three recently-discovered mutations in the 
E2 enzyme of PDC encountered in indvidual patients. Two of these mutations are unusual 
‘in frame’ three base pair deletions and the third one is a substitution of an amino acid 
located in the proximity of the active site. Structure function relationships are studied by 
mimicking  the  natural  mutations  in  a  PDC  recombinant  model.  These  mutations  and 
subsequent  analysis  of  their  effects  on  PDC  assembly  and  enzymatic  functions  are 
described in Chapter 4.  Chapter 1  
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This study is designed not only to generate new information on the precise consequences 
of the mutations at a molecular level and of their underlying consequences leading to the 
appearance of clinical symptoms, but also to establish the utility of this recombinant PDC 
model  as  a  vehicle  for  conducting  more  comprehensive  studies  of  this  kind  in  future. 
Analysis of such mutant PDCs carrying the appropriate single amino acid substitutions/ 
deletions within the E2 and E3BP core polypeptides should provide important new insights 
into the PDC structure, assembly, mode of action and regulation and will be of potential 
clinical value for the future.  
A  minor  ancillary  aim  of  this  thesis  also  involves  preliminary  study  of  subunit 
interaction/organisation of components OGDC as described in Chapter 5, with a view to 
mapping  the  domain  organization  of  E1o  more  precisely,  in  particular  those  regions 
involved in maintaining
 critical subunit contacts. This will provide more information on the 
structural organisation of OGDC and will be a step towards creating a recombinant model 
of OGDC that is increasingly implicated in various metabolic, genetic and autoimmune 
disorders.  Chapter 2  
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Chapter 2  
 
 
Materials and Methods  
 
 
 
2.1 Biological materials 
2.1.1 Bacterial strains  
E. coli strains BL21 (DE3), BL21 (DE3) Star, BL21 (DE3) plysS as well as Top 10 and 
DH5a were purchased from Invitrogen. 
 
2.1.2 Bacterial media 
Luria Broth (LB) was prepared by dissolving 10 g Bacto–tryptone, 5 g Bacto-yeast-extract 
and 10 g NaCl per litre of distilled H2O, pH 7.5. LB plates were made by adding 7.5 g of 
micro  agar  to  500  ml  LB.  All  media  were  autoclaved  before  use.  Wherever  it  was 
necessary, broth and LB plates were supplemented with ampicillin at 50  g/ml, kanamycin 
at 30  g/ml and chloramphenicol at 34  g/ml. 
 Chapter 2  
 
38 
38 
 
2.1.3 Mutagenic primers 
The  following  mutagenic  primers  were  ordered  from  Sigma  Genosys.  The  mutations 
created are shown in colour. 
Primers for lysine-46 to glutamine mutation in E2-PDC 
K46Q forward  
5’-GAG ATA GAA ACT GAC CAG GCC ACT ATA GGT TTT TG-3’ 
K46Q reverse  
5’-CAA AAA CCT ATA GTG GCC TGG TCA GTT TCT ATC TC-3’ 
Primers for lysine-175 to glutamine mutation in E2-PDC 
K175Q forward 
5’-GAG GTT GAA ACT GAT CAG GCC ACT GTT GGA TTT GAG-3’ 
K175Q reverse  
5’-CTC AAA TCC AAC AGT GGC CTG ATC AGT TTC AAC CTC-3’ 
Primers for lysine-44 to glutamine mutation in E3BP-PDC 
K44Q forward 
5’-GAA ATT GAG ACT GAC CAG GCT GTG GTT ACC-3’ 
K44Q reverse 
3’-GGT AAC CAC AGC CTG GTC AGT CTC AAT TTC-5’  
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Primers for glutamate-35 deletion in E2-PDC  
 E35 E2 forward 
5’-GAG GGG GAC AAA ATC AAT GGT GAC CTA ATT GCA GAG-3’ 
 E35 E2 reverse 
5’-CTC TGC AAT TAG GTC ACC ATT GAT TTT GTC CCC CTC-3’ 
Primers for glutamate-35 to glutamine mutation in E2-PDC 
E35Q E2 forward 
5’-GAG GGG GAC AAA ATC AAT CAG GGT GAC CTA ATT GCA GAG-3’ 
E35Q E2 reverse 
5’-CTC TGC AAT TAG GTC ACC CTG ATT GAT TTT GTC CCC CTC-3’ 
Primers for glutamate -35 to aspartate mutation in E2-PDC 
E35D E2 forward 
5’-GGG GGA CAA AAT CAA TGG TGA CCT AAT TGC AGA G-3’ 
E35D E2 reverse 
5’-CTC TGC AAT TAG GTC ACC ATC ATT GAT TTT GTC CCC-3’ 
Primers for phenylalanine- 490 to leucine mutation in E2-PDC 
P490L E2 forward  
5’-GGA ATT AAG AAT TTA TCT GCT ATT ATT AAC CCA CC-3’ 
P490L E2 reverse  
5’-GGT GGG TTA ATA ATA GCA GAT AAA TTC TTA ATT CC-3’ 
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Primers for valine-455 deletion in E2-PDC 
 V455 E2 forward 
5’-GAA ACC ATT GCT AAT GAT GTT TCT TTA GCA ACC AAA GCA AG-3’  
 V455 E2 reverse 
5’-CTT GCT TTG GTT GCT AAA GAA ACA TCA TTA GCA ATG GTT TCC-3’ 
 
2.1.4 Oligonucleotide primers  
 
The  following  oligonucleotide  primers  were  ordered  from  MWG-Biotech  AG.  The 
restriction sites created are shown in colour.  
Primers for E1-OGDC construct  
OGDE1(Nde1) forward  
5’-GCT CAT ATG AGA CCA TTG ACG GCT TCC CAG-3’ 
OGDE1(Xho1) reverse  
5’-AGG CTC GAG CTA CGA GAA GTT CTT GAA GAC G-3’ 
Primers for N-terminal E1 (166amino acid) GST fusion construct  
E1BamH1 forward  
5’-CAT TTT CAG GAT CCA GAC CAG CAG CAG CTA GG- 3’ 
E1500EcoR1 reverse 
5’-GCA CTG GAA TTC TCA GAA AGT GGT GGT GGG CAA G-3’ Chapter 2  
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Primers for N-terminal E1 (83 amino acids) GST fusion construct  
E1BamH1 forward 
5’-CAT TTT CAG GAT CCA GAC CAG CAG CAG CTA GG- 3’ 
E1250EcoR1 reverse  
5’-GAC CAG GAA TTC TCA ATG GGC CAC AGC AGC AGC CAG-3’ 
 
All PCR primers were designed to obtain a balanced G:C composition, compatible melting 
temperatures and contain a GC clamp at the 3’ termini. They were screened for internal 
secondary structures e.g. hairpin loops or possible dimerisation using software available at 
the Sigma Genosys website (http://orders.sigma-genosys.eu.com/). 
 
2.1.5 Chemicals and standard materials  
 
Ampicillin,  kanamycin,  chloramphenicol,  rubidium  chloride,  L-glutathione  reduced,  N-
ethylmaleimide (NEM), lipoic acid, lipoamide, L-cysteine, NADPH, NADH, NAD
+, CoA, 
thiamine  diphosphate,  trypsin,  phosphotransacetylase,  acetyl  phosphate,  pepstatin, 
leupeptin, aprotinin, Ponceau S dye, ethidium bromide and glutaraldehyde were purchased 
from Sigma. 
QIAquick Gel Extraction kit, Penta His-HRP kit and Ni-NTA Agarose were purchased 
from Qiagen. Quick Ligation Kit was purchased from New England Biolabs. Wizard SV 
DNA Minipreps Kit, restriction enzymes, Taq polymerase, dNTP and 10 kb DNA ladders 
were from Promega. Quick Change Site-directed Mutagenesis Kits were from Stratagene.  
HiPrep 16/60 Sephacryl S-300 High Resolution and Glutathione Sepharose 4B columns, 
nitrocellulose membrane (ECL Hybond), ECL Western blotting detection reagents, low 
molecular  weight  SDS  Marker  Kits,  thrombin,  zinc  chloride  and  PD10  columns  were Chapter 2  
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purchased  from  Amersham.  20  MC  metal  chelate  resin  was  purchased  from  Applied 
Biosystems,  USA.  Dialysis  cassettes  of  various  cut  off  sizes  were  obtained  from  Pierce 
(USA).  
Precast  4-12%  Bis-Tris  gels  and  MES  SDS  Buffer  were  purchased  from  Invitrogen. 
Protease  inhibitor  EDTA-free  and  Complete  Protease  Inhibitor  Mini  tablets  were 
purchased from Roche. Imidazole was from VWR. Centricon filters with cut off sizes 5, 
30, 60 and 100 kDa and N, N, N
-1 N
-1- tetramethylethylene diamine (TEMED) were from 
Fisher. Acrylamide 30% (w/v) was from Thistle Scientific. Bradford reagent was from 
BioRad.  Bacto-tryptone,  Bacto  yeast  extract,  DTT,  and  IPTG  were  from  Melford 
Laboratories Ltd. Coomassie Blue dye was obtained from Fluka and sodium borohydride 
from Aldrich. Monoclonal antibody PD2 (patient derived hybridoma IgG) was a kind gift 
from Professor Freda Stevenson, University of Southampton.  
 
2.2 Molecular biology methods  
2.2.1 Polymerase chain reaction 
  
Polymerase  chain  reactions  were  carried  out  in  a  PTC  100 
TM  thermocycler  (Genetic 
Research Instrumentation). A typical single 100 µl reaction mixture using the Promega 
PCR kit consisted of the following ingredients-  
    10x PCR buffer                                         10.0 µl  
    dNTP mixture                                           16.0 µl  
    5' primer                                                      5.0 µl  
    3' primer                                                      5.0 µl  
    Platinum
®Taq DNA polymerase                 0.5 µl (2.5 units) 
    DNA template                                             50 ng 
     Sterile water                                              to a final volume of 100 µl Chapter 2  
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Platinum
®  Taq  DNA  Polymerase  High  Fidelity  is  an  enzyme  mixture  composed  of 
recombinant Taq DNA polymerase, Pyrococcus species derived thermostable polymerase, 
and Platinum
® Taq Antibody. Pyrococcus species polymerase possesses a proofreading 
ability by virtue of its 3' to 5' exonuclease activity. Mixture of the proofreading enzyme 
with Taq DNA polymerase increases fidelity approximately six times over that of Taq 
DNA polymerase alone. Additionally, because a proofreading enzyme is present in the 
mixture, amplification of simple and complex DNA templates over a large range of target 
sizes is possible. Targets 12-20 kb can be amplified with some optimization. 
One of the most critical factors for successful amplification of DNA is the magnesium ion 
concentration.  Too  much  MgCl2  will  cause  high  levels  of  non-specific  amplification, 
whereas too little will inhibit the reaction. Therefore, in this protocol 1.5 mM MgCl2 was 
used as the final concentration for the Taq DNA polymerase. Template was denatured for 5 
min  at  94  °C  prior  to  the  initial  cycle.  A  typical  cycling  temperature  profile 
was: denaturing at 94 °C for 45 s, annealing at 60 °C for 45 s and extension at 72 °C for 1 
min for 25-30 cycles. A 10 min extension at 72 °C was given at the end of each cycle. 
Annealing  temperatures  were  critical  and  required  experimental  optimisation.  Low 
temperature  annealing  increases  non-specific  amplification;  high  temperatures  inhibit 
annealing but may increase specificity. Typical annealing reactions were performed in the 
range of 55 °C to 65 °C. PCR products were viewed by agarose gel electrophoresis using 
1% (w/v) agarose. 
 
2.2.2 Agarose gel electrophoresis 
 
The appropriate amount of agarose was dissolved in 1X TAE (40 mM Tris, 1mM EDTA, 
40  mM  glacial  acetic  acid,  pH  7.5)  for  pouring  agarose  gel  slabs.  DNA  samples  for 
analysis were diluted fivefold by the addition of loading buffer (0.25% (w/v) bromophenol 
blue, 0.25% (v/v) xylene cyanol FF, 15% (w/v) Ficoll), before being loaded on the agarose 
gel. These were run at 100 V/250 mA for 40 min to 1 h until the dye front was about 1 cm 
from  the  bottom  of  the  gel.  Gels  were  then  stained  with  a  small  volume  of  ethidium 
bromide before being viewed under a UV transilluminator. Chapter 2  
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2.2.3 Extraction of DNA from agarose gel  
 
DNA was purified from agarose gels using the QIAquick Gel Extraction kit. The DNA was 
run on the gel and excised using a sterile scalpel blade. The excised agarose containing the 
DNA was solubilised at 50 
oC in the appropriate buffer and 100% (v/v) isopropanol. This 
solubilised mixture was applied to a spin column and centrifuged for 1 min to allow the 
DNA  to  bind  to  the  column.  The  column  was  washed  with  750  ml  of  Wash  Buffer 
containing 80% (v/v) ethanol. Residual ethanol was removed by centrifuging the column 
for 2 min before eluting the DNA in 50 ml of Buffer EB (10 mM Tris-HCl, pH 8.5). The 
quantity and quality of DNA was analysed by agarose gel electrophoresis. 
 
2.2.4 Restriction digestion  
 
Restriction digestions were performed either as a step prior to cloning for preparing vector 
and insert or for diagnostic purposes. Restriction enzymes and buffers from Promega were 
used as per manufacturer’s instructions. Digestions were usually performed at 37 
oC for 60 
min and analysed by agarose gel electrophoresis. 
 
2.2.5 Ligation 
 
Vector  was  cut  with  appropriate  restriction  enzymes,  treated  with  calf  intestinal 
phosphatase and gel purified. The insert was ligated into the vectors at a 3:1 insert : vector 
ratio using the Quick Ligation Kit. The Quick Ligation Kit enables ligation of cohesive end 
or  blunt  end  DNA  fragments  in  5  min  at  room  temperature  (25  °C).  Products  were Chapter 2  
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transformed into chemically competent E. coli DH5α cells and grown overnight on LB-
ampicillin plates at 37 °C. 
 
2.2.6 Ethanol precipitation of DNA 
 
Before sending DNA for sequencing, ethanol precipitation was carried out. A solution of 3 
M sodium acetate (50  l) was added to about 50  l DNA suspension and left on ice for 30 
min in an Eppendorf tube. Thereafter, it was centrifuged at 13,000 rpm for 15 min. The 
supernatant was discarded and 250  l of ice cold 70% (v/v) ethanol was added before 
centrifuging it again for 15 min. After again discarding the supernatant, tubes were left to 
air dry for 20-30 min.  
 
2.2.7 DNA sequencing 
 
Ethanol precipitated DNA samples were sent for sequencing, which was carried out by 
MWG Biotech. The sequencing results were read and analysed by Gene-Jockey software. 
 
2.2.8 Production of competent cells 
 
Competent cells were made using the rubidium chloride method. The appropriate E. coli 
strains were streaked on a LB-agar plate and grown overnight at 37 
oC. A single colony 
was picked and cultured overnight in 5 ml LB. This 5 ml culture was subcultured into 100 
ml LB and grown at 37 
oC with continuous shaking until an optical density at 550 nm of 
0.50 was obtained. The culture was chilled on ice for 5 min and then spun at 2000 -3000 Chapter 2  
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rpm in an Allegra
Tm 6R centrifuge at 4 
oC in 50 ml sterile Falcon tubes. The supernatant 
was poured off and each pellet was resuspended gently by pipetting in 20 ml buffer 1 (30 
mM potassium acetate pH 5.8, 100 mM rubidium chloride, 10 mM calcium chloride, 50 
mM manganese chloride and 15% (v/v) glycerol). The solution was re-spun in the same 
manner as before and the supernatant discarded. The pellet was resuspended in 2 ml buffer 
2 (10 mM MOPS, pH 6.5, 75 mM calcium chloride, 10 mM rubidium chloride and 15% 
(v/v) glycerol) by gentle pipetting and chilled on ice for 15 min before storing in 200  l 
aliquots. Competent cells were stored at -80 
oC until required. 
 
2.2.9 Transformation of competent bacteria 
 
Competent cells were thawed on ice. To 50  l of competent bacteria, 1  l DNA (about 0.1-
50 ng) was added. The bacterial cells were chilled on ice for 15 min. Cells were then heat 
shocked for 90 s at 45 
oC and then returned to ice for 2 min. To these cells, 450 µl LB 
media was added and this bacterial cell suspension was incubated at 37 
oC for 45 min with 
continuous shaking. About 200  l of suspension was plated on a LB plate containing the 
appropriate antibiotic and incubated overnight at 37 
oC. 
 
2.2.10 Purification of DNA from bacterial cultures (Miniprep) 
 
DNA  was  purified  using  the  Wizard  SV  DNA  Miniprep  kit.  The  kit  was  used  as  per 
manufacturer’s instructions. A single colony grown on a LB plate was picked and cultured 
in 5 ml LB medium containing the same antibiotic. The culture was incubated at 37 
oC 
overnight with continuous shaking and cells pelleted by centrifuging at 10,000 rpm for 5 
min  in  an  Allegra
Tm  6R  centrifuge.  The  pellet  was  re-suspended  in  250   l  Cell  Re-
suspension solution (50 mM Tris-HCl, pH 7.8, 10 mM EDTA, 100  g /ml RNAse A). 
Cells were lysed by the addition of 250  l of Cell Lysis Solution (0.2 M NaOH, 1% (w/v) 
SDS) and incubated for 5 min in the presence of 250  g alkaline protease to inactivate any Chapter 2  
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endonucleases released during cell lysis. Cell Neutralising Buffer 350  l (4.09 M GdmCl, 
0.759 M potassium acetate, 2.12 M acetic acid) was added and the mixture was centrifuged 
at 10,000 rpm for 10 min in a Sanyo Microcentaur benchtop centrifuge to pellet the cell 
debris. The supernatant was poured into a spin column and centrifuged briefly to allow the 
DNA to bind to the membrane of the spin column. The column was washed twice with 
Column Wash Solution (60 mM potassium acetate, 10 mM Tris-HCl, pH 7.8, 60% (v/v) 
ethanol) prior to elution of the DNA with 100  l nuclease free water. The quality of the 
DNA was analysed by agarose gel electrophoresis.  
 
2.2.11 Site-directed mutagenesis 
 
The QuikChange Site-directed mutagenesis kit  was employed to make  point mutations 
using  PfuTurboDNA  polymerase.  The  DNA  template  in  which  mutations  were  to  be 
created,  was  prepared  by  the  standard  Miniprep  protocol.  For  the  PCR  reaction,  the 
mixture consisted of 5  l  10x reaction buffer, 50 ng double stranded DNA template, 125 
ng each of forward and reverse primers, 1 µl of dNTP mix and double distilled water to 
make a  final volume of 50 µl. Cycling parameters were as follows: initial denaturing at 95 
°C for 1 min, followed by 12-18 cycles involving 95 °C for 1 min, annealing at 50-60 °C 
for 1 min and extension at 65 °C for 1-2 minutes/kb of plasmid length. PCR was carried 
out in a PTC 100 
TM Programmable Thermal Controller. Following temperature cycling, 
the  product  was  treated  with  10  U/ l  Dpn  I.  The  Dpn  I  endonuclease  is  specific  for 
methylated and hemimethylated DNA and is used to digest the parental DNA template and 
to select for mutation-containing, newly-synthesized DNA. DNA isolated from almost all 
E.  coli  strains  is  dam  methylated  and  therefore  susceptible  to  Dpn  I  digestion.  Dam 
methylation is the addition of a methyl group to adenine in the sequence 5'-GATC-3' in 
newly-synthesized DNA. The nicked vector DNA containing the desired mutations was 
then transformed into XL1-Blue supercompetent cells. Cells were heat pulsed for 45 s at 
42  °C  followed  by  returning  to  ice  for  2  min.  LB  media  (0.5  ml)  was  added  to  the 
transformation reaction and incubated at 37 °C for 1 h with shaking at 225-250 rpm. About 
100-200  µl  incubated  reaction  mixture  was  plated  on  LB  plates  containing  ampicillin. 
Plates were incubated at 37 °C for 16 h. Colonies were picked and grown in LB media Chapter 2  
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containing ampicillin overnight at 37 °C. Next day, plasmids were purified from these 
cultures and sent for sequence analysis to enable detection of the desired mutation.   
 
2.3 Protein methods  
2.3.1 Large-scale protein induction 
 
A single colony was picked and added to 15 ml of LB medium containing the appropriate 
antibiotic. Cells were grown at 37 °C overnight with continuous shaking. At this stage, 500 
ml LB supplemented with antibiotic was inoculated with 10-15 ml overnight culture and 
grown at 37 °C with constant shaking until an A600 of 0.5 was reached. For small-scale 
induction 100 ml LB was inoculated with 1-5 ml overnight culture. The cultures were 
induced by the addition of 1 mM IPTG. For overexpression of E2-PDC, E3BP or OGDC 
proteins,  0.1  mM  lipoic  acid  was  also  added  to  the  medium.  Individual  cultures  were 
shaken at 200-220 rpm at various temperatures ranging from 16-37 °C for different lengths 
of times as required. Samples (1 ml) were taken at regular time intervals to check for 
overexpression.  These  were  pelleted  by  centrifugation  and  the  pellets  resuspended  in 
Laemmli sample buffer (10  l per 0.1 A600 unit) and viewed by SDS-PAGE as described in 
section 2.3.4. Cells were harvested by centrifugation at 10,000 rpm for 10-15 min at 4°C in 
a JA14 rotor in a Beckman J2-21 centrifuge and pellets stored at –20 °C. 
 
2.3.2 French press treatment   
 
E. coli pellets from 500 ml cultures were mixed with 20 ml of appropriate binding buffer 
(50 mM KH2PO4, 1M NaCl, 0.5 mM Imidazole, pH 8) or PBS (170 mM NaCl, 3 mM KCl, 
10 mM Na2HPO4, 1 mM KH2PO4, pH 7.2). Protease inhibitor cocktail tablets were added 
at this point. Cells were disrupted by 3-4 passes through a French pressure cell at 950 psi. Chapter 2  
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The  disrupted  cells  were  spun  at  10,000  rpm  at  4  °C  for  10  min  and  the  supernatant 
containing soluble protein was kept for protein purification.    
 
2.3.3 Checking the solubility of recombinant proteins 
 
Overexpression cultures (50 ml) were centrifuged at 3,000 rpm for 15 min at 4 
oC. The 
supernatant was discarded and pellets re-suspended in 3 ml binding buffer prior to French 
press treatment. An aliquot (100  l) was kept aside for SDS-PAGE for analysing whole 
cell extracts. An aliquot (100  l) of the disrupted cell extract was centrifuged at 4 
οC at 
13,000 rpm in a Sanyo Microcentaur benchtop centrifuge and the supernatant was saved 
while the pellet was re-suspended and washed with PBS buffer 3 times; each time the 
supernatant  was  discarded  and  replaced  with  fresh  PBS  buffer.  Finally  the  pellet  was 
suspended in binding buffer (100  l) and the suspension saved for a pellet sample. An 
equal  volume  of  Laemmli  sample  buffer  was  mixed  with  the  whole  cell  extract, 
supernatant fraction and pellet suspension and the solubility of the recombinant protein 
reviewed by SDS-PAGE. 
 
2.3.4 Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
 
Sodium dodecyl sulphate (SDS) is an anionic detergent that denatures proteins and confers 
a net negative charge. In denaturing SDS-PAGE, separation of proteins is based not on the 
intrinsic  electrical  charge  of  the  polypeptide  but  on  molecular  weight.  The  following 
buffers were prepared for making SDS gels: - Chapter 2  
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SDS-PAGE buffers  
Resolving gel :   8-15% (w/v) acrylamide,  
                           0.5 M Tris-HCl buffer, pH 8.8 
                           0.1% (w/v) SDS 
                           0.1% (w/v) ammonium persulphate  
                           0.1% (v/v) N,N,N
-1 N
-1- tetramethylethylene diamine (TEMED) 
 
Stacking gel :     5.4% (w/v) acrylamide 
                           0.06 M Tris-HCl buffer, pH 6.8 
                           0.1% (w/v) SDS 
                           0.1% (w/v) ammonium persulphate 
                           0.1 % (v/v) TEMED  
 
SDS buffer          0.025 mM Tris-HCl buffer, pH 8.3 
                            0.2 M glycine 
                            1% (w/v) SDS  Chapter 2  
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Laemmli sample buffer   2% (w/v) SDS  
                                       10% (w/v) sucrose 
                                       62.5 mM Tris-HCl, pH 6.8 
                                        Pyronin Y dye (trace). 
Samples for SDS-PAGE were suspended in 10  l Laemmli sample buffer and DTT (150 
mM final concentration) was added prior to boiling for 5 min to ensure that all proteins 
were denatured. The denatured protein samples were loaded either onto precast 4-12% Bis-
Tris gels using ready-made MES SDS buffer (1M MES, 1M Tris base, 69.3 mM SDS, 20.5 
mM  EDTA,  free  acid,  pH  7.5)  and  run  at  a  constant  current  of  125  mA  per  gel. 
Alternatively, the gels were made with a 4% stacking gel and 10-15% resolving gel, the 
composition of which is described above. SDS buffer (as above) was employed as running 
buffer at a constant current of 125 mA per gel. Proteins were stained with 0.1% (w/v) 
Coomassie Brilliant blue dye dissolved in 50% (v/v) methanol, 10% (v/v) acetic acid for 
30 min with shaking. Protein bands were visualised by destaining the gels in 10% (v/v) 
methanol and 10% (v/v) acetic acid overnight.  
 
2.3.5 Non denaturing gel electrophoresis  
 
Non denaturing or native gels were prepared to separate proteins based on their size and 
charge. A native gel comprised both a stacking gel and a resolving gel. For preparing these 
gels, separating buffer (1.5 M Tris-HCl, pH 8.8) and stacking buffer (0.05 M Tris, pH 6.8) 
were prepared initially.  
For a 6% resolving gel, 2 ml 30% (w/v) acrylamide, 2.5 ml separating buffer, 2 ml distilled 
water, 50  l 10% (w/v) ammonium sulphate and 8  l TEMED were mixed together. The 
mixture  was  poured  into  a  glass  plate  sandwich  and  allowed  to  polymerise.  A  space 
(approx 0.5 cm) on the top of the sandwich was left for the stacking gel but was first filled Chapter 2  
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with  dH2O.  For  preparing  the  5%  stacking  gel,  2.3  ml  water,  0.67  ml  30%  (w/v) 
acrylamide, 1 ml stacking buffer, 30  l of 10% (w/v) ammonium persulphate and 7  l 
TEMED were mixed. When the resolving gel was fully polymerised, the water on its top 
was discarded and stacking gel mixture was poured onto it. A comb was inserted into this 
mixture to make wells for protein samples. Stacking gel was allowed to polymerise and the 
comb  was  removed  when  polymerisation  was  complete.  After  securing  the  gel  in  the 
electrophoresis tank, electrophoresis buffer (25 mM Tris, 192 mM glycine; pH 8.8) was 
poured into the chamber. Protein samples (10-20  l) were first suspended in sample buffer 
(312.5 mM Tris-HCl, pH 6.8, 50% (v/v) glycerol, 0.05% (w/v) bromophenol blue and 1.4 
ml water) before loading into wells. Unused wells were also filled with sample buffer. 
Electrophoresis was carried out at 100-200 volts at constant current until the dye front 
migrated to the bottom of the gel. The gels were removed and viewed after staining with 
Coomassie Brilliant blue dye.   
 
2.3.6 Purification of His-tagged proteins 
 
Buffers for purification of His-tagged proteins by affinity chromatography- 
Stripping buffer          50 mM EDTA, 1M NaCl 
Zinc Loading buffer    0.1 M ZnCl2, pH 4.5 
Salt Wash buffer          0.5 M NaCl  
Buffer A                      50 mM KH2PO4, 1 M NaCl, 0.5 mM imidazole; pH 8 
Buffer B                     50 mM KH2KPO4, 1M NaCl, 500 mM imidazole; pH 6 
All buffers were filtered through Whatman filters of pore size 2  m using a vacuum pump 
and stored at 4
  οC. Distilled water was also filtered. His-tagged proteins were purified 
using metal chelate affinity chromatography on a BioCAD Sprint workstation (Applied 
Biosystems, USA). A 20 MC column (Applied Biosystems) was washed initially with 5 
column  volume  (CV)  of  stripping  buffer  to  remove  any  remaining  metal  ions  from Chapter 2  
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previous use. This was followed by a wash with 5 CV of dH2O. Zinc ions were loaded on 
to the column matrix by passing 30 CV of Zinc Loading buffer prior to a wash with 5 CV 
of dH2O. Unbound zinc ions were removed with a 5 CV wash of Salt Wash buffer and the 
column was equilibrated with 5 CV of buffer B followed by 10 CV of buffer A. Samples 
were injected in 5 ml aliquots and washed through with 3 CV of buffer A. After the final 
injection, the column was washed with 9 CV of buffer A. Finally, the His-tagged protein 
was  eluted  from  the  column  employing  a  0-100%  gradient  of  buffer  B  and  the  eluate 
collected in 2 ml fractions.  
 
2.3.7 Ni-NTA affinity purification 
 
The E1 enzyme of PDC was purified using nickel nitrilo-triacetic acid (Ni-NTA) resin. The 
following buffers were prepared for Ni-NTA affinity purification. 
E1 Lysis buffer  
50 mM KH2PO4, pH 7. 
 0.2 mM MgCl2                                                 
0.2 mM thiamine diphosphate  
5 mM β-mercaptoethanol 
 
E1 Buffer A 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate  
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E1 Imidazole Wash buffer 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate 
50 mM imidazole 
E1 Buffer B 
50 mM KH2PO4, pH 7.5 
100 mM KCl 
0.2 mM MgCl2 
0.2 mM thiamine diphosphate 
500 mM imidazole 
Four  pellets,  each  from  a  500  ml  culture,  were  suspended  in  25  ml  E1  Lysis  buffer 
containing four tablets of Complete protease inhibitor cocktail (EDTA-free) and disrupted 
by French press treatment (section 2.3.2). The lysate was spun for 20 min at 10,000 rpm in 
a Beckman J2-21 centrifuge using a JA-17 rotor and the supernatant collected in a fresh 
tube. Ni-NTA resin (1 ml) contained in ethanol was added to a second Falcon tube and left 
to settle. The resin supernatant was sucked out with a pipette and the resin washed with E1 
Buffer A. Washed resin was then mixed with the lysate supernatant with gentle rotation for 
1 h at room temperature. The supernatant and resin mix was poured into an empty PD-10 
column.  The  resin  was  washed  with  200  ml  E1  Buffer  A  and  then  with  50  ml  of  E1 
Imidazole Wash buffer. The protein was eluted with 1 ml E1 buffer B in three separate 1 
ml elutions. Aliquots of eluted fractions were checked for purity by analysing on SDS-
PAGE.  
  Chapter 2  
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2.3.8 Dialysis of proteins  
 
In  order  to  exchange  buffers,  proteins  were  dialysed  in  4-5  l  of  the  buffer  of  choice 
overnight at 4 
oC. Dialysis was usually conducted according to manufacturer’s instructions 
in dialysis cassettes.  
 
2.3.9 Concentration of proteins  
 
Proteins were concentrated by centrifuging the samples in a Centricon concentrator with a 
specific molecular weight ‘cut off’ depending on the protein under investigation. Samples 
were centrifuged at a speed of 3000 rpm in an Allegra 
Tm 6R centrifuge for various times 
until the desired volume was achieved. 
 
2.3.10 Determination of protein concentration  
 
Dividing the measured absorbance of a protein solution by the calculated or known molar 
extinction coefficient (ε) yields the molar concentration of the protein.  The absorbance of 
various proteins was measured using an Ultospec 4300 Pro uv/visible spectrophotometer, 
whereas, the molar extinction coefficient was determined by analysing the known sequence 
of  the  protein  in  PROTPRAM  (http://expasy.org/tools/protparam.html).  The  extinction 
coefficient for the 60: 12 meric E2:E3BP was calculated as 217,590 M
-1 cm 
-1 at 280 nm. 
The extinction coefficient for the outer lipoyl domain protein was determined as 50,450 M
-
1 cm
-1 at
 280 nm, while the extinction coefficient for the E3 dimer was calculated as 22600 
M
-1 cm
-1, exploiting FAD absorbance at 450 nm. Similarly, for E1 an extinction coefficient Chapter 2  
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at  280  nm  was  determined  as  140,000  M
-1  cm 
-1.  The  concentration  (in  mg/ml)  was 
calculated by multiplying the molar concentration by the respective molecular weight of 
the protein.  
 
2.3.11 Measuring protein concentration using the Bradford assay 
 
Bio-Rad assays were also performed to determine protein concentration on occasions and 
to ensure equal loading of wild-type and mutant versions of the same protein. The dye 
Coomassie  Brilliant  Blue  G-250  is  converted  from  red  to  blue  upon  protein  binding 
followed  by  an  increase  in  absorption  at  595  nm.  A  standard  curve  was  plotted  using 
known  concentrations  of  IgG  versus  A595  values  of  IgG  bound  to  this  dye.  The 
concentrations  of  unknown  protein  bound  to  dye  were  thereafter  calculated  using  this 
standard curve. A Shimadzu UV-2101 PC UV-VIS scanning spectrophotometer was used 
for these determinations.  
 
2.3.12 Size exclusion chromatography 
 
Size  exclusion  chromatography  was  performed  using  a  HiPrep  16/60  Sephacryl  S-300 
High Resolution column (bed volume 120 ml) attached to a BioCAD 700E workstation. 
The  column  was  equilibrated  with  2  CV  of  gel  filtration  buffer  (50  mM  potassium 
phosphate, 150 mM NaCl; pH 7.5) at a flow rate of 0.5 ml/minute. A concentrated protein 
sample (1 ml) was loaded onto the column and absorbance was monitored at 280 nm. Peak 
fractions were collected and analysed by SDS-PAGE. An estimate of the molecular mass 
of protein was carried out from a standard curve generated by plotting the ratio of elution 
volume  to  void  volume  (Ve/Vo)  versus  log10  molecular  mass  of  a  range  of  standard 
proteins of known sizes (Fig. 4.16 A; Chapter 4). Chapter 2  
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2.3.13 Purification of glutathione S-transferase (GST) tagged 
proteins  
 
The following buffers were prepared for the purification of GST tagged proteins:- 
PBS buffer - 170 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 1 mM KH2PO4, pH 7.2 
Glutathione elution buffer - 50 mM Tris-HCl buffer, pH 8.0, 10 mM reduced  
glutathione.  
GST-fusion proteins were produced in 500 ml LB cultures for 3-5 h and the E. coli pelleted 
by centrifugation. The bacterial pellet from 250 ml culture medium was resuspended in 10 
ml  PBS  buffer.  One  tablet  of  Protease  inhibitor  (EDTA  free)  was  added  to  10  ml 
suspension followed by disruption using French press treatment. The crude extract was 
centrifuged at 10,000 rpm at 4 
οC in a Beckman J2-21 centrifuge using a JA17 rotor. The 
soluble supernatant fraction was used for further purification. A glutathione Sepharose 4B 
column with bed volume 5 ml, attached to BioCAD Sprint workstation was washed with 5 
CV of PBS. The supernatant was passed through the column followed by 5 CV washes of 
PBS. The bound protein was eluted in glutathione buffer and collected in 2 ml fractions. 
The  fractions  were  concentrated  and  visualised  by  SDS–PAGE  after  staining  with 
Coomassie Brilliant blue.  
 
2.3.14 Removal of GST tag  
 
Purified GST-tagged proteins were dialysed against either PBS or 50 mM Tris buffer, pH 
7.5. Thrombin was added at 100 U/ mg protein and incubated with gentle shaking either at 
room temperature or at 37 °C for 4-16 h. Cleavage of the GST-tag was viewed by taking 
samples at 2 h time intervals and visualising by SDS-PAGE. Chapter 2  
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2.3.15 Western Blotting  
 
Proteins  were  separated  by  SDS-PAGE  and  electrophoretically  transferred  onto 
nitrocellulose membrane (ECL Hybond, Amersham) at 425 mA for 45 min in the presence 
of transfer buffer (25 mM Tris-HCl buffer, pH 7.2, 192 mM glycine, 0.02% (w/v) SDS, 
20% (v/v) methanol). The nitrocellulose membrane was briefly checked for the presence of 
transferred proteins by staining with Ponceau S solution. This was followed by shaking for 
1  min  and  washing  with  dH2O.  Excess  binding  sites  were  blocked  by  immersing  the 
nitrocellulose membrane in blocking solution (20 mM Tris-HCl buffer, pH 7.2, 15 mM 
NaCl, 5% (w/v) milk powder, 0.25% (v/v) Tween-20) for 1 h at room temperature with 
constant shaking. The membrane was washed twice with wash solution (20 mM Tris-HCl 
buffer, pH 7.2, 15 mM NaCl, 1% (w/v) milk powder, 1% (v/v) Tween-20), each for 10 
min. After these washes, the membrane was incubated in primary antibody solution (20 
mM Tris-HCl buffer, pH 7.2, 15 mM NaCl, 5% (w/v) milk powder, 0.25% (v/v) Tween-20 
and a 1:2500 dilution of primary antibody) at room temperature for 1 h. Excess primary 
antibody was removed by 4 changes of wash solution and membrane was again incubated 
at room temperature in secondary antibody solution (20 mM Tris-HCl buffer, pH 7.2, 15 
mM NaCl, 5% (w/v) milk powder, 0.25 (v/v) Tween-20 and a 1:1000 dilution of secondary 
antibody conjugated with horseradish peroxidase). In the case of anti-His tag antibody, the 
primary  antibody  was  already  conjugated  with  horseradish  peroxidase;  therefore  no 
secondary antibody was required. 
The membrane was then washed for 15 min with wash solution followed by a 30 min wash 
in  high  salt  solution  (20  mM  Tris-HCl  buffer,  pH  7.2;  150  mM  NaCl).  Detection  of 
immune complex was carried out according to the manufacturer’s instructions employing 
the ECL Western blotting reagents.  
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2.3.16 Dihydrolipoamide acetyltransferase (E2) assay   
 
E2 activity was measured by monitoring the formation of acetyldihydrolipoamide at 232 
nm (Yang et al., 1997).  
The  following  stock  buffers  and  chemicals  were  prepared  for  dihydrolipoamide 
acetyltransferase assay:            
1 M Tris-HCl, pH 7.4 
100 mM acetyl phosphate  
1 mM CoA 
1 mM Dihydrolipoamide 
Preparation  of  dihydrolipoamide  (DHL):  For  preparing  dihydrolipoamide,  lipoamide 
(DL-6,8-thioctic acid amide) (1 g) was dissolved in 25 ml 80% (v/v) methanol and cooled 
on ice. Sodium borohydride (1 g) was dissolved in 5 ml distilled H2O and also cooled on 
ice before adding to the lipoamide solution while stirring on ice. At this stage the mixture 
was  removed  from  ice,  stirred  for  a  further  20  min  at  room  temperature  and  the  pH 
adjusted  to  2.0  with  0.25  M  HCl.  DHL  was  extracted  from  the  solution  by  mixing 
thoroughly with 50 ml chloroform. The mixture was allowed to settle into two phases; the 
bottom  organic  phase  was  decanted  into  another  flask  and  the  chloroform  extraction 
process was repeated 4 times. Chloroform was removed by evaporation using a rotary 
evaporator.  The  resulting  precipitate  was  dissolved  in  a  2.5:  1.0  ratio  of  toluene  and 
heptane and heated to ensure complete re-suspension. The mixture was dried until a small 
volume was left using a rotary evaporator. This was further dried until a white precipitate 
of DHL formed. The precipitate was stored at -20 
 οC. The quality of the DHL was checked 
by assaying E3 activity with increasing amounts of DHL, dissolved in 100% ethanol at a 
concentration of 20 mg/ml (100 mM) until no further increase in the activity was recorded.  Chapter 2  
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The assay was performed at 30 
oC 
 in a total reaction volume of 1 ml in a quartz cuvette 
containing 30 mM Tris-HCl, pH 7.4, 1 mM DHL, 1 mM acetyl phosphate, 20  M CoA and 
2U  phosphotransacetylase. A baseline was established before E2 samples were added. The 
change  in  absorbance  was  measured  over  45  s  using  a  Shimadzu  UV-2101  UV-VIS 
scanning  spectrophotometer  and  recorded  as   A232  min
-1.  E2  activity  is  expressed  as 
change in absorbance/min since the extinction coefficient of the immediate product, 8-
acetyldihydrolipoamide has not been determined accurately. 
 
2.3.17 PDC assay 
 
Enzymatic activity of PDC was determined by  monitoring production of NADH at 340 nm 
(Brown and Perham, 1976). For enzymatic assays of recombinant and native PDC, the 
following solutions were prepared:- 
Solution A  
3 mM NAD
+, 
2 mM MgCl2. 6H2O, 
0.2 mM ThDP  
All the above ingredients were dissolved in approx. 5 ml of 1 M KPi buffer, pH 7.6. After 
dissolving, 70 ml of water was added. The pH of the solution was adjusted to 7.6 with 
KOH and the volume was finally adjusted to 100 ml with dH2O.  
Solution B  
0.13 M Cysteine   HCl 
6.8 mM CoASH (tri-lithium salt) 
The above ingredients were dissolved in 20 ml dH2O.  Chapter 2  
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Solution C 
Pyruvate (100 mM) was dissolved in dH2O.  
For enzymatic assay of PDC, 670 ml of solution A and 14 ml of solution B were added to 
plastic cuvette at 30 °C. To this 14 ml of solution C was added immediately prior to adding 
10-50 ml purified PDC. The solution was mixed rapidly and the change in absorbance at 
340 nm ( A340 nm) was monitored over the first 90 s. 
 
2.3.18 Structure prediction by Swiss modelling 
 
A  preliminary  structure  of  the  E2  outer  lipoyl  domain  and  its  mutant  version  was 
determined based on sequence homology to other resolved protein structures in the Protein 
DATA Bank using SWISS MODEL (Schwede et al., 2003). Then a model of the domain 
was generated using RASMOL 2.6. 
 
2.3.19 Analytical Centrifugation  
2.3.19.1 Calculation of buffer densities and viscosities 
Buffer  densities  and  viscosities  were  calculated  from  the  buffer  composition  using  the 
computer program SEDNTERP (Laue et al., 1992). 
2.3.19.2 Sedimentation velocity  
Sample optical density was in the range of 0.1 to 1. Protein samples (380  l) each present 
in gel filtration buffer (50 mM potassium phosphate, 150 mM NaCl, pH 7.5) were loaded 
into 12 mm path length, charcoal-filled, epon double sector centrepieces. A high speed of 
20k rpm was used to cause rapid sedimentation of solute towards the bottom of the cell. Chapter 2  
 
62 
62 
This high speed produces a depletion of solute near the meniscus and formation of a sharp 
boundary between the depleted region and the uniform concentration of sedimenting solute 
(the plateau) (Fig. 2.1). The rate of movement of this boundary was measured leading to 
the determination of sedimentation coefficients that depend directly on the mass of the 
particles and inversely on the frictional coefficients, which is in turn a measure of effective 
size. A series of scans was collected using interference optics. The data were analysed 
using  the  computer  program  SEDFIT  (Schuck,  2000;  Schuck  et  al.,  2002)  and 
sedimentation coefficients determined. 
 
2.3.20 Circular dichroism (CD) 
 
Circular  dichroism  spectroscopy  measures  differences  in  the  absorption  of  left-handed 
polarized light versus right-handed polarized light which arise due to structural asymmetry. 
For CD studies, proteins were dialysed against 50 mM K2HPO4 buffer, pH 7.5. Circular 
dichroism  experiments  were  performed  at  room  temperature  on  a  Jasco  J-810 
spectropolarimeter  scanning  the  spectra  in  the  far  and  near  uv  regions.  All  circular 
dichroism experiments were performed in collaboration with Dr. S. Kelly IBLS, University 
of Glasgow.  
 
2.2.21 Tryptophan fluorescence 
 
Tryptophan fluorescence is widely used as a tool to monitor changes in protein structure 
and to make inferences regarding local structure and dynamics. Protein samples in 50 mM 
K2HPO4 buffer, pH 7.5 were excited at 295 nm and fluorescence emission spectra were 
recorded  at  320-350  nm  in  a  Perkin  Elmer  LS  50B  spectrophotometer.  All  tryptophan 
fluorescence  experiments  were  carried  out  in  collaboration  with  Dr.  S.  Kelly  IBLS, 
University of Glasgow.  Chapter 2  
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Figure 2.1: Schematic representation of sedimentation of solute in a sedimentation 
velocity experiment  
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Chapter 3 
 
Production and assessment of a 
recombinant human PDC model system  
 
3.1 Introduction 
 
The  pyruvate  dehydrogenase  complex  (PDC)  is  a  nuclear-encoded,  mitochondrial 
multienzyme assembly that provides the primary link between glycolysis and the TCA 
cycle by catalysing the irreversible conversion of pyruvate to acetyl-CoA. Human PDC is 
composed  of  multiple  copies  of  three  distinct  enzymes  E1,  E2  and  E3  and  another 
structural protein termed E3BP. Inborn errors of PDC were initially described about 35 
years ago and are the most common cause of congenital lactic acidosis.  
Over 200 naturally-occurring mutations in this complex have been identified in the human 
population at the genetic level. More than 90% of the cases of PDC deficiency involve 
defects in the E1 enzyme. There have been a small number of deficiencies involving E2 
and E3. In addition, there have been reports of both E3BP and E1 phosphatase defects 
(Patel et al., 1992). Clinical presentation of these mutations is highly variable ranging from 
mild  lactic  acidosis  and  muscular  weakness  to  severe  developmental  and 
neurodegenerative conditions. In most of the cases, mutational analysis is not sufficient to Chapter 3  
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explain  the  clinical  heterogeneity  of  the  PDC  deficiency.  The  clinical  investigation  of 
specific  enzymatic  and  regulatory  defects  in  PDC  is  limited  largely  because  the  main 
clinical  symptom  namely,  lactic  acidosis,  is  common  to  many  other  mitochondrial 
disorders. Analysing mutations using human tissues also poses many challenges; lack of 
access to tissues from individual patients being the main problem owing to the practical 
and ethical issues involved.   
Analysis of these pathological mutations becomes even more important as no systematic 
therapeutic approaches  are  available for treating PDC deficiency. Alternative strategies 
have been utilized to treat the major symptoms but unfortunately, none of the approaches 
have been tested in a systematic fashion and there is no clear evidence of any universally 
effective  therapy.  Early  interventions  included  vitamin  supplementation  and  dietary 
manipulation such as ketogenic diets to provide an alternative source of acetyl–CoA. These 
therapies  do  lower  the  blood  lactate,  but  do  not  dramatically  improve  neurological 
function.  With  the  characterisation  of  PDC  deficiency  at  a  molecular  level,  its 
pathophysiology should become clearer and it should also be possible to evaluate different 
therapeutic approaches more effectively.  
The aim of this study was to produce a recombinant model PDC by overexpressing its 
constituent enzymes in E. coli followed by purification and reconstitution in vitro. This 
could  then  be  used  subsequently  to  conduct  detailed  analysis  of  naturally  occurring 
mutations of particular interest in human PDC. For assembly of recombinant PDC, all the 
human  clones  of  PDC  subunits  were  already  available  in  the  laboratory.  Each  of  the 
individual enzymes i.e. E1, E2:E3BP and E3 were also His-tagged permitting rapid metal-
based affinity  chromatography, leading to high  yields  and routine rapid purification of 
fully-active enzymes. As the His-tag is a small peptide it normally does not affect the 
folding  and  function  of  proteins.  Protease  cleavage  is,  therefore,  usually  not  necessary 
before reconstitution, although it is an option with most modern vectors that normally have 
a specific protease cleavage site engineered into the plasmid. Moreover, this system allows 
anchorage of the protein to resins that have a high binding capacity and also permits the 
study of interactions between proteins in which one of the potential partners is not tagged.  
Another  major  aim  of  this  study  was  to  test  the  validity  and  effectiveness  of  the 
recombinant  PDC  model  to  conduct  in  depth  analyses  of  genetic  defects  in  PDC 
encountered in the human population. Once this ability could be verified successfully, it 
was anticipated that it would be possible to carry out comprehensive evaluation of the Chapter 3  
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underlying molecular basis of PDC malfunction in specific cases of interest. This would be 
invaluable  in  relating  patient  symptoms  to  the  effects  of  specific  mutations  and  in 
developing  improved  therapies  and  treatment  protocols  in  future  for  recently  detected 
mutations. Thus, reconstituted recombinant PDC should provide us with an ideal biological 
tool to mimic many natural mutations and correlate their effects on function/assembly with 
patient symptoms.  
Before the advent of recombinant DNA technology, it was necessary to rely entirely on 
extraction of proteins and enzymes from natural sources, which was often laborious and 
time consuming. It was usually impossible to procure mutant protein samples in the case of 
genetic diseases owing to lack of access to patient tissue. Use of the recombinant model to 
study these defects overcomes many of these challenges and is a non invasive and efficient 
method  for  obtaining  mutant  enzymes  for  further  analysis.  Human  growth  hormone, 
human insulin, follicle stimulating hormone are some of the human recombinants that have 
replaced the original enzymes harvested from animal and human tissues. In addition, there 
are others like erythropoietin granulocyte colony stimulating hormone, alpha-glactosidase 
and alpha-L-iduronidase that are readily available only in recombinant form. Development 
of  a  functional  recombinant  PDC,  a  massive  molecular  machine,  that  is  implicated  in 
various  genetic,  metabolic  and  autoimmune  diseases  like  PDC  deficiency,  diabetes, 
Alzheimer’s  disease  and  primary  biliary  cirrhosis  represents  the  largest  recombinant 
multienzyme system produced to date in E. coli. 
Although genetic defects in PDC are considered to be rare, their frequency of occurrence is 
difficult to estimate owing to the diverse and non-specific pattern of clinical presentation. 
In particular the most common manifestation, the presence of metabolic lactic acidosis to 
varying degrees can be attributed to a wide range of metabolic disorders and is a sign of 
mitochondrial  dysfunction  in  general.  It  is  now  clear  that  its  frequency  has  been 
underestimated in the past and more patients are being diagnosed with PDC deficiencies 
than ever before. In this study, the effects of 3 rare, recently-discovered mutations in the 
E2 enzyme on overall complex function and assembly are investigated with a view to 
obtain a more detailed understanding of its catalytic mechanism, regulation and mode of 
assembly (see Chapter 4).  
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Before  carrying  out  such  an  investigation  and  to  gain  experience  in  developing  and 
handling this reconstituted PDC model system, it was important to test the ability of the 
recombinant  model  in  terms  of  mimicking  such  mutations.  Therefore,  it  was  decided 
initially to test the overall properties of reconstituted wild-type and mutant PDCs carrying 
all  possible  combinations  of  active  and  inactive  lipoyl  domains  and  also  PDC  totally 
lacking the E3BP subunit. This chapter describes reconstitution of recombinant PDC from 
overexpressed and purified E2:E3BP, E1 and E3 and various experiments performed to test 
the validity of this recombinant PDC model. Initially wild-type recombinant PDC and PDC 
lacking E3BP were reconstituted and the effects of adding increased amounts of E3 on the 
overall complex activity were investigated. Mutant PDCs lacking the full complement of 
active lipoyl domains were also generated and a comprehensive evaluation carried out on 
the  effect  of  reduced  lipoylation  on  overall  complex  activity.  In  the  last  section, 
recombinant  wild-type  PDC  and  PDC  lacking  E3BP  have  been  used  to  determine  a 
possible  role  for  E3BP  subunit  in  the  so-called  diacetylation  reaction  that  is  a  unique 
characteristic of mammalian and yeast PDCs. These experiments not only validated the 
usefulness of the recombinant PDC model for subsequent analysis of natural mutations but 
also  generated  interesting  additional  data  on  structure-function  relationships  at  the 
molecular level.   
 
3.2 Post-translational mixing of E2 and E3BP   
 
Initial  experiments  revealed  that  successful  production  of  functional  E2:E3BP  core 
required  co-expression  of  E2  and  E3BP.  Thus  these  two  components  that  are  tightly 
integrated into the ‘core’ assembly do not co-associate if mixed post-translationally. In this 
study,  E2  in  pET-11b  (without  His-tag)  and  E3BP  in  pET-28b  (with  His-tag)  were 
expressed separately in E. coli BL21 (DE3) Star cells at 30 ºC for 5 h. After individual 
expression, bacterial pellets were disrupted by French press treatment (see section 2.3.2) 
and mixed together. The mixed supernatant of both cultures was subjected to zinc chelate 
chromatography (see section 2.3.6). It was observed that only His-tagged E3BP could be 
purified and E2 failed to associate with it post-translationally (Fig. 3.1) and came out in the 
‘flow through’ (data not shown). This was in contrast to a similar purification (see section 
3.3) in which co-transformed E2 and E3BP in the same bacterial host cells were found to Chapter 3  
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co-integrate successfully into a purified oligomeric E2:E3BP assembly. In addition, it was 
found that protein E3BP that has a marked tendency to precipitate when purified alone did 
not precipitate in the latter case, presumably as a direct result of its integration into the 
oligomeric E2 core. 
 
3. 3 Overexpression of E2 and E3BP 
 
E. coli BL21 (DE3) Star cells were transformed with two separate plasmids, pET-11b and 
pET-28b  housing  E2  and  E3BP  respectively  to  obtain  a  functional  60-meric:12-meric 
E2:E3BP core, using double antibiotic selection with ampicillin and kanamycin. Successful 
overexpression  was  achieved  (Fig.  3.2)  after  induction  with  1  mM  isopropyl  β-
thiogalactopyranoside (IPTG). Overexpressions were originally carried out in E. coli BL21 
(DE3), BL21 (DE3) plysS, and BL21 (DE3) Star strains as described in Methods section 
2.3.1 and the latter found to be the most effective. In this expression system, only E3BP 
contained  a  His-tag  and  its  expression  was  limiting  to  ‘core’  assembly  so  that  only 
assembled  E2:E3BP  ‘core’  was  purified  with  E2  being  present  by  virtue  of  its  stable 
association with His-tagged E3BP. E3BP has been shown to be tightly associated with the 
E2 core assembly and in contrast to E1 and E3, cannot be dissociated even by treatment 
with high salt or high pH. Chaotrophic agents such as p-hydroxymercuriphenylsulfonate or 
5 M urea are required to dissociate E3BP from the E2 core (De Marcucci and Lindsay, 
1985); however, such treatment also promotes general dissociation of the core assembly 
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Figure 3.1: E2 and E3BP do not integrate into a core on post-translational mixing 
 
E2 and E3BP were separately overexpressed at 30 ºC for 5 h (lanes 3 and 5, respectively). 
SDS-PAGE  analysis  on  a  4-12%  Bis-Tris  gel  shows  that  only  His-tagged  E3BP  was 
purified  on  zinc  chelate  chromatography  (lane  6),  indicating  that  on  post-translational 
mixing the two subunits do not associate to form a native core assembly. Molecular weight 
markers (Mw) are in lane 1. 
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Figure 3.2: Overexpression of E2:E3BP core 
 
SDS-PAGE  analysis  on  a  4-12%  Bis-Tris  gel  showing  overexpression  of  wild-type 
E2:E3BP core at 15 ºC in E. coli BL21 (DE3) Star cells at zero time (T0) and 15 h post 
induction (T15). Molecular weight markers (Mw) are in lane 1.  
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3.4 Purification of E2:E3BP 
 
E2:E3BP  core  assembly  was  purified  by  zinc  chelate  chromatography  as  described  in 
Methods section 2.3.6. In this system only E3BP was His-tagged and E2 was co-purified 
owing  to  its  stable  interaction  with  E3BP.  After  initial  isolation,  the  core  was  further 
purified by gel filtration in GFC buffer (50 mM KH2PO4, 150 mM NaCl, pH 7.5) using a 
Sephacryl HiPrep S-300 High Resolution column attached to a BioCAD 700E workstation. 
The high Mr core was stored at -20 °C in 50% (v/v) glycerol until further use. Interestingly, 
it was observed that excess E3BP produced from this plasmid that was not integrated into 
core could be separated by gel filtration (Fig. 3.3 A). The integrated core eluted at the void 
volume as expected, but excess E3BP eluted later with an elution volume corresponding to 
a Mr value of 100,000 consistent with its presence as a dimeric species (Fig. 3.3 A & B). 
 
3.5 Lipoylation of E2:E3BP core 
 
Interestingly, the essential covalent modification of human E2 and E3BP lipoyl domains, 
namely  insertion  of  the  lipoic  acid  co-factor,  can  be  achieved  in  E.  coli.  This  is 
accomplished  through  the  action  of  its  endogenous  bacterial  lipoyl  ligase.  The  two 
peripherally located lipoyl domains of E2 (present in tandem repeat at its N-terminus) and 
the single lipoyl domain of E3BP (also with a similar N-terminal location), both require the 
covalent  attachment  of  the  lipoic  acid  moiety  to  a  specific  lysine  residue  within  these 
domains that is situated at the exposed tip of a type 1 β-turn. Complete lipoylation was 
ensured by addition of exogenous lipoic acid (0.1 mM) to the medium during induction of 
heterologous protein synthesis and checked by employing PD2 (patient derived hybridoma 
IgG)  monoclonal  antibody  that  recognises  only  the  lipoylated  forms  of  E2  and  E3BP 
exclusively (Thomson et al., 1998). Successful lipoylation of E2:E3BP core was found to 
be  occurring  on  Western  blotting  with  PD2  antibody  (Fig.  3.4)  confirming  that  the 
heterologous human lipoyl domain is recognised by the bacterial lipoylation machinery. 
Initially it was thought that E. coli lipoyl ligase was capable of recognising a specific DKA Chapter 3  
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motif present on the lipoyl domains of E2 and E3BP. Later, however, it was demonstrated 
that  it  was  primarily  a  precise  structural  cue  that  was  recognised  by  the  lipoylating 
machinery  of  the  cell  as  opposed  to  a  conserved  sequence  motif  (Wallis  and  Perham, 
1994).  
 
3.6 Solubility of E2:E3BP core 
 
Checking the solubility of recombinantly produced oligomeric cores prior to purification is 
an  important  step  in  their  characterisation  as  the  presence  of  soluble  protein  generally  
suggests  that  they  are  capable  of  folding  into  their  native  or  near  native  state  in  the 
bacterial host and in addition that the N-terminal His-tag has not adversely affected folding 
or expression. Bacterial cells containing overexpressed E2:E3BP core were disrupted by 
French press treatment to permit the release of soluble protein into the supernatant fraction 
and insoluble cellular debris was removed by centrifugation. To achieve optimal solubility 
and  production  of  the  E2:E3BP  core,  it  was  initially  overexpressed  at  different 
temperatures after induction with IPTG. In one set, expression was induced at 30 °C for 4-
5 h with 1 mM IPTG and in a second set at 37 °C for 3 h. In the third set, overexpression 
was induced with 1 mM IPTG at 22 °C for 5-6 h while a similar induction was also carried 
at 15 ºC overnight for 18 h with 0.5 mM IPTG. All the overexpressions were studied using 
E. coli BL21 (DE3) Star cells. Although, E2:E3BP could be expressed successfully at all 
temperatures, on solubility checking, it was found to be most soluble when expressed at 15 
°C  (Fig.  3.5).  Therefore,  E2:E3BP  core  was  overexpressed  at  this  temperature  in 
subsequent experiments in E. coli BL21 (DE3) Star cells. 
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Figure 3.3: His-tag purification and gel filtration of E2:E3BP core  
 
(A) His-tagged E2:E3BP core, purified by zinc chelate chromatography was gel filtered 
through a Sephacryl HiPrep S-300 High Resolution column attached to a BioCAD 700E 
workstation.  (B)  On  SDS-PAGE  analysis,  the  peak  eluting  at  the  void  volume 
corresponded to E2:E3BP core (lane 2) and the second peak to excess E3BP (lane 4) not 
bound to the core. Molecular weight markers (Mw) are in lanes 1 and 3. 
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Figure 3.4: Western blot analysis of the wild-type E2:E3BP core with PD2 antibody  
 
Panel A shows SDS-PAGE analysis of E2:E3BP core prior to Western blot analysis (panel 
B)  with  PD2  antibody.  The  blot  shows  that  the  core  was  lipoylated  as  PD2  antibody 
recognises only lipoylated subunits of PDC (Thomson et al., 1998). 
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Figure 3.5: Solubility checking of wild-type E2:E3BP core overexpressed at various 
temperatures 
 
E2:E3BP core was overexpressed at 15 °C, 22 °C, 30 °C and 37 °C in E. coli BL21 (DE3) 
Star cells. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows that at 30 °C, 37 °C and 22 
°C, E2:E3BP was largely insoluble and present mainly in the pellet samples (PS) (lanes 4, 
7 and 10 respectively) and not in supernatant samples (SS) (lanes 3, 6 and 9 respectively). 
When expressed at 15 ºC overnight, the core assembly was soluble and present in the 
supernatant sample (SS) (lane 12) and not in the pellet sample (PS) (lane 13). Whole cell 
extracts (WE) in lanes 2, 5, 8 and 11, respectively. Molecular weight markers (Mw) are in 
lane 1. 
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3.7 Overexpression of E3 
 
E. coli BL21 (DE3) plysS cells were transformed with E3 cDNA housed in the pET-14b 
vector. Overexpression was induced by the addition of 0.1mM IPTG at 22 °C and viewed 
by  SDS-PAGE  analysis  (Fig.  3.6).  E3  was  overexpressed  at  this  temperature  in  all 
experiments unless stated otherwise.  
 
3.8 Overexpression of E1 
 
Co-expression  of  the  α  and  ß  subunits  of  E1  was  first  successfully  achieved  in  the 
laboratory by co-transformation of E. coli with two separate plasmids, pET- 28b for E1α  
and pET-141b for E1ß using double antibiotic selection with ampicillin and kanamycin. 
However, difficulties were experienced in reconstituting active, soluble hetero-tetrameric 
human E1, although high levels of expression of both subunits were readily attained. This 
problem was finally overcome by Dr. Alison Prior, who subcloned the genes for both E1α  
and E1 ß from pET-28b and pET-11b respectively into a modified pQE-9 vector system to 
permit their co-expression from a single plasmid in E. coli M15 cells. These cells contain a 
kanamycin-resistant plasmid, pREP4 which encodes the lac repressor encoded by the lacI 
gene. The levels of expression in this vector system were relatively low, but were sufficient 
to  produce  2-3  mg  of  E1  protein  on  a  routine  basis  (Fig.  3.7)  from  2-3  l  of  culture. 
Overexpression was induced by 1 mM IPTG at 18 ºC overnight.  
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 Figure 3.6: Overexpression of E3 
 
Overexpression of the E3 enzyme was carried out in E. coli BL21 (DE3) plysS cells at 22 
°C. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows expression levels at zero time (T0) 
and after 5 h of induction (T5). Molecular weight markers (Mw) are in lane 1. 
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Figure 3.7 Overexpression of co-transformed E1a a a a and E1b b b b subunits  
 
E1α and E1 β were co-expressed in E. coli M15 cells at 18 °C overnight. SDS-PAGE 
analysis on a 12% Bis-Tris gel shows samples at zero time (T0) and 15 h after induction 
(T15). Molecular weight markers (Mw) are in lane 1.  
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3.9 E3 purification  
 
E3 was purified by zinc chelate chromatography (see section 2.3.6). Purified fractions were 
gel filtered using GFC buffer (50 mM KH2PO4, pH 7.5, 150 mM NaCl) prior to SDS-
PAGE analysis for checking the purity of pooled fractions (Fig. 3.8). The enzyme was 
stored at 4 ºC until required. 
 
3.10 E1 purification  
 
E1 was purified by the protocol described in the Methods section 2.3.7. Attempts to dialyse 
purified  E1  resulted  in  precipitation  of  the  enzyme.  Therefore,  purified  fractions  were 
concentrated in a Centricon concentrator with a ‘cut off’ size of 100 kDa with addition of 
excess Buffer A (50 mM KH2PO4 , 1 M NaCl, 0.5 mM imidazole, pH 8), to lower the 
concentration of imidazole. SDS-PAGE analysis was performed to check its purity (Fig. 
3.8). Purified enzyme was stored at -20 ºC in 50 % (v/v) glycerol. 
 
3.11 Reconstitution of recombinant PDC 
 
For reconstituting recombinant PDC from its constituent enzymes, the concentration of 
each purified enzyme was measured using its extinction co-efficient (see Methods section 
2.3.10). Then enzymes were mixed together in stoichiometric amounts i.e. for each  mole 
of E2:E3BP core, 12  mole E3 and 30  mole E1 were added at room temperature. After 
mixing  the  individual  components,  reconstituted  PDC  was  immediately  assayed. Chapter 3  
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Recombinant  PDC  was  found  to  assemble  spontaneously  from  its  constituent  enzymes 
within a 2 min preincubation period when they were mixed in the equivalent ratios to those 
found  in  the  native  complex.  PDC  activity  was  measured  using  standard 
spectrophotometric  assay  techniques  (see  Methods  section  2.3.17)  in  which  NADH 
production was monitored spectrophotometrically at 340 nm in the presence of pyruvate as 
substrate.  Reconstituted  recombinant  PDC  appeared  to  be  fully  active  and  displayed  a 
similar specific activity (3.5-4  mol NADH min 
–1 mg protein
–1 ) to reported values for the 
native, wild-type complex isolated from human heart (Palmer et al., 1993). 
 Chapter 3  
 
81 
81 
 
 
 
                                             
                                            
Figure 3.8: Reconstitution of PDC from individual components  
 
SDS-PAGE  analysis  on  a  4-12%  Bis-Tris  gel  shows  PDC  (lane  1)  reconstituted  from 
stoichiometric  amounts  of  purified  E1  (lane  2),  E3  (lane  3)  and  E2:E3BP  (lane  4). 
Molecular weight markers (Mw) are in lane 5.  
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3.12 Effect of increasing amounts of E3 on wild-type PDC 
activity 
 
Recombinant human PDC assembled spontaneously from its constituent enzymes within a 
2 min preincubation period when they were mixed in the equivalent ratio as the native 
complex  i.e.  in  stoichiometric  amounts.  This  reconstituted  recombinant  human  PDC 
appeared to be fully active and displayed a similar specific activity to PDC purified from 
human tissue. These initial studies confirmed that the individual components of PDC retain 
their  capability  to  interact  with  each  other  in  the  recombinant  model  and  mimic  the 
functional  abilities  of  the  native  complex.  Recombinant  PDC  was  reconstituted  as 
described in section 3.11 of this Chapter. Enzymatic assay of wild-type recombinant PDC 
in the presence of excess amounts of purified E3 (up to 200-fold) was performed using the 
spectrophotometric  method  described  in  Methods  section  2.3.17.  With  the  addition  of 
increasing amounts of E3, there was a slight but significant decline (20-25%) in overall 
PDC  activity  as  shown  in  Fig.  3.9.  The  decline  in  activity  is  probably  caused  by 
displacement of the rate-limiting E1 enzyme from its binding site on E2 by excess E3 
confirming earlier observations (McCartney et al., 1997) that E3 displays a residual affinity 
for E2.  
 
3.13 Effect of increasing amounts of E3 on the activity of 
PDC lacking E3BP 
 
Recombinant PDC was reconstituted by adding stoichiometric amounts of E1 and E3 to 
recombinant E2 core produced in the absence E3BP. Activity assays were performed in the 
same way as for native PDC. Recombinant PDC lacking E3BP displayed little activity (3-
8%) with stoichiometric amounts of E1 and E3. However, overall activity rose gradually 
with increasing E3 with activity levels reaching approx. 50% of wild-type values with a Chapter 3  
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200-fold  excess  of  this  component  (Fig.  3.9).  These  results  were  in  agreement  with 
previous  studies  on  the  native  bovine  complex  (McCartney  et  al.,  1997)  and  again 
suggested that the partial activity of PDC detected in the total absence of E3BP stems from 
the ability of E3 to interact with the E1 binding site on E2 with low affinity.  Chapter 3  
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Figure 3.9: Effect of increasing amounts of E3 on the activity of recombinant wild-
type PDC and recombinant PDC devoid of E3BP  
 
A decline in the activity of native PDC is observed with increasing amounts of added E3 
(blue) whereas there is a marked increase in the activity of recombinant PDC (without 
E3BP) with increasing amounts of E3 (red). Added E3 ranges from stoichiometric amounts 
to a 200-fold excess. 
                                 Fold excess of E3 Chapter 3  
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3.14  Effect  of  differing  combinations  of  active  and 
inactive lipoyl domains in E2:E3BP core on overall PDC 
activity 
 
The lipoyl group is attached in amide linkage to the N
6-amino group of a lysine residue 
located on an exposed type-1 b turn within lipoyl domains. It is a highly specific post-
translational modification carried out by an ATP-dependent lipoate protein ligase (Morris 
et al., 1994). A major advantage of producing recombinant human E2 components of PDC, 
in E. coli is that the bacterial ligase is capable of inserting exogenous lipoic acid onto the 
key lysine of a variety of heterologous lipoyl domains. The apodomains can be lipoylated 
in vitro also with partially purified E. coli lipoate protein ligase (Quinn et al., 1993). This 
ligase is also responsible for the octanoylation of lipoyl domains in the absence of lipoic 
acid or when there is excessive production of apodomains (Ali et al., 1990; Dardel et al., 
1990; Quinn et al., 1993). While overexpressing wild-type and mutant E2 and E2:E3BP 
cores, exogenous lipoic acid was added to ensure complete lipoylation. The effects of loss 
of lipoylation of recombinant E2 and E3BP lipoyl domains and its effect on overall activity 
was assessed in this study.  
A series of mutant E2:E3BP cores was created lacking the full complement of active lipoyl 
domains.  In  these  mutant  cores,  lipoylation  was  prevented  by  selectively  altering  the 
lipoylatable  lysine  to  glutamine  in  individual  domains,  thereby  preventing  co-factor 
insertion. As discussed earlier also, the lipoyl domains play a crucial role in coupling the 
activities of the three enzyme components of PDC by providing ‘swinging arms’ that are 
mobile  and  responsible  for  substrate  transfer  among  the  three  successive  active  sites 
(Fussey  et  al.,  1991;  Yeaman  et  al.,  1978).  Thus,  eight  distinct  ‘cores’  containing  all 
possible combinations and numbers of active/ inactive E2/E3BP lipoyl domains namely 
++/+,  ++/-,  +-/+,  +-/-,  -+/+,  -+/-,  --/+  and  --/-  were  constructed  using  site-directed 
mutagenesis. A schematic representation of these cores is depicted in Fig. 3.10. 
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Figure 3.10: Schematic representation of eight wild-type and mutant constructs of 
E2:E3BP cores 
 
Representation shows either lipoylated (green) or non-lipoylated domain (black); E2 outer 
lipoyl domain (OD), E2 inner lipoyl domain (ID) and E3BP lipoyl domain (XD) in eight 
E2:E3BP cores generated to determine the effect of lipoylation status on overall complex 
activity.  
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The ‘+’ represents wild-type lipoylated domain in E2:E3BP core, whereas, ‘-’is a mutant 
lipoyl  domain  created  in  the  core  by  lysine  to  glutamine  replacement  employing  site-
directed mutagenesis (Methods section 2.2.11). The appropriate mutants were created by 
A.  S.  Stephanou,  University  of  Glasgow,  by  designing  and  using  mutagenic  primers 
described in Materials and Methods, section 2.1.3. In all the constructs, wild-type, K46Q, 
K175Q and K46Q:K175Q E2 were contained in the pET-11b vector exhibiting ampicillin 
resistance  whereas  wild-type  and  K44Q  E3BP  were  housed  in  pET-28b  displaying 
kanamycin resistance. After checking for the correct mutations by DNA sequencing, wild-
type and mutant E2 and E3BP constructs were co-transformed into E. coli BL21 (DE3) 
Star cells in eight different combinations as shown in Fig. 3.10. Co-transformed cells were 
induced to overexpress at 30 ºC in LB medium with 1 mM IPTG and with the addition of 
0.1  mM  lipoic  acid.  Wild-type  and  mutant  cores  were  isolated  by  zinc  chelate 
chromatography as described in Methods section 2.3.6 and subsequently gel filtered as 
described in Methods section 2.3.12. SDS-PAGE analysis was conducted to check their 
purity (Fig. 3.11). 
Western  blot  analysis  of  these  eight  wild-type  and  mutant  ‘cores’  with  PD2  antibody 
revealed varying degrees of lipoylation in which the wild-type core displayed a strong E2 
signal whereas cores with either a single  active inner or outer lipoyl domain displayed less 
cross-reactivity.  Mutant  E2  core  with  both  inner  and  outer  lipoyl  domains  inactive 
exhibited no signal with E2. Active E3BP lipoyl domain in mutant and wild-type cores 
also gave a signal, although weak as compared to lipoylated E2 domains. Complete loss of 
signal indicating no lipoylation was observed when all the lipoyl domains were rendered 
inactive in E2 as well as E3BP (Fig. 3.11).  
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Figure 3.11: SDS-PAGE and Western blot analysis of wild-type and mutant E2:E3BP 
cores by PD2 antibody 
 
 SDS-PAGE (1A) and Western blot analysis with PD2 antibody (1B) of ++/+, -+/+ and +-
/+ E2:E3BP cores in lanes 1, 2 and 3 respectively. SDS-PAGE (2A) and Western blot 
analysis with PD2 antibody (2B) of --/+, ++/-, -+/-, +-/- and --/- E2:E3BP cores in lanes 4, 
5, 6, 7 and 8 respectively. The ‘+’ represents wild-type lipoylated domain in E2:E3BP 
core, whereas, ‘-’ is a mutant non-lipoylated domain. 
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To  investigate  the  effect  of  the  differing  combinations  of  active  and  inactive  lipoyl 
domains on overall PDC activity, eight sets of recombinant PDCs were reconstituted from 
the various wild-type and mutant cores by adding stoichiometric amounts of E1 and E3 
employing the protocol described in section 3.11. Equal amounts of wild-type and mutant 
PDCs were assayed in duplicate as described in Methods 2.3.17 and the activity compared 
to the wild-type PDC as control (100% activity). Mutant PDCs were found to sustain high 
levels of activity (65-75%) with approx. half of their full complement of lipoyl domains 
(only inner or outer lipoyl domain active on E2). Moreover, the presence or absence of a 
functional lipoyl domain on E3BP had no additional significant effect on activity with E2s 
possessing  either  one  or  two  active  lipoyl  domains  (Fig.  3.12).  Interestingly,  however, 
PDC  with  only  E3BP-linked  active  lipoyl  domain  retained  approx.  15%  of  wild-type 
activity while total loss of activity required non-lipoylation of all 3 domains. Chapter 3  
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Figure 3.12: Effect of differing combinations of active and inactive lipoyl domains on 
recombinant PDC activity 
  
Histogram  corresponds  to  enzymatic  activity  of  recombinant  PDCs  with  the  following 
types of E2:E3BP cores: 1 ++/+, 2 ++/-, 3 +-/+, 4 +-/-, 5 -+/+, 6 -+/-, 7 --/+ and 8 --/-. The 
‘+’ represents wild-type lipoylated domain in E2:E3BP core whereas, ‘-’ is a mutant non-
lipoylated domain. Samples were assayed in duplicate and error bars indicate extent of 
variation between duplicates. 
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3.15 Discussion  
 
Recombinant PDC could be successfully reconstituted from purified E2:E3BP, E1 and E3. 
Its enzymatic function was fully restored indicating that all the enzymes were correctly 
folded. It displayed a specific activity (3.5-4  mol NADH min 
–1 mg protein
–1 ) similar to 
PDC  purified  from  human  heart  (Palmer  et  al.,  1993).  Interaction  between  the  three 
components was further tested in an assay where increasing amounts of E3 were added to 
the recombinant PDC. With the addition of increasing E3, overall complex activity was 
found to decrease gradually, presumably due to partial displacement of the E1 enzyme by 
excess  E3.  This  result  was  consistent  with  surface  plasmon  resonance  measurements 
performed by Dr. Susan Richards in our laboratory (unpublished data). In this study the 
affinity of E3BP for E3 was found to be approx. 100-fold higher (Kd value of 5.31 x 10
-9 
M) than for the equivalent E2-E3 interaction (Kd value 3.39 x 10
-7 M) confirming that the 
E1 binding site on E2 retains a residual affinity for E3. This residual affinity for E3 has 
also been reported previously (McCartney et al., 1997). Interestingly, it is reminiscent of 
the situation in B. stearothermophilus PDC, where E1 and E3 must compete for a single 
binding site on E2 and are capable of displacing each other (Lessard et al., 1996).     
When increased amounts of E3 were added to recombinant PDC lacking the E3BP subunit 
and overall complex activity monitored, it was found that the activity gradually rose to 
approx. 50% of wild-type activity levels in the presence of a 100-200 fold E3 excess. 
These data are also compatible with the presence of a low affinity binding site for E3 on 
the  E2  core  assembly  that  is  able  to  partially  substitute  for  the  E3BP-located  subunit 
binding domain in the absence of the latter subunit.  
All these  findings are  also in agreement  with the previous surprising identification (in 
collaboration  with  French  colleagues)  of  PDC  deficient  patients  with  metabolic  lactic 
acidosis who totally lack E3BP. These patients possess a partially active PDC (10-20% of 
wild-type) as compared to the control group (Geoffroy et al., 1996; Marsac et al., 1997) 
again indicating that even in vivo the E2 subunit provides a weak secondary E3 binding 
site. However in this genetic defect, E3 is not stably integrated into the mutant complex Chapter 3  
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which functions much less efficiently under these conditions. In summary, these studies 
highlighted  the  partial  functional  redundancy  of  the  E3BP  subunits,  while  also 
demonstrating that E2 and E3BP display both overlapping and distinct functions. Analysis 
of E3BP deficient PDC, both in vitro and in vivo, has contributed to a better understanding 
of the  role of E3BP subunit and has provided  a rational basis  for  conducting prenatal 
diagnosis for possible E3BP deficiency in affected families (Marsac et al., 1993).  
The effect of differing combinations of active and inactive lipoyl domains of E2:E3BP 
core on lipoylation status was also studied using a series of 8 mutant PDCs. On Western 
blotting with PD2 antibody, it was seen that mAb cross-reactivity was at a maximum when 
all  the  lipoyl  domains  were  fully  functional  and  gradually  declined  with  the  loss  of 
lipoylatable domains on E2 and E3BP. Overall complex activity also declined gradually 
with the loss of functional lipoyl domains. However, inactivation of inner or outer lipoyl 
domains on E2 caused minor reduction in overall complex activity indicating considerable 
redundancy at this level. Thus reducing the complement of lipoyl domains by approx. 50% 
led to a 25-35% loss of activity. Moreover, introduction of E3BP with a non-functional 
lipoyl domain had no further significant effect on activity in comparison to wild-type PDC 
or in the case of mutants carrying an inactive outer or inner lipoyl domain on E2. Finally, 
PDC in which only the 12 lipoyl domains of E3BP were lipoylated also retained partial 
activity (15%) and only complete loss of lipoylation led to complete inhibition. 
This study represents the first systematic investigation of the effects of alterations in the 
lipoylation  status  of  the  E2:E3BP  core  on  mammalian  PDC  complex  activity.  The 
enzymatic  activity  results  were  found  to  be  consistent  with  the  lipoylation  status  as 
determined by Western blotting. The observation that recombinant PDC displayed 15% 
activity with only E3BP containing active lipoyl domains (12 out of a possible 132/108) is 
in agreement with the results of Rahmtullah and co-workers (Rahmatullah et al., 1990) and 
Sanderson and co-workers (Sanderson et al., 1996a) where 10-15 % activity is retained 
with the proteolytical removal of lipoyl domains of E2 on  collagenase  treatment. This 
suggested that E3BP-linked domains can substitute to some extent for the lipoyl domains 
of E2 in overall complex catalysis. These data also demonstrated considerable functional 
redundancy  at  this  level  that  is  genetically  advantageous  as  null  mutations  producing 
totally inactive PDC would be expected to be embryonically lethal. Interestingly, this study 
is the first in mammalian PDC in which the correctly folded E2 and E3BP domains have 
been  retained  in  a  non-functional  state.  Previous  studies  have  employed  genetically 
engineered or proteolytically modified E2:E3BP core assemblies, where the entire domain Chapter 3  
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is absent, potentially allowing greater flexibility and improved access to catalytic sites for 
the remaining active domains. Our data, however, tend to confirm and extend these earlier 
studies and indicate that inner and outer lipoyl domains of E2 or the single E3BP lipoyl 
domain  are  all  effective  substrates  for  E1,  E2  and  E3  and  that  there  is  no  obvious 
preferential recognition of individual domains by these enzymes. In addition, the presence 
of a full complement of domains in which a high proportion is inactive does not produce 
any apparent steric hindrance effects.  
 
3.16 Study on involvement of E3BP in diacetylation  
 
In  PDC,  acetyl  group  transfer  occurs  after  the  initial  decarboxylation  step,  which  is 
catalysed  by  E1  with  the  production  of  CO2  and  an  enzyme-bound  hydroxyethylidene 
thiamine diphosphate derivative. There is then E1-mediated reductive acetylation of the 
lipoamide  cofactor  attached  to  E2  and  /or  E3BP  leading  to  formation  of  a  S
8-acetyl 
intermediate. Subsequently acetyl groups migrate between the S
6 and S
8 positions (Koike 
and Koike, 1976). In the final step, E3 re-oxidises E2 and E3BP linked lipoamide cofactors 
followed by reduction of NAD
+
.
 
It  is  a  unique  property  of  mammalian  PDC  to  be  able  to  generate  a  S
6,  S
8  diacetyl–
dihydrolipoamide intermediate on addition of either pyruvate in the absence of CoASH or 
NADH and acetyl CoA. Treatment of PDC with pyruvate or NADH and acetyl CoA leads 
to rapid initial generation of a S
8–acetyldihydrolipoamide intermediate and exchange of 
acetyl groups between S
6 and S
8 sulphur atoms on the dithiolane ring. The formation of the 
S
6, S
8 diacetyl–dihydrolipoamide intermediate by mammalian PDC was initially detected 
by 
13C-NMR spectroscopy (O'Connor et al., 1982). 
This property does not require the presence of E2 lipoyl domains as the capacity of E3BP 
lipoamide thiols to undergo the diacetylation reaction is shown to be unaffected by the 
removal  of  E2  lipoyl  domains  in  collagenase-modified  PDC  complex  (which  causes 
selective removal of lipoyl domains of E2). This was shown by studies on 
14C–acetylation 
in bovine heart PDC, where the single lipoyl domain of E3BP was shown to be capable of 
diacetylation  (Sanderson  et  al.,  1996b).  Moreover,  collagenase-treated  PDC  possessed Chapter 3  
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residual activity (about 15%), indicating that protein-E3BP-linked lipoamide groups could 
substitute for the lipoyl domains of E2 in overall complex catalysis. 
Interestingly, the ability to catalyse diacetylation is absent in the bacterial PDC complex 
and so is the E3BP subunit. However, it has been demonstrated in bovine and S. cerevisiae 
PDC complexes, where the E3BP polypeptide  has been well characterised (Hodgson et al., 
1986). The equivalent phenomenon is also absent in the OGDC complex where transfer of 
a succinyl group occurs and a single S
6 or S
8 succinyl-dihydrolipoamide intermediate is 
formed.  Therefore,  it  was  suspected  that  formation  of  the  diacetyl  dihydrolipoamide 
intermediate  could  be  uniquely  mediated  through  E3BP.  This  reaction  might  be  of 
physiological relevance to permit PDC to act as a reservoir for acetyl groups and electrons 
under conditions of excess acetyl CoA and NADH production, e.g. on high fat diets or in 
abnormal states such as starvation and diabetes. In these conditions, each molecule of PDC 
could  bind  a  maximum  of  264  acetyl  groups  (assuming  a  60E2:12E3BP  core)  and  an 
equivalent  number  of  electrons,  thereby  providing  a  safe  buffer  against  production  of 
ketone bodies and regulate the formation of NADH. If indeed E3BP is involved uniquely 
in  diacetylation,  then  it  could  be  of  great  physiological  importance.  The  cell  lines  of 
patients deficient in E3BP were of considerable interest in this regard (Marsac et al., 1993). 
In  this  study,  reconstituted  recombinant  PDC  provided  an  important  tool  to  study  this 
potential enzymatic and physiological role of E3BP as no specific catalytic function for 
E3BP has been revealed to date.   
It has been shown that the E2 component of E. coli PDC can be inactivated selectively by 
maleimides in the presence of pyruvate or NADH (Brown and Perham, 1976; Danson and 
Perham, 1976). The E2-bound lipoyl moieties become reductively acetylated or reduced 
and  the  corresponding  intermediates  react  with  NEM  when  there  are  free  thiol  groups 
present leading to inactivation of the complex. Hodgson et al. (1986) also showed that the 
presence of NADH or pyruvate promoted incorporation of NEM into E2 as well as E3BP 
components.  
On the addition of NADH and acetyl CoA to PDC, however, it has been shown that the 
complex is rapidly protected once again from inhibition by NEM. Hodgson et al. (1986) 
also demonstrated that the group incorporating NEM in E3BP was in all respects similar to 
the lipoyl groups on the E2 subunit. Chapter 3  
 
95 
95 
The extent of protection against NEM inhibition, was found to be greater as the time of 
preincubation  was  increased  (Cate  et  al.,  1980)  and  formation  of  a  S
6,  S
8  diacetyl–
dihydrolipoamide intermediate under these conditions was identified.  
To elucidate whether addition of a second acetyl group to the S-acetyldihydrolipoamide 
intermediate is a unique catalytic function of E3BP, a recombinant PDC was reconstituted 
from purified E1, E2, a molar excess of E3 and devoid of E3BP. As discussed earlier, 
reconstituted PDC complex in the absence of E3BP shows limited activity (3-8%) as E3 is 
not stably integrated into the complex in these conditions. Native bovine PDC extracted as 
per the protocol described by De Marcucci and co-workers (De Marcucci et al., 1988) was 
used as a control in this experiment.  
Four conditions were tested using recombinant PDC (without E3BP) and native PDC (Fig. 
3.13). In the first reaction, native as well as recombinant PDC (devoid of E3BP) were 
incubated with 0.2 mM NADH and 1 mM NEM. In the second reaction instead of NADH, 
0.2 mM NAD
+ was added followed by addition of 1 mM NEM. In the third reaction, native 
as well as recombinant PDC (devoid of E3BP) were incubated with 0.2 mM NADH and 
0.4 mM AcCoA followed by incubation with 1 mM NEM. In the fourth reaction, both the 
complexes  were  treated  with  NAD,  AcCoA  and  NEM  as  before.  In  all  the  reaction 
mixtures, 50 mM DTT was added to quench excess NEM. After 10 min NEM treatment, 
activity assays of all the individual complexes (100 ml) were performed as described in 
Methods section 2.3.17.  Chapter 3  
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Figure 3.13: Recombinant PDC devoid of E3BP is protected from inhibition by NEM 
due to formation of diacetylated dihydrolipoamide groups  
Native bovine PDC and recombinant PDC reconstituted from stoichiometric amounts of 
E2, E1 and a 200-fold excess of E3, were individually incubated with following chemicals 
for the stated times and conditions before the enzymatic assays were carried out . 
1 PDC + 0.2 mM NADH (10 min) + 1 mM NEM (10 min) + 50 mM DTT (10 min).                        
2 PDC + 0.2 mM NAD
+ (10 min) + 1 mM NEM (10 min) + 50 mM DTT (10 min). 
3 PDC + 0.2 mM NADH (10 min) + 0.4 mM AcCoA (10 min) + 1 mM NEM (10 min) + 
50 mM DTT (10 min). 
4 PDC + 0.2 mM NAD
+ (10 min) + 0.4 mM AcCoA (10 min) +1 mM NEM (10 min) + 50 
mM DTT (10 min). 
Bars  represent  percentage  activity  of  native  (purple)  and  recombinant  (blue)  PDC 
complexes in above four conditions. Samples were assayed in duplicate and error bars 
indicate extent of variation between duplicates. Native PDC (100 mg) and recombinant 
PDC (200 mg) were employed for each analysis to account for the large molar excess of E3 
in the recombinant PDC. Activity of native bovine PDC was taken as 100% control. 
 
           
          Recombinant PDC devoid of E3BP 
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3.17 Results and discussion on diacetylation of E3BP 
 
In the first reaction, native and recombinant PDC were monitored and incubated with NEM 
in the presence NADH; the activities were found to be inhibited in both the complexes 
(Fig. 3.13). This was in agreement with the previous studies (Brown and Perham, 1976; 
Danson  and  Perham,  1976)  where  NADH  was  shown  to  cause  reduction  of  lipoamide 
groups on E2 and E3BP, facilitating incorporation of NEM and thus inhibiting overall PDC 
function.  
When the same reaction was carried out in the presence of NAD
+, instead of  NADH, 
reduction of lipoamide groups did not take place as anticipated and no loss of activity was 
observed in both PDC complexes (Fig. 3.13). Similar results have been reported in earlier 
studies with bovine PDC (Hodgson et al., 1986).  
In the third reaction, on the addition of acetyl CoA in combination with NADH to both 
these PDC cores, incubation with NEM did not cause inhibition of the activities of either 
complex. One explanation for this restored activity of PDC has been given by Hodgson et 
al. (1986). Preincubation of PDC with NADH and AcCoA leads to formation of a S
6, S
8 –
diacetyl-dihydrolipoamide intermediate that is not amenable to modification by NEM and 
the activity of the complex is retained. The presence of this activity in the recombinant 
complex lacking the E3BP subunit, demonstrates that E3BP is not uniquely involved in 
diacetylation. Similar results were obtained in the fourth reaction, where instead of NADH, 
NAD
+ was added as a control. It was seen earlier that with the addition of NEM in the 
presence  of  NAD
+,  PDC  activity  was  maintained  as  anticipated.  These  reactions 
demonstrate  that  the  recombinant  model  of  PDC  can  be  used  to  determine  potential 
physiological roles of individual components.  
The tight association of protein E3BP with E2 core prevents the detailed analysis of its 
functional involvement in the complex. Specific deletion of the region encoding subunit 
binding domain of E3BP in S. cervisiae PDC showed loss of high-affinity binding of E3 
and  concomitant  loss  of  overall  activity  (Lawson  et  al.,  1991).  Moreover,  collagenase Chapter 3  
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treatment of native PDC complex provided information about the substitutional catalytical 
role of E3BP linked lipoamide groups for E2 lipoyl domains (Rahmatullah et al., 1990). 
Earlier 
14C- acetylation studies in bovine heart PDC showed that lipoyl domains of E3BP 
are capable of E2 type reactions including diacetylation (Hodgson et al., 1986). Production 
of a versatile recombinant PDC model is another step towards understanding the structural 
and functional roles of E3BP under normal and disease conditions.    
In  this  study,  a  potential  role  of  E3BP  in  promoting  diacetylation  of  E2  enzyme  was 
investigated. This phenomenon could be responsible for giving PDC a unique role as a 
metabolic  ‘reservoir’  harbouring  excess  electrons  and  acetyl  groups  under  abnormal 
physiological conditions. However, the diacetylation phenomenon was still found to occur 
in recombinant PDC devoid of E3BP. As this process appears to be exclusive to yeast and 
mammalian PDCs, it is presumably a characteristic property of the eukaryotic E2 enzyme. Chapter 4  
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Chapter 4 
 
Analysis of naturally occurring mutations 
in human PDC  
 
4.1 Introduction 
 
This  chapter  focuses  on  the  investigation  and  analysis  of  three  recently-discovered 
mutations in the 60-meric E2 enzyme of PDC that lead to clinical manifestation of PDC 
deficiency by unknown mechanisms. Clinical presentation and progression of this disorder 
is highly variable. An abnormal lactate build-up results in non-specific symptoms (e.g., 
severe lethargy, poor feeding, tachypnea), especially during times of illness, stress, or high 
carbohydrate  intake.  A  number  of  acquired  conditions  including  infections,  severe 
catabolic  states,  tissue  anoxia,  dehydration  and  poisoning  can  give  rise  to  hyperlactic 
acidaemia. All these causes should be ruled out before considering inborn errors of PDC 
metabolism. When the lactate / pyruvate ratio is normal or low, PDC deficiency is highly 
probable (Poggi-Travert et al., 1996).  
The  definitive  diagnosis  of  PDC  deficiency  is  usually  established  by  enzyme  assay  in 
patients’  cells  or  tissues  commonly  by  measuring 
14CO2  production  from 
14C-labelled 
pyruvate  with  subsequent  confirmation  of  the  basic  defect  by  Western  blotting  with 
antibodies against subunits of the complex and /or by direct cDNA or genomic sequencing 
(Eschbach et al., 1987; Old and De Vivo, 1989; Otero et al., 1998). Detection of mutations Chapter 4  
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in  the  E1α  gene  using  reverse  transcription  of  total  RNA,  polymerase  chain  reaction 
amplification  of  the  coding  region  of  the  gene  and  single-strand  conformation 
polymorphism (SSCP) analyses have been found to be rapid and efficient approaches in 
the detection of gene defects (Matsuda et al., 1995). SSCP is the electrophoretic separation 
of single-stranded nucleic acids based on subtle differences in sequence (often a single 
base pair) which results in a different secondary structure and a measurable difference in 
mobility through a gel.  
 The  mutations  in  this  study  were  discovered  for  the  first  time  at  the  Oxford  Medical 
School by Dr. Garry Brown and his colleagues, where the patients are currently under 
clinical investigation. The mutations were detected by employing patients’ white blood 
cells to derive mRNA to prepare the relevant cDNA as a template for subsequent DNA 
sequencing.  Two  of  these  mutations  are  homozygous  unusual  ‘in-frame’  3  base  pair 
deletions in E2. One mutation is in the outer lipoyl domain of E2 leading to the deletion of 
glutamate 35 whereas the second mutation causes the loss of valine at position 455 that is 
located in the C-terminal domain. The third mutation leads to substitution of leucine for a 
phenylalanine at position 490 near the active site of E2. The main objective of this study 
was to evaluate the potential of our model recombinant PDC system for analysing newly- 
discovered genetic defects of this type. This evaluation should not only test the usefulness 
of this recombinant PDC model, but also lead to a detailed understanding of the precise 
basis of the molecular defects underlying the malfunctioning of the PDC complex in these 
patients.  Another  important  aim  was  to  correlate  the  findings  with  the  severity  of  the 
clinical phenotype, methods of treatment and disease prognosis. These mutations could be 
producing  a  clinical  phenotype  by  affecting  a  variety  of  properties  of  PDC  including 
enzymatic function, enzyme-enzyme cooperativity, cofactor insertion, protein folding and 
complex assembly or stability. A description of the results achieved on detailed analysis of 
these three mutations is presented in this chapter. Chapter 4  
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4.2 Valine- 455 deletion in the E2 enzyme of PDC 
 
This case study was characterised by deletion of a highly conserved valine at position 455 
in the catalytic region of the E2 enzyme. A patient presented at Oxford Medical School 
with clinical symptoms corresponding to PDC deficiency. On clinical investigation, no 
detectable levels of E3BP were found. E2 levels were also found to be reduced, although 
this could represent partial loss of an epitope leading to loss of E2 recognition by the anti-
E2  monoclonal  antibody.  A  detailed  analysis  of  E3BP  DNA  was  carried  out  for  the 
presence of any mutation; however, genomic and cDNA for E3BP was found to be free of 
mutations. This led to further analysis of E2  genomic DNA with the  discovery of the 
absence of a 3 base pair sequence encoding a highly conserved valine at position 455. 
Interestingly, the patient was found to be heterozygous for this mutation at the genomic 
level; however, at the cDNA level only the mutant transcript was detected and the genetic 
basis  for  the  absence  of  mRNA  corresponding  to  the  normal  allele  is  still  under 
investigation (unpublished data). As this deletion is in the C-terminal region, it had the 
potential to disrupt E2 core assembly or its interaction with E3BP. In previous studies also, 
mutations  in  one  enzyme  subunit  have  been  found  to  promote  concomitant  loss  of  its 
binding partner. Thus, in the E1 enzyme of PDC, amino acids at positions 88, 263 and 382-
387 were found to be essential for the linking of the alpha subunit with the beta subunit 
and for the activity of the holoenzyme (Marsac et al., 1997). In this study, these mutations 
in the gene for E1a caused depletion in the levels of not only E1a, but also of E1b.  
E3BP does not normally have an independent existence and it was postulated that the E2-
located  valine  deletion  may  affect  integration  of  E3BP  into  the  native  core  assembly. 
Therefore,  examining  whether  or  not  the  absence  of  E3BP  protein  was  a  secondary 
phenomenon induced by the E2-linked valine 455 deletion was the main focus of this 
study.  
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4.2.1  Creating  the  ∆V455  mutation  in  the  E2  enzyme  by  site-
directed mutagenesis 
 
To mimic this mutation, standard site-directed mutagenesis was performed as discussed in 
Methods (section 2.2.11) using full length E2 cDNA housed in pET-14b as well as a non 
His-tagged version housed in pET-11b for co-expression with E3BP (housed in pET-28b). 
Mutagenic primers as described in Materials & Methods section 2.1.3 were used in both 
constructs. The insertion of the correct mutation was checked by DNA sequencing. 
 
4.2.2 Overexpression and purification of the ∆V455 E2 enzyme 
 
E2-pET-14b was transformed into E. coli BL21 (DE3) Star cells and overexpressed at 30 
ºC for 4-5 h. Overexpression was checked by SDS-PAGE analysis (Fig. 4.1). Mutant E2 
was purified in the same way as the wild-type using zinc metal chelate chromatography 
and  gel  filtration.  Purified  fractions  were  analysed  by  SDS-PAGE  (Fig.  4.2).  Purified 
mutant enzyme was subsequently used for comparing its acetyltransferase activity with 
wild-type E2 as described in section 4.2.4.  
 
4.2.3  Checking  assembly  of  the  ∆V455  E2:E3BP  core  by 
overexpression and purification 
 
The purification protocol for the co-expressed E2:E3BP ‘core’ relies on capturing E2 only 
when it is tightly bound to His-tagged E3BP so if E3BP failed to integrate correctly, the 
mutant  E2  subunit  will  either  be  completely  absent  in  purified  E3BP  preparations  or 
present in reduced amounts. A failed association of mutant E2 and E3BP was predicted as 
a possible outcome resulting from this mutation. Clinical evaluation had also indicated the Chapter 4  
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absence  of  E3BP,  possibly  due  to  non  integration,  leading  to  its  subsequent  rapid 
degradation.  
To test this hypothesis, wild-type and  V455 E2 pET-11b constructs were co-transformed 
respectively, with the E3BP pET-28b construct. Both wild-type and mutant E2:E3BP cores 
were overexpressed and purified in the same way as previously described for the wild-type 
E2:E3BP  core  (Chapter  3,  sections  3.3  &  3.4)  The  mutant  core  was  also  found  to  be 
associating properly and the subunit composition of wild-type and mutant cores appeared 
very  similar  as  judged  by  SDS-PAGE  analysis  (Fig.  4.3).  The  same  experiment  was 
repeated  by  overexpressing  wild-type  and  mutant  cores  at  37  ºC  i.e.  normal  body 
temperature  to  determine  whether  the  mutation  was  temperature  sensitive.  However, 
similar results were obtained compared to the experiment carried out at 30 ºC (data not 
shown).  Chapter 4  
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Figure 4.1 Overexpression of wild-type, ∆V455 and F490L E2 enzymes 
 
SDS-PAGE analysis of overexpression of wild-type (lane 3), F490L (lane 5) and  V455 
(lane  7)  recombinant  E2  enzymes  on  a  4-12%  Bis-Tris  gel.  The  overexpressions  were 
carried out in E. coli BL21 (DE3) Star cells at 30 ºC for 4-5 h and are shown at zero time 
(T0) and 5 h after induction (T5). Molecular weight markers (Mw) are in lane 1. See section 
4.3.2 for further analysis of the F490L mutation. 
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Figure 4.2: Purification of wild-type, ∆V455 and F490L E2 enzymes 
 
SDS-PAGE analysis of purified  V455 (lanes 1 & 2), F490L (lane 3) and wild-type (lane 
4) E2 enzymes on a 4-12% Bis-Tris gel. Wild-type and mutant enzymes were purified by 
zinc chelate chromatography. Molecular weight markers (Mw) are in lane 5.  
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Figure 4.3: Integration of E3BP with E2 in ∆V455 and wild-type E2:E3BP cores 
 
(A) Gel filtration profile of the  V455 E2:E3BP core showing a single peak eluting at the 
void volume. Prior to gel filtration on a HiPrep 16/60 Sephacryl S-300 High Resolution 
column  attached  to  a  BioCAD  700E  workstation,  the  His-tagged  E2:E3BP  core  was 
purified by zinc metal chelate chromatography.  
(B) SDS-PAGE analysis of  gel filtered wild-type and  V455 E2: E3BP cores on a 4-12% 
Bis-Tris  gel  shows  that  E3BP  is  integrated  into  the   V455  E2  core  (lane  3)  and  was 
comparable to wild-type E2:E3BP core (lane 2). Molecular weight markers (Mw) are in 
lane 1. 
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4.2.4 Enzymatic activities of the ∆V455 E2 enzyme, E2:E3BP core 
and reconstituted PDC 
 
The acetyltransferase activities of the wild-type and  V455 E2 recombinant enzymes were 
determined according to the protocol described in Methods section 2.3.16. The enzymatic 
activity of the mutant E2 was approx. 50% of wild-type, taken as 100% control (Fig. 4.4 
A).  Similarly,  the  acetyltransferase  activities  of  recombinant  wild-type  and  mutant 
E2:E3BP cores were determined to check whether the presence of E3BP led to retention of 
normal activity. However, the activity of the mutant core was again found to be low as 
compared to the wild-type E2:E3BP core (Fig. 4.4 B). In the next step, wild-type and 
recombinant PDCs were reconstituted from purified recombinant PDC components and 
enzymatic  activities  determined  as  described  in  Methods  section  2.3.17.  The  overall 
activity of the mutant complex was also reduced to approx. 50% as compared to wild-type 
complex (Fig. 4.4 C). All enzymatic assays were performed in duplicate and equal amounts 
of enzymes used in each experiment.  
 
4.2.5 Western blot analysis of the wild-type and ∆V455 E2: E3BP 
cores 
 
Purified wild-type and  V455 E2:E3BP recombinant cores were subjected to Bradford 
assays  and  equal  amounts  were  used  to  perform  Western  blotting  with  a  monoclonal 
antibody (PD2) that recognises only lipoylated components of PDC. 
The  ability  of  the   V455  E2:E3BP  core  to  undergo  lipoylation  was  not  lost  and  was 
comparable to wild-type core as determined by Western blotting (Fig. 4.5).  Chapter 4  
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Figure 4.4: Comparison of enzymatic activities of the wild-type and D D D DV455 E2 
recombinant enzymes, E2:E3BP cores and PDCs 
 
Panels A & B show the reduced acetyltransferase activities of the mutant E2 and E2:E3BP 
cores a as compared to the wild-type E2 and the core. In panel C, wild-type and mutant 
PDCs were reconstituted from individual components and enzymatic activities compared. 
The activity of the mutant PDC is reduced as compared to the wild-type. All samples were 
assayed in duplicate and error bars shown where necessary.  
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Figure 4.5: Western blot analysis of wild-type and ∆V455 E2:E3BP cores 
  
(A) SDS-PAGE analysis of wild- type (lane 2) and  V455 E2:E3BP (lane 3) cores on  a 4-
12%  Bis-Tris  gel.  Equal  amounts  of  protein  were  loaded  prior  to  Western  blotting. 
Molecular weight markers (Mw) are in lane 1. 
(B) Western blot analysis of wild-type and   V455 E2:E3BP cores with PD2 antibody 
shows  that  mutant  core  (panel  B,  lane  2)  was  also  lipoylated  and  lipoylation  was 
comparable to wild-type E2:E3BP core (panel B, lane 1).  
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4.2.6 Far uv and fluorescence emission spectra of the wild-type 
and ∆V455 E2:E3BP cores  
 
Purified and gel filtered recombinant wild-type and  V455 E2:E3BP cores, dialysed in 50 
mM KH2PO4 buffer, were subjected to far uv spectrophotometry in the 190 to 260 nm 
range as described in Methods section 2.3.20. At these wavelengths the chromophore is the 
peptide  bond.  Alpha-helix,  beta-sheet  and  random  coil  structures  each  give  rise  to  a 
characteristic shape and magnitude of CD spectrum. The CD profile shown in Fig. 4.6 
suggested that there was no major change in the structure of the mutant core as its overall 
line-shape is the same as for wild-type. It was not possible to determine the alpha helix and 
beta sheet content as the data were not of good quality below 200 nm. 
A potential change in structure was also studied using intrinsic tryptophan fluorescence as 
described  in  Methods  section  2.3.21.  No  shift  in  the  wavelength  of  the  fluorescence 
emission spectrum was observed in the mutant core and the result was comparable to wild-
type E2:E3BP (Fig. 4.7).  Chapter 4  
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Figure 4.6: Far uv CD spectra of wild-type and D D D DV455 E2:E3BP cores 
 
Wild-type and DV455 E2:E3BP cores were subjected to circular dichroism analysis and 
spectra recorded in the far uv region (190-260 nm). The CD signal was measured as molar 
ellipticity in degrees cm
2 dmol
-1 (Y-axis) as a function of wavelength (X-axis).   
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Figure 4.7: Fluorescence emission spectra of the wild-type and D D D DV455 E2:E3BP cores 
 
Wild-type and DV455 E2:E3BP cores were excited with uv light of wavelength 295 nm. 
Fluorescence  emission  (in  arbitrary  units)  was  recorded  over  a  range  of  310-420  nm. 
Maximum emission of fluorescence occurred at 330 nm for wild-type as well as for the 
DV455 E2:E3BP core.  
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4.2.7 Comparison of sedimentation coefficients of the wild-type 
and D D D DV455 E2: E3BP cores 
 
Sedimentation velocity is an analytical ultracentrifugation method that measures the rate at 
which molecules move in response to centrifugal force. This sedimentation rate provides 
information about both the molecular mass and the shape of molecules. Sedimentation 
velocity experiments were performed as described in Methods section 2.3.19.2 to obtain 
more information on the assembly of the DV455 E2:E3BP core as compared to the wild-
type core. For sedimentation velocity experiments, wild-type and mutant E2:E3BP cores 
were co-expressed, purified (see sections 3.3 & 3.4), gel filtered (Methods section 2.3.12) 
and SDS-PAGE analysis performed to check the purity of the cores. No proteolysis or 
degradation was evident from SDS-PAGE analysis (Fig. 4.8 E). The sample concentrations 
were 3.33, 1.07 and 1.00  M for the wild-type and 3.17, 3.45 and 0.88  M for the mutant. 
Samples (380  l) were loaded into 12 mm double sector centrepieces and data recorded  at 
4 ºC at a rotor speed of 20,000 rpm using interference optics. A series of 360 scans, 60 s 
apart  was  taken  for  each  sample.  Sedimentation  coefficients  were  determined  using 
SEDFIT  (Schuck,  2000).  The  weight  average  s4,w    values  were  corrected  to  s20,w.  The 
weight average sedimentation coefficient, s20,w for the wild-type core was determined as 
30.61+ 0.36 S (Fig. 4.8 A). The reported value of human E2:E3BP core is 32 S (Hiromasa 
et al., 2004). Behal et. al. (1994) reported sedimentation coefficients of 30 and 32 S for 
native E2:E3BP core at A280 = 0.25 and 0.5 respectively. They also observed sedimentation 
coefficient heterogeneity with increasing concentration. The weight average sedimentation 
coefficient, S20,w for the mutant cores was determined as 28.89 + 0.0 S (Fig. 4.8 C), slightly 
lower  than  for  its  wild-type  equivalent.  The  mutant  core  also  appeared  to  be  more 
heterogenous than the wild-type indicating that there might be a degree of perturbation in 
its structure. However, this difference could also be caused by sample variability as only 
one sample preparation was analysed due to time constraints. More rigorous analysis of 
several mutant preparations would be necessary to confirm a significant difference.   
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Figure 4.8: Comparison of the sedimentation velocity analyses of the wild-type and 
D D D DV450 E2: E3BP cores 
 
c(s) distribution from SV interference data for 3.33  M (
____ ) , 1.07  M (
____) and 1.00  M 
(
___) wild-type E2:E3BP core (Fig. A) and distribution of the same after maximising c(s) to 
the peak observed at 30.40 S (Fig. B). c(s) distribution from SV interference data for 3.17 
 M(
___),  3.45   M  (
___)  and  0.88   M  (
___)  DV450  E2:E3BP  core  (Fig.  C)  and  c(s) 
distribution of the same after maximising c(s) to the peak observed at 28.89 S (Fig. D). 
SDS-PAGE analysis of the wild-type and mutant cores used in SV experiment (Fig. E).  
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4.2.8 Discussion of the effects of valine-455 deletion on the E2 
enzyme of PDC 
 
Our PDC model was employed here to study the influence of a specific valine deletion (val 
455) in the catalytic region of the E2 enzyme. This deletion was encountered in a patient 
with no detectable E3BP and reduced levels of E2. Therefore, it was anticipated that this 
deletion  could  be  disrupting  the  formation  of  the  E2:E3BP  core  with  the  subsequent 
degradation of E3BP. Such disruption has also been observed in patients with a defect in 
the E1α component leading to severe concomitant depletion of E1β (Saijo et al., 1996) 
presumably induced by an impaired ability to form heterotetrameric E1. However, no large 
scale disruption was detected in the recombinant mutant core and integration of E3BP 
appeared normal at both 30 ºC and 37 ºC (Fig. 4.3). Moreover, lipoylation of the E2:E3BP 
domains was not affected as predicted since this mutation is located in the C-terminal 
domain away from N-terminal lipoyl domains (Fig. 4.5). No major changes in secondary or 
tertiary  structure  were  detected  as  determined  by  far  uv  spectrophotometry  and 
fluorescence emission spectroscopy (Fig. 4.6 & Fig. 4.7) also suggesting that there was no 
gross  perturbation  of  the  E2:E3BP  core  assembly.  A  degree  of  heterogeneity  of 
sedimentation coefficient was observed as compared to wild-type core (Fig. 4.8) although 
there was insufficient time to investigate the reproducibility of this phenomenon. 
However, this mutation did result in an overall reduction of PDC activity. The loss of 
activity was found in the mutant E2 enzyme, E2:E3BP core and at PDC level also (Figs. 
4.4 A, B & C). This could be due to partial disruption of the catalytic function of the E2 
enzyme.  Indeed  the  deleted  valine  455  is  in  the  C-terminal  region  that  houses  the 
acetyltransferase active site. Resolution of the structure of the E2 of A. vinelandii showed 
two  highly  conserved  residues-a  histidine  and  an  aspartic  acid  implicated  in  catalysis 
(Mattevi et al., 1993c). A third important residue His-610 in A. vinelandii  E2 PDC was 
also confirmed to play a catalytic role (Mattevi et al., 1993a). A conserved sequence motif, 
DHRXXDG, is thought to accommodate the histidine and aspartate necessary for catalysis 
(Radford et al., 1987). The valine residue deletion currently under investigation, is located 
76 amino acids before the conserved sequence motif in human E2. Chapter 4  
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Defects in the E2 enzyme of PDC were reported for the first time by (Robinson et al., 
1990) with clinical symptoms comprising reduced PDC activity and lactic acidaemia. Only 
two other mutations in E2 have been recently reported (Brown et al., 2004).   
In this analysis, it was seen that a stable E2:E3BP core was forming as assessed by AUC 
(Fig.  4.8).  Possible  structural  alterations  in  the  E2:E3BP  core  were  evident  from  the 
heterogeneity  of  the  peak  of  the  mutant  as  compared  to  the  wild-type  core  on 
sedimentation  analysis.  However,  no  major  changes  were  detectable  by  far  uv  CD 
spectrophotometry and tryptophan fluorescence. In addition, there was significant loss of 
mutant PDC activity as compared to the wild-type PDC (Fig. 4.4 C). Substantial residual 
activity was retained in the mutant recombinant complex which was comparable to the 
patient’s  PDC  activity  as  measured  by  CO2  release  assay  (unpublished  data,  personal 
communication, G. Brown). As the E2 enzyme is the structural and functional centre of the 
PDC, its complete disruption is unlikely since it is required to sustain foetal development. 
Our data in this case could not readily be reconciled with the patient’s situation, because 
this mutation seemed to cause disruption of E2:E3BP core with reduced amounts of E2 and 
complete absence of E3BP in the patient. Interestingly, the genomic DNA analysis carried 
out by Dr. Garry Brown and colleagues detected no abnormality in E3BP genomic DNA. 
Moreover, the patient appears to produce mRNA exclusively from the mutant E2 allele. A 
complete re-evaluation of the patient’s enzymatic, immunological and genetic status with 
regard to PDC deficiency is currently in progress.  
Another  similar  type  of  case  has  been  reported  recently,  where  a  patient  displayed  a 
clinical  phenotype  consistent  with  PDC  deficiency  (Dahl  et  al.,  1992).  Cultured  skin 
fibroblasts from this patient demonstrated 55% reduction in PDC activity and markedly 
decreased  immunoreactivity  for  the  E1b.  Surprisingly  there  were  no  pathological 
mutations  in  PDHA  and  PDHB  genes  coding  for  E1a  and  E1b  subunits,  respectively. 
However, PDC activity could be restored in cells from this patient and normal levels of 
E1b detected following treatment with MG132, a specific proteasomal inhibitor and with 
tryphostin  23,  a  specific  inhibitor  of  epidermal  growth  factor  receptor  protein  tyrosine 
kinase (EGFR-PTK). This study proposed that high basal levels of EGFR-PTK activity led 
to ubiquitination of cellular proteins. However, in this study it was unclear that why only 
E1b  protein  was  prone  to  this  process  in  the  absence  of  any  mutations  and  how 
mitochondrial proteins gained access to proteasomes located in the cytosolic and nuclear 
compartments.  Chapter 4  
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In our study, the reduced levels of E2 and loss of E3BP in the patient could be due to 
enhanced  degradation  where  E2  harbours  a  potentially  pathological  mutation  and  as  a 
result E3BP may  also remain unbound to E2 leading to their  reduced  levels. No such 
degradation could be observed employing our recombinant PDC model produced in E. coli 
where there is no equivalent proteasomal machinery and no translocation or processing of 
precursor polypeptides is required; hence, the defective mature protein may also assemble 
to form a core structure under these conditions.  
Indeed the data in this study suggest that although there may be some minor structural 
changes in the E2:E3BP core and there is an overall reduction in enzymatic activity the 
core has not failed to assemble in E. coli. However, this may not be the case in human cells 
where  mutant  or  partially–misfolded  proteins  may  be  more  readily  recognised  and 
degraded leading to a more obvious phenotype.   
 
4.3 Phenylalanine–490 to leucine mutation  
 
This case study was characterised by substitution of phenylalanine- 490 by leucine in the 
catalytic region of the E2 enzyme. A male patient born to first cousins presented at Oxford 
Medical  School  with  clinical  symptoms  mainly  of  episodic  dystonia,  but  also  with 
significant developmental delay. Development was normal until 11 months of age but, 
after that there were episodes of arching of the body, stiffening of the limbs with flexion of 
wrists,  eye-rolling  and  distress.  Developmental  progress  slowed  down,  paroxysmal 
dystonia  continued  and  at  the  age  of  eight  years  the  patient  was  wheelchair  bound. 
Dystonia,  either  as  a  main  clinical  feature  or  in  combination  with  other  neurological 
manifestations, is increasingly being recognized in patients with PDC deficiency (Brown et 
al., 2004; Lissens et al., 1996). The lactate concentration in both blood and cerebro-spinal 
fluid in the patient was normal. Neuropathology of PDC deficient patients has been found 
to  be  quite  variable.  In  this  patient,  localised  neuroradiological  findings  revealed 
circumscribed lesions restricted to the globus pallidus bilaterally. However, this finding 
and other clinical symptoms were also not distinctive and consistent with features of PDC 
deficiency. Therefore, diagnosis alone on clinical symptoms and biochemical tests was not 
enough and prompted more detailed investigations.  Chapter 4  
 
118 
118 
Various other conditions were ruled out before this mutation was diagnosed by using the 
patient’s  mRNA  to  prepare  the  relevant  cDNA  as  a  template  for  subsequent  DNA 
sequencing by Dr. Garry Brown and his colleagues. They further found an approx. 50% 
decline in PDC activity in crude fibroblast extracts by the radiolabelled CO2 release assay. 
This  assay  is  not  particularly  accurate  as  the  extent  of  inhibition  is  difficult  to  assess 
precisely  since  normal  (wild-type)  levels  of  PDC  activity  vary  over  a  2-fold  range  in 
individual patients. Moreover, from this assay alone, it was not clear whether the decline in 
activity  was  caused  by  loss  of  E2  activity  per  se  or  as  an  indirect  effect  caused  by 
disruption in E2 interaction with E3BP or alterations in the core assembly. Therefore, the 
focus of this study was to determine if this represented a straightforward case of reduced 
enzymatic activity of E2 resulting from alterations in a residue that may be involved in the 
catalytic mechanism. Changes in structure and assembly of the E2:E3BP core were also 
assessed in the following experiments. 
 
4.3.1  Creating  the  F490L  mutation  in  the  E2  enzyme  by  site-
directed mutagenesis 
 
To mimic this mutation, site-directed mutagenesis was performed by preparing and using 
appropriate primers described in Materials & Methods section 2.1.3. Standard site-directed 
mutagenesis was performed as discussed in Methods section 2.2.11 using full length E2 
cDNA housed in pET-14b and also in pET-11b for co-expression with E3BP in pET- 28b. 
The presence of the correct mutation was checked by DNA sequencing.  Chapter 4  
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4.3.2 Overexpression and purification of the F490L E2 enzyme 
 
E2 pET-14b was transformed into E. coli BL21 (DE3) Star cells and overexpressed at 30 
ºC for 4-5 h. Overexpressions were analysed by SDS-PAGE (Fig. 4.1). Mutant E2 enzyme 
was purified in the same way as wild-type using zinc chelate chromatography and gel 
filtration. To check the purity of the proteins, SDS-PAGE analysis of purified fractions 
was performed (Fig. 4.2). Purified mutant enzyme was subsequently used for comparing 
acetyltransferase activity with the wild-type E2 as described in section 4.3.4.  
 
4.3.3  Checking  integration  of  the  F490L  E2:E3BP  core  by 
overexpression and purification  
 
F490L E2-pET-11b was co-expressed with the E3BP pET-28b construct at 15 ºC. Mutated 
and wild-type E2:E3BP cores were purified in the same way as wild-type core described in 
Chapter 3, section 3.4. The core was not found to be disrupted by the presence of the 
F490L mutation, as was evident from zinc chelate chromatography and gel filtration. In 
this case also, E2 was found to interact stably with E3BP and the integrated core could be 
purified owing to the presence of the N-terminal His-tag on E3BP (Fig. 4.9).   
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 Figure 4.9: Integration of E3BP with E2 in F490L mutation   
 
SDS-PAGE analysis of purified wild-type and F490L E2:E3BP cores on a 4-12% Bis-Tris 
gel. The presence of E2 in the F490L core shows that E3BP is integrated into E2 (lane 3) 
and was comparable to wild-type E2:E3BP core (lane 2). Molecular weight markers (Mw) 
are in lane 1. 
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4.3.4 Enzymatic activities of the F490L E2 enzyme, E2:E3BP core 
and PDC 
 
The acetyltransferase activities of the recombinant wild-type and F490L E2 enzymes were 
determined using the protocol described in Methods section 2.3.16. The activity of the 
mutant E2 was found to be approx. 50% of native E2 taken as 100% control (Fig. 4.10 A). 
Similarly, the acetyltransferase activity of the wild-type and F490L E2:E3BP cores were 
determined using the same protocol. The activity of the mutant core was also found to be 
low as compared to wild-type E2:E3BP core (Fig. 4.10 B). Wild-type and mutant PDCs 
were reconstituted as per the protocol described in Chapter 3 (see section 3.10). Enzymatic 
activity was determined as described in the Methods section (2.3.17). The overall activity 
of the F490L PDC was found to be reduced by approx. 30% as compared to wild-type 
complex (Fig. 4.10 C).   
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Figure 4.10: Comparison of the enzymatic activities of recombinant wild-type and 
F490L E2 enzyme, E2:E3BP core and PDC 
 
Panels A & B show the reduced acetyltransferase activities of the mutant E2 and E2:E3BP 
cores are as compared to the wild-type E2 and core. In Panel C, wild-type and mutant PDC 
were  reconstituted  from  individual  components  and  enzymatic  activities  compared. 
Activity  of  the  mutant  PDC  is  also  reduced  compared  to  wild-type.  All  samples  were 
assayed in duplicate and error bars shown where necessary. 
Wild- type E2 
Wild type PDC 
F490L E2:E3BP    Wild-type E2:E3BP 
          F490L PDC 
           A 
 
  B 
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          F490L E2 Chapter 4  
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4.3.5 Far uv and fluorescence emission spectra of the wild-type 
and F490L E2:E3BP cores  
 
The secondary structure of the mutant core was estimated using far uv spectrophotometry 
in the far uv spectral region (190-250 nm) as described in Methods section 2.3.20. The data 
were not of good quality in the 190-200 nm region (not shown) and therefore percentage of 
alpha  helices  and  beta  sheets  could  not  be  estimated.  However,  the  line  shapes  of  the 
spectra in the 200-280 nm region were similar overall for the mutant as well as wild–type 
core. This indicated that there were no major changes in the secondary structure of the 
mutant core as compared with the wild-type core (Fig. 4.11).  
Change  in  structure  was  also  studied  using  tryptophan  fluorescence  as  described  in 
Methods section 2.3.21. However, no shift in the spectral emission peak (330 nm) was 
observed between the mutant and the wild-type E2:E3BP cores (Fig. 4.12). This suggested 
that there was no perturbation of the local environment in the region occupied by the six 
tryptophan residues located in the E2:E3BP core. 
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Figure 4.11: Far uv CD spectra of the wild-type and F490L E2:E3BP core 
 
Wild-type and F490L E2:E3BP cores were subjected to circular dichroism and spectra 
recorded  in  the  far  uv  region  (190-260  nm).  The  CD  signal  was  measured  as  molar 
ellipticity in degrees cm
2 dmol
-1 (Y- axis) plotted as a function of wavelength (X -axis).   
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Figure 4.12: Fluorescence emission spectra of wild-type and F490L E2:E3BP cores  
 
Wild-type and F490L E2:E3BP cores were excited with uv light of wavelength 295 nm. 
Emission of fluorescence was recorded over a range of 310-420 nm. The figure shows that 
the maximum emission of fluorescence occurred at 330 nm wavelength for wild-type and 
F490L E2:E3BP cores.  
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4.3.6 Discussion of phenylalanine–490 to leucine mutation 
 
This mutation was found to cause reduced PDC activity and various clinical symptoms in a 
patient  (Brown  et  al.,  2004).  Our  data  provided  an  explanation  for  the  functional 
consequences  of  this  deletion.  The  E2:E3BP  core  appeared  to  be  integrating  stably  as 
evidenced from zinc chelate chromatography, gel filtration (Fig. 4.9), circular dichroism 
(Fig. 4.11) and tryptophan fluorescence studies (Fig. 4.12). However, there was loss of 
enzymatic activity in mutant E2, E2:E3BP core and recombinant PDC (Figs. 4.10 A, B & 
C). Earlier also, this mutation was shown to be responsible for reduced PDC activity by 
functional  complementation  in  which  activity  was  restored  by  transfecting  normal  E2 
cDNA into patient’s fibroblasts (Brown et al., 2004). However, in that study full activity 
could  not  be  restored.  Demonstration  of  loss  of  acetyltransferase  activity  using  a 
recombinant model of PDC not only substantiated the functional complementation study 
but also provided more definitive diagnosis. The recombinant mutant PDC in this study 
lost about 50% enzymatic activity as compared to the normal or wild-type PDC. Thus, this 
mutation appears to be the reason for the loss of PDC activity in the patient also.  
This  mutated  phenylalanine  residue  is  highly  conserved  across  various  eukaryotic  and 
prokaryotic  species  and  is  reported  to  be  responsible  for  substrate  specificity  in  E2 
(Mattevi  et  al.,  1993b)  thus  replacement  of  the  phenylalanine  by  the  smaller  leucine 
residue could potentially affect acetyltransferase activity. In the corresponding position in 
the E2 enzyme of BCOADC, this position is occupied by serine, and it is proposed that the 
larger phenylalanine limits access to the active site to the smaller acetyl group substrate of 
E2-PDC (Mattevi et al., 1993c). Another plausible explanation could be that the catalytic 
activity is affected as this mutation is located 42 amino acids from the conserved motif, 
DHRXXXDG that is important for E2 catalytic activity and could potentially perturb the 
local environment in this active site region. Substantial residual enzymatic activity was 
retained, however, in agreement with PDC activity measurements on patient fibroblasts 
employing the CO2 release assay. Thus it is apparent that this mutation does not cause 
large-scale changes in the assembly of the ‘core’ that might have caused more severe loss 
of PDC function. In general all of these data are consistent with the F490L mutation having 
a direct affect on E2 activity and the underlying catalytic mechanism. Chapter 4  
 
127 
127 
  
4.4 Glutamate 35 deletion in the E2 enzyme  
 
In this section the role of the glutamate 35 deletion in the outer lipoyl domain of the E2 
enzyme in a young patient was investigated. The patient was a male born at term to first 
cousins. He was in a good mental condition and the main clinical features were ataxia and 
dystonia, which developed at an early stage. He was introduced to a ketogenic diet that 
significantly  resolved  the  symptoms.  However,  residual  problems  in  fine-motor 
coordination still persisted at the age of 11 years. As ataxia and dystonia are increasingly 
being noted in PDC deficient patients, this led to a check for any abnormalities in genes 
encoding PDC subunits leading to discovery of this mutation.  
On sequencing cDNA derived from patient’s white blood cells, a highly conserved 3 base 
pair sequence encoding glutamate 35 in the outer lipoyl domain of the E2 enzyme was 
found to be missing. The involvement of this deletion in promoting reduced PDC activity 
was determined by functional complementation by expressing normal E2 in the patient’s 
fibroblasts. However, many questions remained unanswered as to how this mutation could 
lead  to  PDC  deficiency  since  it  affected  only  one  lipoyl  domain  out  of  three  in  the 
E2:E3BP core. In previous studies, the presence of all E2-linked lipoyl domains were not 
found to be necessary for maximal E. coli PDC activity in vitro (Fussey et al., 1988). 
However, isogenic E. coli strains with three active lipoyl domains outgrew those with just 
one or two indicating that the loss of lipoyl domains does reduce PDC efficiency in vivo 
(Fussey et al., 1988). In this case study, however, there was about 70% reduction in PDC 
activity, as determined by CO2 release assay. This drastic loss of activity could not be 
readily accounted for solely by potential loss of lipoylation in the outer lipoyl domain 
since, there are an additional 72 inner and E3BP lipoyl domains in PDC, that should  be 
unaffected. Our own data in this thesis in Chapter 3 (see section 3.14, Fig. 3.12) also 
suggest that loss of lipoylation of the outer  domain in E2-PDC only causes 25-30% loss of 
enzymatic  activity.  Therefore,  the  main  aim  of  this  study  was  to  determine  how  this 
mutation induced such a substantial decline in overall PDC activity.  
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4.4.1  Creating  the  E35D,  E35Q  and  ∆E35  mutants  of  the  outer 
lipoyl domain  
 
To study the role of this mutation, a 3 base pair ‘in frame’ deletion encoding glutamate 35 
in a GST outer lipoyl domain fusion construct (already available in laboratory) was created 
by site-directed mutagenesis using primers described in Materials & Methods section 2.1.3.  
Two  other  mutants  of  the  lipoyl  domain  fused  with  GST  were  also  created.  In  one 
construct, glutamate-35 was substituted by an aspartate (E35D) and in the other with a 
glutamine  (E35Q)  again  by  employing  the  relevant  primers  (Materials  and  Methods, 
section 2.1.3). These mutants were created to study the possible influence of charge and 
size of amino acid at this position when comparing with the  E35 mutant of the outer 
lipoyl domain. All mutations were checked by DNA sequencing as described in Methods 
section 2.2.7. 
 
4.4.2  Overexpression  and  purification  of  the  wild-type,  E35D, 
E35Q and ∆E35 lipoyl domains   
 
Wild-type,   E35,  E35D,  E35Q  outer  lipoyl  domains  and  non-lipoylated  K173Q  inner 
lipoyl domain constructs in pGEX-2T were transformed into E. coli BL21 (DE3) cells, 
respectively. Transformed cells were grown and protein expression induced with IPTG at 
30 ºC for 4-5 h after cultures attained an A600 of 0.5. All the fusion proteins were found to 
be overexpressed in soluble form as analysed by SDS-PAGE. Recombinant lipoyl domain 
GST  fusion  proteins  were  purified  by  glutathione  Sepharose  4B  chromatography  as 
described in Methods section 2.3.13 and analysed by SDS-PAGE (Fig. 4.13 A).  
 Chapter 4  
 
129 
129 
4.4.3  Western  blot  analysis  of  wild-type,  E35D,  E35Q  and ∆E35 
lipoyl domains 
 
Western blotting of wild-type,  E35, E35D, E35Q outer lipoyl domain and K173Q inner 
lipoyl  domain  fusion  proteins  was  performed  using  a  monoclonal  antibody  (PD2)  that 
recognises lipoylated components of PDC using a protocol described in Methods section 
2.3.15. On Western blotting it was found that the  E35 lipoyl domain was not lipoylated 
when compared to the wild-type and the result was comparable to the non-lipoylatable 
mutant inner lipoyl domain (K173Q). The other two mutants of the outer lipoyl domain, 
E35D and E35Q, created to investigate the effect of change in charge and size on the 
folding and lipoylation status of this domain were found to be fully lipoylated (Fig. 4.13 
B). 
 
4.4.4 Non denaturing gel electrophoresis of the wild-type, E35D, 
E35Q and ∆E35 lipoyl domains 
 
The GST tags of wild-type,  E35, E35D and E35Q outer lipoyl domains were removed 
with thrombin by the protocol described in Methods section 2.3.14. Interestingly, it was 
noted  that  tags  could  be  removed  from  the   E35  outer  lipoyl  domain  in  a  short  time 
interval (2 h), whereas for the wild-type and other two mutants it took about 8-10 h. After 
the removal of the GST tags, the proteins were first analysed by SDS-PAGE for checking 
of purity. Thereafter, they were analysed on a 6% native gel (Methods section 2.3.5). The 
 E35 outer lipoyl domain was found to  exhibit a markedly decreased  mobility on the 
native gel as compared to the wild-type and the other mutants (Fig. 4.14) indicating either 
a major change in charge, conformation or aggregation state or a combination of these 
factors. 
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Figure 4.13: SDS-PAGE and Western blot analysis of the wild-type, E35D, E35Q, 
∆E35 outer lipoyl domains and K173Q inner lipoyl domain  
 
(A) SDS-PAGE analysis of purified wild-type (lane 2), E35D (lane 3), E35Q (lane 4), 
 E35 (lane 5) outer lipoyl domain GST fusion proteins and K173Q inner lipoyl domain 
GST fusion protein (lane 6) resolved on a 4-12% Bis-Tris gel. Wild-type and mutant fusion 
proteins were purified by glutathione Sepharose 4B chromatography. Molecular weight 
markers (Mw) are in lane 1.  
(B) Western blot analysis of wild-type (lane 2), E35D (lane 3) E35Q (lane 4),  E35 (lane 
5) outer lipoyl domain GST fusion proteins and K173Q inner lipoyl domain GST fusion 
protein (lane 6) with PD2 antibody. The  E35 outer lipoyl domain is not detected (lane 5) 
and is comparable to the negative control, K173Q inner lipoyl domain (lane 6). 
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4.4.5 Structural prediction for the wild-type and ∆E35 outer lipoyl 
domains 
 
 A possible structural change in the  E35 lipoyl domain was suspected on the basis of ease 
of removal of its GST tag by thrombin, Western blotting and native gel electrophoresis. 
Therefore, it was decided to ascertain if any change in the structure of the mutant domain 
was predicted on the basis of Swiss modelling (see section 2.3.18). The structure of the 
outer  human  lipoyl  domain  has  not  been  solved  either  by  NMR  or  by  X-ray 
crystallography; therefore both the structures were created based on sequence homology. 
The potential structure for the mutant lipoyl domain was found to be similar to the wild-
type lipoyl domain (Fig. 4.15 A & B). Overall its conformation appeared to be very similar 
to the lipoyl domain of B. stearothermophilus which consists of two 4-stranded antiparallel 
β sheets in the form of a flattened β-barrel with the lipoylatable lysine residue located on 
an exposed type-1 β turn in one of the β sheets (Dardel et al., 1993) (Fig. 4.15 C).  Chapter 4  
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Figure 4.14: Non denaturing gel electrophoresis of the wild-type, E35D, E35Q and 
∆E35 lipoyl domains 
 
Native gel analysis on a 6% polyacrylamide gel shows that the  E35 outer lipoyl domain 
(lane 4) is either aggregated or has a major change in charge and/or shape as compared to 
wild-type (lane 1), E35D (lane 2) and E35Q (lane 3) outer lipoyl domains.   
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Figure 4.15: Structure prediction of the wild-type and ∆E35 lipoyl domain using 
Swiss modelling 
 
The structure of the wild-type (A) and  E35 (B) outer lipoyl domains as predicted by 
Swiss modelling (Schwede et al., 2003) was not found to be significantly altered and was 
similar  to  the  structure  of  the  lipoyl  domain  of  B.  stearothermophilus  E2-PDC.  (C) 
Adapted from Dardel et al. (1993). 
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4.4.6 Molecular weight determination of the wild-type, E35D, E35Q 
and ∆E35 lipoyl domains by size exclusion chromatography 
Size exclusion chromatography (SEC) separates proteins based on their size, shape or their 
hydrodynamic volume. SEC allows the separation of folded and unfolded forms, as the 
folded polypeptide elutes much later due to its more compact structure. The purified wild-
type,  E35 and E35D outer lipoyl domains were passed through a HiPrep 16/60 Sephacryl 
S-300 High Resolution column attached to a BioCAD 700E workstation as described in 
Methods section 2.3.12 and elution profiles compared. Similarly, the wild-type and  E35 
lipoyl domain GST fusion proteins were also subjected to gel filtration chromatography on 
the same column for comparative purposes.        
It  was  observed  that  the  wild-type  and  E35D  outer  lipoyl  domains  eluted  at  the  same 
elution volume whereas the  E35 outer lipoyl domain appeared at an earlier stage in the 
elution profile (Fig. 4.16 B). Ratio of elution volume to void volume Ve/Vo was calculated 
for each protein and was found to be 2.21 for the wild-type and for the E35D outer lipoyl 
domains, whereas for the  E35 lipoyl domain, this ratio was 1.98. Similarly, the main peak 
for the  E35 lipoyl domain GST fusion protein was also observed at an earlier stage and 
displayed a Ve/Vo of 1.52 whereas for the wild-type-GST construct, this value was 1.68 
(Fig. 4.16 C). 
The  molecular  masses  of  these  proteins  were  calculated  employing  a  calibration  curve 
generated by plotting logarithm of molecular weights of known proteins on the Y-axis and 
Ve/Vo on the X-axis (Fig. 4.16 A). It was found that the molecular weight of the  E35 
outer  lipoyl  domain  was  twice  that  of  wild-type  lipoyl  domain.  Thus,  the  predicted 
molecular mass of this domain was 20.7 kDa; however, the observed molecular mass as 
determined  from  the  standard  curve  (Fig.  4.16  A)  was  45  kDa.  A  similar  trend  was 
observed when the molecular mass of the wild-type and mutant domains fused with GST 
were compared. The predicted molecular mass of the GST fusion mutant was 90 kDa; 
however, the observed molecular mass using the standard curve was 180 kDa. In both 
cases, the  E35 lipoyl domain was present as a dimeric species whilst also displaying an 
increased tendency to form aggregates of higher order and showing a substantial peak at 
the void volume in the case of the lipoyl domain GST fusion protein (Fig. 4.16 B & C).  Chapter 4  
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Figure 4.16: Molecular mass determination of the wild-type, E35D, E35Q and ∆E35 
lipoyl domains by size exclusion chromatography 
 
(A) Standard curve generated by plotting the logarithm of molecular weights of known 
proteins on the Y-axis and ratio of elution to void volume Ve/Vo on the X-axis. Ve/Vo of 
the test samples were determined by resolving on a HiPrep 16/60 Sephacryl S-300 High 
Resolution  column  attached  to  BioCAD  700E  workstation.  (B)  Gel  filtration  elution 
profiles and Ve/Vo ratios of the wild-type, E35D,  E35 lipoyl domains (C) Gel filtration 
elution profiles and Ve/Vo ratios of the wild-type and  E35 lipoyl domain GST fusion 
proteins.  
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 4.4.7 Cross linking of the wild-type and ∆E35 lipoyl domains by 
glutaraldehyde treatment  
 
If two proteins physically interact with each other forming dimers or oligomers of higher 
order, then they can be covalently cross-linked chemically. Chemical cross linking offers a 
direct method of identifying both transient and stable interactions. This technique involves 
the formation of covalent bonds between two interacting proteins by using bifunctional 
reagents  containing  reactive end groups that link to functional groups such as primary 
amines and thiol groups of amino acid residues. Homo-bifunctional reagents, specifically 
reacting with primary amine groups (i.e. ε-amino groups of lysine residues) have been used 
extensively as they are soluble in aqueous solvents and can form stable inter- and intra-
subunit covalent bonds. Glutaraldehyde is a popular homo-bifunctional reagent, which is 
extensively used for cross linking. SDS polyacrylamide gels of oligomeric proteins, for 
instance  dimeric  proteins,  after  treatment  with  glutaraldehyde  will  show  cross  linked 
dimers where inter-subunit cross linking has occurred. In this experiment, purified wild-
type  and   E35  outer  lipoyl  domains  were  treated  with  2%  (v/v)  glutaraldehyde 
respectively for 30 min at room temperature. Thereafter, SDS-PAGE analysis of the treated 
samples was carried out employing the routine protocol outlined in Methods section 2.3.4. 
It was found that the wild-type lipoyl domain migrated at its normal molecular mass (20 
kDa) even after glutaraldehyde treatment whereas the  E35 outer lipoyl domain migrated 
more slowly corresponding to a molecular mass of approx. 45 kDa, consistent with its 
existence as a homodimer prior to cross linkage (Fig. 4.17).  
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Figure 4.17: SDS-PAGE analysis of the wild-type and ∆E35 lipoyl domains cross- 
linked with glutaraldehyde  
 
The Bis-Tris (4-12%) SDS gel was stained with Coomassie blue and shows that the DE35 
lipoyl domain present as a dimer after treatment with 2% glutaraldehyde (lane 3), whereas 
the wild-type outer lipoyl domain treated in same way is monomeric (lane 1). Wild-type 
and  DE35  lipoyl  domains  without  glutaraldehyde  treatment  are  in  lanes  2  and  4, 
respectively. Molecular weight markers (Mw) are in lane 5. 
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4.4.8 Analysis of the far uv spectra of the wild-type, E35D, E35Q 
and ∆E35 lipoyl domains by circular dichroism  
 
Secondary structure can be estimated by CD spectroscopy in the far-uv spectral region 
(190-250 nm). Samples of the wild-type,  E35, E35D and E35Q outer lipoyl domains, all 
free of their GST tags, were prepared as discussed in Methods section 2.3.20. Domains 
were examined for possible changes in secondary structure using CD spectroscopy in the 
far uv   region. The CD spectrum of the  E35 outer lipoyl domain was quite distinct when 
compared with the wild-type and other mutants (Fig. 4.18). Secondary structures  were 
estimated using the CDSSTR algorithm which is available from the online DICHROWEB 
server hosted by the Birkbeck college (http://www.cryst.bbk.ac.uk). From the spectral data, 
the  algorithm  estimated  that  the  wild-type  and  mutants  E35D  and  E35E  consisted  of 
predominantly beta sheet structure (approx. 45%), whereas, the  E35 outer lipoyl domain 
consisted mainly of random coil.  
 
4.4.9 Near uv spectra of the wild-type E35D, E35Q and ∆E35 lipoyl 
domains by circular dichroism 
 
The CD spectrum of a polypeptide in the near-uv spectral region (250-350 nm) can be 
sensitive  to  certain  aspects  of  tertiary  structure.  Over  this  wavelength  range  the  major 
chromophores are the aromatic amino acids and disulphide bonds, that can give rise to 
individual spectral contributions and the CD signals produced can be a sensitive probe for 
detecting alterations in the overall tertiary structure of the protein. Signals in the region 
from 250-270 nm are attributable to phenylalanine residues, signals from 270-290 nm to 
tyrosine and those from 280-300 nm to tryptophan. Disulphide bonds give rise to broad 
weak signals throughout the near-uv spectrum. Samples of the wild-type,  E35, E35D and 
E35Q outer lipoyl domain were prepared as mentioned in Methods section 2.3.20. Near uv 
CD spectra in this region indicated that in the wild-type, E35D and E35Q outer lipoyl Chapter 4  
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domains, the aromatic amino acids such as tyrosine were in a rigid environment giving rise 
to well-defined troughs in this region. In contrast, in the  E35 outer lipoyl domain, this 
rigid environment was lost as indicated by the disappearance of the characteristic troughs 
centred around 278 nm, 286 nm and 292 nm (Fig. 4.19).  
 
4.4.10  Fluorescence  emission  spectra  of  the  wild-type,  E35D, 
E35Q and ∆E35 outer lipoyl domains  
 
Fluorescence  emission  spectra  of  the  wild-type,  E35D,  E35Q  and   E35  outer  lipoyl 
domains were generated and analysed by exciting the individual samples at 295 nm as 
described in Methods section 2.3.21. The fluorescence emission spectra were recorded at 
320-350 nm. Maximum emission occurred at 330 nm for the wild-type, E35D and E35E 
outer lipoyl domains whereas maximum emission for the  E35 lipoyl domain shifted to 
345 nm (Fig. 4.20). This indicated that the single buried tryptophan residue in the  E35 
lipoyl domain was exposed to the external aqueous phase and this domain appeared to be 
largely unfolded as compared to the wild-type and other mutants. Chapter 4  
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Figure 4.18: Far uv CD spectra for the wild-type, E35D, E35Q and ∆E35 lipoyl 
domains 
 
The wild-type, E35Q, E35D and DE35 outer lipoyl domains were subjected to circular 
dichroism and spectra recorded in the far uv region (190-260 nm). The CD signal was 
measured  as  molar  ellipticity  in  degrees  cm
2  dmol
-1  (Y-axis)  plotted  as  a  function  of 
wavelength (X-axis).   
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Figure 4.19: Near uv CD spectra for the wild-type, E35D, E35Q and ∆E35 lipoyl 
domains 
  
The wild-type, E35Q, E35D and DE35 outer lipoyl domains were subjected to circular 
dichroism and spectra recorded in the near uv region (250-320 nm). The CD signal was 
measured as molar ellipticity in degrees cm
2 dmol
-1 (Y-axis) as a function of wavelength 
(X- axis).   
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Figure 4.20: Fluorescence emission spectra of the wild-type, ∆E35, E35D and E35Q 
outer lipoyl domains 
The wild-type,  E35, E35D and E35Q outer lipoyl domains were excited with uv light of 
wavelength 295 nm. Emission of fluorescence was recorded over the wavelength range 
310-420 nm. The data show that maximum emission of fluorescence occurs at 330 nm for 
the wild-type, E35D and E35Q lipoyl domains, whereas for the  E35 outer lipoyl domain, 
the peak of fluorescence emission shifts to 345 nm.  
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4.4.11 Creating the ∆E35, E35D and E35Q mutants of full length 
E2  
 
The glutamate-35 mutation was created in full length E2 cDNAs housed in pET-14b and 
pET-11b  vectors  respectively  by  site-directed  mutagenesis  using  appropriate  primers 
(Materials & Methods section 2.1.3). In the same way, E35D and E35Q mutants of E2 in 
pET-14b  and  pET-11b  were  also  created  for  detailed  analysis  of  these  mutations.  The 
primers specified in Materials & Methods (section 2.1.3) were used for creating E35D and 
E35Q  E2  mutants.  On  DNA  sequencing,  the  correct  mutations  were  found  to  be 
incorporated into all the mutant constructs. Six mutant constructs of E2 namely:  E35 
pET-14b,  E35 pET-11b, E35D pET-14b, E35D pET-11b, E35Q pET-14b and E35Q pET-
11b were generated in this manner. The pET-14b constructs were required to study the 
effects of the glutamate 35 deletion on E2 activity whereas, the pET-11b constructs of E2 
facilitated co-expression with E3BP in pET-28b to obtain mutant E2:E3BP cores described 
in Section 4.4.14, enabling us to study the effects of this mutation on the E2:E3BP core 
and overall PDC activity. 
 
4.4.12  Overexpression  and  purification  of  the  wild-type,  ∆E35, 
E35D and E35Q E2 enzymes 
 
To  overexpress  wild-type,   E35,  E35D  and  E35Q  E2  enzymes,  pET-14b  constructs 
housing  the  relevant  cDNAs  were  transformed  into  E.  coli  BL21  (DE3)  cells. 
Overexpressions were carried out at 30 ºC for 5-6 h and visualised by SDS-PAGE (Fig. 
4.21). The N-terminally His-tagged proteins were purified by zinc chelate chromatography 
and viewed by SDS-PAGE (Fig.  4.22). 
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Figure 4.21: Overexpression of the wild-type, ∆E35, E35D and E35Q E2 enzymes 
 
SDS-PAGE analysis of overexpression of the wild-type (lane 3),  E35 (lane 5), E35D 
(lane  7)  and  E35Q  (lane  9)  recombinant  E2  enzymes  on  a  4-12%  Bis-Tris  gel.  The 
overexpressions were carried out in E. coli BL21 (DE3) cells at 30 ºC for 4-5 h and are 
shown at zero time (T0) and 5 h after induction (T5). Molecular weight markers (Mw) are 
in lane 1. 
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Figure 4.22: SDS-PAGE analysis of purified wild-type, ∆E35, E35D and E35Q E2 
enzymes 
 
SDS-PAGE analysis of the purified wild-type (lane 4),  E35 (lane 3), E35D (lane 2) and 
E35Q (lane1) recombinant E2 enzymes on a 4-12% Bis-Tris gel. Wild-type and mutant 
enzymes were purified by zinc chelate chromatography. Molecular weight markers (Mw) 
are in lane 5.  
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4.4.13 Enzymatic activity of wild-type and ∆E35, E35D and E35Q 
mutants of E2  
The  acetyltransferase  activities  of  the  purified  wild-type,   E35,  E35D  and  E35Q  E2 
enzymes  were  compared  spectrophotometrically  following  the  protocol  described  in 
Methods section 2.3.16. Equal amounts of wild-type and mutant E2 enzymes were used to 
determine acetyltransferase activity by initially performing Bradford assays (see section 
2.3.11). Further SDS-PAGE analysis of these enzymes was carried out to ensure that equal 
amounts were assayed for acetyltransferase activity. All activity assays were performed in 
duplicate  with  wild-type  control  and  the  E35D  mutant  displaying  100%  activity.  In 
comparison, the E35Q E2 mutant displayed approx. 80%, whereas DE35 E2 displayed only 
approx.  20%  activity  (Fig.  4.23).  These  results  were  found  to  be  reproducible  with  3 
different preparations of recombinant wild-type and mutant E2s. 
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Figure 4.23: Comparison of acetyltransferase activity of the wild-type, ∆E35, E35D 
and E35Q E2 enzymes   
 
Percentage enzymatic activities of wild-type and mutant E2 enzymes are shown. Error bars 
indicate extent of variation between duplicates.  
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4.4.14  Co-transformation  and  overexpression  of  the  wild-type, 
∆E35, E35D and E35Q E2:E3BP cores 
Wild-type E2 cDNA in pET-11b and E3BP cDNA in pET-28b were co-transformed into E. 
coli  BL21  (DE3)  Star  cells  and  single  colonies  employed  for  overexpression  studies. 
Overexpression yielded the most soluble E2:E3BP core at 15 ºC (Chapter 3, Fig. 3.5). The 
 E35,  E35D  and  E35Q  E2:E3BP  cores  were  successfully  overexpressed  in  the  same 
manner. Lipoic acid (0.1 mM) was added to each before induction with 1 mM IPTG. The 
solubility of the  E35 E2:E3BP core was also checked at 37 ºC, 30 ºC, 22 ºC and 15 ºC, 
and was found to be maximal at 15 ºC (Fig. 4.24). Therefore, in subsequent experiments, 
wild-type and mutant E2:E3BP cores were all overexpressed at 15 ºC overnight.   
 
4.4.15  Purification  of  the  wild-type  and  ∆E35,  E35D  and  E35Q 
E2:E3BP cores 
The E2:E3BP cores contained only N-terminally His-tagged E3BP and consequently their 
purification relied on the formation of a stable E2:E3BP core assembly in which E3BP co-
integrated with its E2 partner. Mutant cores could be purified successfully by metal chelate 
chromatography in a similar manner as described for the wild-type core in Chapter 3 (see 
section 3.4). The purified wild-type and mutant cores were also subjected to gel filtration 
on a HiPrep 16/60 Sephacryl S-300 High Resolution column attached to a BioCAD 700E 
workstation before viewing by SDS-PAGE (Fig. 4.25). On SDS-PAGE analysis, the  E35 
core was found to contain reduced levels of E2 and a high proportion of E3BP as compared 
to the wild-type core. Several preparations of this mutant core analysed by routine SDS-
PAGE  consistently  displayed  this  feature,  which  was  the  first  indication  of  abnormal 
assembly.   
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Figure 4.24: Solubility check of ∆E35 E2:E3BP core overexpressed at various 
temperatures 
 
The  E35 E2:E3BP core was overexpressed at 15 ºC, 22 ºC, 30 ºC and 37 ºC in E. coli 
BL21 (DE3) Star cells. SDS-PAGE analysis on a 4-12% Bis-Tris gel shows that at 37 ºC, 
30 ºC and 22 ºC, mutant E2:E3BP was largely insoluble and present in the pellet fraction 
(PS)( lanes 3, 6 and 10 respectively). When overexpressed at 15 ºC overnight, this protein 
was present in the soluble supernatant (SS) (lane 12). Whole cell extracts (WE) in lanes 1, 
4, 8 and 11, respectively. Molecular weight markers (Mw) are in lane 7.   
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 Figure 4.25: SDS-PAGE of the purified wild-type, ∆E35, E35D and E35Q E2:E3BP 
cores 
 
SDS-PAGE analysis of the purified wild-type (lane 2),  E35 (lane 3), E35D (lane 6) and 
E35Q (lane 7) recombinant E2:E3BP cores on a 4-12% Bis-Tris gel. Wild-type and mutant 
enzymes were purified by zinc chelate chromatography and gel filtration. Gel also shows 
 V455  and  F490L  E2:E3BP  cores  in  lanes  4  and  5,  respectively.  Molecular  weight 
markers (Mw) are in lane 1.  
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4.4.16 Enzymatic activity of the wild-type, ∆E35, E35D and E35Q 
E2:E3BP cores 
Purified  wild-type,   E35,  E35D  and  E35Q  E2:E3BP  cores  (see  section  4.4.13)  were 
checked for protein levels by performing Bradford assays as described in Methods section 
2.3.11. SDS-PAGE analysis was also carried out to ensure that equal amounts of wild and 
mutant  cores  were  assayed  for  acetyltransferase  activity.  Assays  were  conducted  to 
compare wild-type (taken as a 100% control) with the mutant cores, in the same manner as 
for the wild-type and mutant E2 enzymes (see section 4.4.13). In the previous E2 assay, it 
was  seen  that   E35  E2  showed  very  low  activity  (80%  reduction).  The  purpose  of 
employing E2 cores containing E3BP was to establish if the presence of E3BP had any 
influence on  E35 E2 activity. As previously however, the E35D core displayed 100% 
activity, the E35Q core displayed approx. 80% whereas  the  E35 core assembly displayed 
only 20% of the control activity levels, in agreement with the values obtained employing 
the wild-type and mutant E2 enzymes. Thus the pattern of results on assembled native and 
mutant E2:E3BP cores was similar to those obtained for the equivalent set of purified E2 
samples.  
 
4.4.17  Comparison  of  overall  PDC  activity  in  recombinant 
preparations  of  reconstituted  wild-type,  ∆E35,  E35D  and  E35Q 
core assemblies 
 
Wild-type,  E35, E35D and E35Q E2:E3BP cores were reconstituted into wild-type and 
mutant PDCs by adding stoichiometric amounts of E1 and E3 respectively (see Chapter 3, 
section 3.11). Enzymatic assays were performed in duplicate with freshly prepared wild-
type and mutant PDCs as per the protocol described in Methods section 2.3.17. Wild-type 
PDC was taken as control with 100% activity. In comparison, the E35D PDC displayed 
80%, E35Q PDC 75%, whereas the  E35 PDC displayed consistently low activity of about 
10 -12 % (Fig. 4.27). Chapter 4  
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Fig 4.26: Comparison of enzymatic activity of wild-type, ∆E35, E35D and E35Q 
E2:E3BP cores   
 
Percentage enzymatic activities of mutant E2:E3BP cores relative to the wild-type as 100% 
control are shown. Samples were assayed in duplicate and error bars are shown where 
necessary and indicate extent of variation between duplicates.  
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Figure 4.27: Comparison of recombinant PDC activities reconstituted with the wild-
type, ∆E35, E35D and E35Q E2:E3BP cores 
 
 Enzymatic  activities  of  the  wild-type  and  mutant  PDCs  reconstituted  from  individual 
components  are  shown  with  respect  to  wild-type  complex  as  control.  Samples  were 
assayed  in  duplicate  and  error  bars  shown  where  necessary  indicating  the  extent  of 
variation between duplicates.   
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4.4.18 Far UV spectra of the wild-type, ∆E35, E35D and E35Q E2: 
E3BP cores by circular dichroism  
 
The wild-type and mutant cores were subjected to CD in the region of 190-250 nm and 
spectra recorded as described in Methods section 2.3.20.  
The data were not of high quality in the 190-200 nm region and therefore, quantitative 
estimation of  a helix and b sheet content was not attempted. However, differences were 
observed in the spectra of the  E35 mutant core as compared to the wild type and other 
mutant cores, where a well defined peak at 206 nm is absent in the  E35 core (Fig. 4.28). 
 
4.4.19  Fluorescence  emission  spectra  of  the  wild-type,  ∆E35, 
E35D and E35Q E2:E3BP cores 
 
Fluorescence emission spectra of the wild-type,  E35, E35D and E35Q; E2:E3BP cores 
were  also  compared  as  described  in  the  Methods  section  2.3.21.  It  was  found  that 
maximum fluorescence emission spectrum of  E35 E2:E3BP core shifted from 330 nm to 
343 nm, as compared to the spectra of the wild-type and other mutant cores, which emitted 
maximally at 330 nm (Fig. 4.29). Since the single E2 polypeptide contains 4 tryptophans 
and  E3BP  polypeptide  contains  2,  this  suggests  large  scale  perturbation  of  the  core 
assembly in which several tryptophans are exposed to the aqueous environment.  
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Figure 4.28: Far uv CD spectra of the wild-type, E35Q, E35D and D D D DE35 E2:E3BP 
cores 
 
Wild-type, E35Q, E35D, and DE35 E2:E3BP cores were subjected to circular dichroism 
and spectra recorded in the far uv region (190-260 nm). The CD signal was measured as 
ellipticity in degrees cm
2 dmol
-1 (Y-axis) plotted as a function of wavelength (X-axis).   
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Figure 4.29: Fluorescence emission spectra of wild type, E35Q, E35D, D D D DE35 E2:E3BP 
cores  
 
Wild-type, E35D, E35Q,  E35 E2:E3BP cores were excited with uv light of wavelength 
295 nm. Emission of fluorescence was recorded over a range of 310-420 nm. Figure shows 
that the maximal emission of fluorescence occurred at 326 nm for the wild-type, E35D and 
E35Q cores, whereas for the  E35 core, maximal fluorescence emission shifted to 343 nm.  
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4.4.20  Comparison  of  sedimentation  behaviour  of  the  wild-type 
and ∆E35 E2:E3BP cores 
Major disruption of the  E35 E2:E3BP core was anticipated as observed from circular 
dichroism and intrinsic tryptophan fluorescence studies. Therefore, sedimentation velocity 
experiments  were  conducted  in  order  to  provide  further  insights  into  the  nature  of  the 
mutant core assembly. These experiments were performed as described in the Methods 
section 2.3.19.2 and the sedimentation behaviour of the DE35 E2:E3BP core was compared 
to the wild-type core. Wild-type and mutant cores were co-expressed, purified (see sections 
3.3  &  3.4),  gel  filtered  (see  the  Methods  section  2.3.12)  and  SDS-PAGE  analysis 
conducted for checking the purity of the cores. No proteolysis or degradation was evident 
from SDS-PAGE analysis (Fig. 2.30 E).  
The sample concentrations analysed were 3.33, 1.07 and 1.00  M for the wild-type and 
2.06, 1.72, 1.07, 2.60, 2.26 and 0.50  M for the mutant. Samples (380  l) were loaded into 
12 mm double sector centrepieces and data recorded at 4 ºC at a rotor speed of 20000 rpm 
using interference optics. A series of 360 scans, 60 s apart was taken for each sample. 
Sedimentation coefficients were determined using SEDFIT (Schuck, 2000). The weight 
average s4,w  values were corrected to s20,w. The weight average sedimentation coefficient, 
s20,w  for  the  wild-type  cores  was  determined  as  30.61+0.36  S,  whereas  sedimentation 
coefficient for the mutant core displayed a great degree of heterogeneity (8-40 S). A small 
amount of the mutant core showed a sedimentation coefficient comparable to wild-type 
core, but the vast majority was present as sedimenting species of lower Mr value. This 
result was anticipated, in view of previous CD spectroscopy, fluorescence tryptophan and 
enzymatic assays that indicated the probability of major disruption in its assembly. A range 
of sedimentation coefficients (30-32 S) for normal E2:E3BP core and 8 S for unassembled 
trimers  of  E2  produced  upon  treatment  of  the  core  by  chaotrophic  agents  have  been 
reported    (Behal  et  al.,  1994).  These  8  S  species  associated  non-cooperatively  to  give 
additional assembly intermediates exhibiting sedimentation coefficients of 10-32 S. In this 
case also, the lower sedimenting species (Fig. 2.30 C) could be trimers of E2, which have 
failed to assemble into a proper core as a result of this mutation.   Chapter 4  
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S20,w  
 
                                                                       
Fig. 2.30: Comparison of the sedimentation velocity analyses of wild-type and D D D DE35 
E2:E3BP cores 
 
c(s) distribution from SV interference data collected for 3.33  M (
____), 1.07  M (
____) and  
1.00  M (
___) wild-type E2:E3BP core (Fig. A) and maximising c(s) to the peak observed 
at 30.40 S (Fig. B). c(s) distribution from SV interference data collected for 2.06  M (
__   ), 
1.72  M (
___), 1.07  M (
___), 2.60  M (
___), 2.26  M (
___) and 0.50  M (
___) DE35 E2:E3BP 
core (Fig. C) and maximising c(s) to the peak observed at 34 S (Fig. D). SDS-PAGE 
analysis  of  the  wild-type  and  mutant  cores  used  in  this  SV  experiment  (Fig.  E). 
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
-20 0 20 40 60 80 100 120 140 160 180 200
S
 
-0.05
0
0.05
0.1
0.15
0.2
0.25
0.3
0 20 40 60 80 100 120 140 160 180 200
S
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
-20 0 20 40 60 80 100 120 140 160 180 200
S
C
(
s
)
 
-0.02
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
-20 0 20 40 60 80 100 120 140 160 180 200 220
S
 
A  B 
C 
 
D 
E 
D D D DE35 E2:E3BP 
 
Wild-type E2:E3BP 
s20,w  s20,w 
s20,w 
s20,w 
   
   Chapter 4  
 
159 
159 
 
4.4.21 Discussion of Glutamate 35 deletion 
 
In this chapter the glutamate 35 deletion in the lipoyl domain of the E2 enzyme of PDC, 
encountered  in  a  clinical  case  has  been  analysed  in  detail  employing  our  model 
recombinant PDC. None of the mutations (DE35, DV455 and P490L), discussed in this 
Chapter  have  been  identified  in  50  dihydrolipoamide  acetyltransferase  (DLAT)  alleles 
analysed to date, nor were they found in any DLAT cDNA or genomic sequences in the 
human EST (expressed sequence tag) and genomic DNA databases (Brown et al., 2004). In 
fact, no other mutations have been reported so far in the lipoyl domains of E2 of PDC. This 
may  be  due  to  the  fact  that  such  mutations  might  be  prevalent,  but  do  not  produce  a 
significant phenotype leading to failure of detection in the absence of a real necessity to 
diagnose  them  at  genetic  level.  The  non  severity  of  the  phenotype  could  also  be 
attributable to functional redundancy owing to the presence of multiple lipoyl domains on 
E2 and E3BP that is also genetically advantageous. As a result the affected person may be 
carrying the mutation leading to slightly decreased PDC activity, but without producing 
any major health problems. In contrast, mutations in the E1a and E3 components produce 
mild to severe, but more detectable phenotypes.  
The glutamate deletion was an interesting mutation in the sense that loss of lipoylation per 
se  would  not  be  expected  to  cause  such  severe  clinical  symptoms  in  the  patient. 
Nevertheless it was important to demonstrate that the mutation was indeed the cause of the 
PDC  deficiency  and  also  to  investigate  the  molecular  basis  of  disruption  of  normal 
complex function in this case.  
The precise role of the mutation was studied at three levels- at the lipoyl domain, at the E2 
enzyme and at the PDC level. In all cases, two more mutants were investigated in parallel, 
namely E35D and E35Q, in order to better understand the role of the deleted glutamate 35. 
These mutants enabled us to establish whether a change in charge or size of amino acid 
was  the  over-riding  factor  for  structural  perturbation  or  the  actual  presence  of  the 
glutamate residue was more important. At the lipoyl domain level, it was seen that the 
 E35 lipoyl domain was non-lipoylated as compared to the wild-type and the other two Chapter 4  
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mutant domains. A monoclonal antibody (PD2) was employed for Western blotting, that 
recognises only the lipoylated components of PDC (Thomson et al., 1998). Lipoylation or 
insertion of lipoic acid on a particular lysine is a very specific phenomenon, occurring only 
if a precise structural cue is present (Wallis and Perham, 1994) and is indicative of the 
presence of correctly folded lipoyl domain. In the the case of glutamate 35 deletion, this 
structural  cue  appears  to  have  been  lost.  This  result  was  the  first  indication  that  this 
deletion  caused  a  change  in  the  structure  of  the  lipoyl  domain.  The  other  two  mutant 
domains, however, were still found to be lipoylated (Fig. 4.13) showing that glutamate-35 
is an important and specific residue in this region required for the correct folding of the 
lipoyl domain or the maintenance of its structural stability. This result also confirmed that 
not only the DKA motif at the site of lipoylation is important, but that residues located 
some distance away from the site (12 residues to the N-terminal side in this case) are also 
essential for recognition.  
The relative ease with which GST tags could be cleaved from the  E35 lipoyl domain as 
compared to the wild-type and other mutant domains also indicated that the  E35 mutant  
provided less steric hindrance to proteolytic attack by thrombin, suggesting that it was not 
properly folded. Major alterations were again observed when this domain was run on a 
non-denaturing gel indicating either a gross change in charge or oligomerisation state (Fig. 
4.14).  Striking  differences  were  also  observed  in  intrinsic  tryptophan  fluorescence 
indicating that  E35 lipoyl domain was not folded properly and that its single tryptophan 
was exposed to solvent.  
The  aromatic  amino  acids  tryptophan,  tyrosine  and  phenylalanine  are  all  capable  of 
contributing to the intrinsic fluorescence of proteins. When all three residues are present in 
a protein, pure emission from tryptophan can be obtained by photoselective excitation at 
wavelengths  above  295  nm  (Eftink,  1991).  Although  tyrosine  and  phenylalanine  are 
natural fluorophores, tryptophan is the most extensively used amino acid for fluorescence 
analysis of proteins. In a protein containing all three fluorescent amino acids, observation 
of  tyrosine  and  phenylalanine  fluorescence  is  often  complicated  by  interference  from 
tryptophan caused by resonance energy transfer (Eftink, 1991). The application of tyrosine 
and  phenylalanine  fluorescence  is  therefore  mostly  limited  to  tryptophan-free  proteins; 
however, a recent study reports an exception to this (Ruan et al., 2002). More importantly, 
tyrosine fluorescence is insensitive to environmental factors such as polarity (Ross, 1992). 
Fluorescence of phenylalanine is weak and seldom used in protein studies. Hence, the term 
‘natural protein fluorescence’ is almost always associated with tryptophan fluorescence. Chapter 4  
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Tryptophan residues serve as intrinsic, site-specific fluorescent probes for protein structure 
and  dynamics.  The  well  documented  sensitivity  of  tryptophan  fluorescence  to 
environmental factors such as polarity makes it a valuable tool in studies of this type by 
providing  specific  and  sensitive  information  on  protein  structure  and  its  interactions 
(Eftink, 1991). As a result of the exposure of a buried tryptophan, the maximum emission 
spectrum shifts 10 to 20 nm to longer wavelengths as compared to the spectra of the same 
protein in which tryptophan is still buried. This phenomenon was seen in the glutamate 
deleted  lipoyl  domain  as  well  as  the  mutant  E2:E3BP  core  (Fig.  4.20  &  Fig.  4.29). 
However,  in  the  lipoyl  domain  only  a  single  tryptophan  residue  accounts  for  total 
fluorescence emission. In contrast, in the E2:E3BP core, there are 4 tryptophan residues in 
the single polypeptide chains of E2, one in the outer lipoyl domain, one in the extreme N-
terminal region and two in the catalytic domain. Moreover, there are two tryptophans in the 
E3BP polypeptide, one each in the lipoyl domain and C-terminal catalytic domain. All 
these tryptophans contribute to the net fluorescence emission spectrum for the E2:E3BP 
core. Interestingly, in the mutant core the spectral shift to longer wavelength as compared 
to the wild type core, is contributed by a number of tryptophan residues indicating that 
there are major structural changes. The lipoyl  domains of A. vinelandii OGDC and B. 
stearothermophilus PDC also have a single tryptophan residue occupying the centre of the 
hydrophobic core consisting of a number of residues (Berg et al., 1996; Dardel et al., 1993) 
and is key to stability of this domain by holding the beta sheets together. 
 Loss of secondary and tertiary structure in the  E35 lipoyl domain was visible by far uv 
spectrophotometry, where it appeared as a random coil compared to more structured beta 
sheets  in  the  wild-type  and  other  two  mutants.  In  near  uv  spectrophotometry,  signals 
arising from aromatic amino acids in a rigid environment were also lost in this particular 
mutant as compared to the wild type and other mutants. From all these observations, it was 
evident that  E35 lipoyl domain had undergone a major structural change because of this 
single deletion. This change in structure could not be revealed through structural modelling 
based  on  known  lipoy  domain  structures  (Fig.  4.15)  indicating  the  limitations  of  such 
computer generated structures to mimic structural changes resulting from point mutations.  
It was further observed that the  E35 lipoyl domain had a pronounced tendency to form 
dimers and also aggregates of higher order as viewed by gel filtration (Fig. 4.16). Folding 
of  newly-synthesized  proteins  in  vivo  is  believed  to  be  facilitated  by  the  cooperative 
interaction of a defined group of proteins known as molecular chaperones. Proteins in a 
non-native state are normally protected from aggregation by these chaperones. The first Chapter 4  
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events in the formation of proteins are the most critical. Starting at the ribosome, nascent 
polypeptides undergo complex folding processes that can be endangered by aggregation 
reactions.  Proteins  with  organellar  destinations  such  as  mitochondria  require  correct 
targeting  to  the  translocation  machineries  located  in  the  organellar  membranes  and 
prevention from premature folding. In the case of mitochondrial precursors, maintenance 
of  an  ‘unfolded’  state  is  a  prerequisite  for  permitting  efficient  translocation.  The  high 
precision and speed of these processes is ensured by a cystosolic system consisting of 
molecular chaperones, folding catalysts and targeting factors (Bukau et al., 1996). Folding 
and assembly of mitochondrial protein complexes takes place only as they emerge into the 
mitochondrial matrix.  
Misfolded,  denatured  or  damaged  proteins  present  in  a  non-native  state  may  expose 
‘sticky’ hydrophobic regions or patches that are highly prone to aggregation (Bukau et al., 
1996). Many neurodegenerative diseases are caused by genetic mutations that can lead to 
accumulation of aggregated toxic proteins in neuronal inclusions and plaques (Taylor et al., 
2002). Our data indicate that the  E35 domain is misfolded exposing ‘sticky’ hydrophobic 
surfaces leading to formation of aggregates, mostly dimers but also higher order aggregates 
on occasions. Initially in this study, it was thought that the ‘stickiness’ of the lipoyl domain 
led  to  immobility  of  the  lipoyl  ‘swinging  arms’  and  hence  reduction  of  PDC  activity. 
However, subsequent data revealed an 80% reduction in E2 activity.  This E2 assay is not 
dependent on the lipoyl domain or subunit binding domain regions of E2 so this marked 
reduction in E2 activity suggested that this N-terminal mutation was affecting assembly of 
the C-terminal domain, perhaps because of premature and inappropriate interactions of the 
N-termini. This prompted analysis of the core assembly using AUC, revealing that the 
correct core assembly was not forming in the presence of the glutamate mutation. Based on 
these observations a schematic model is proposed (see Chapter 6, Fig. 6.1) indicating how 
this mutation might affect normal trimer formation and/or subsequent steps in E2:E3BP 
core formation.   
 The effect of this mutation on acetyltransferase activity was studied in the E2 enzyme and 
E2:E3BP core. Intrinsic acetyltransferase activities of the  E35 enzyme and E2:E3BP core 
were found to be reduced by around 80% or more. The overall activity of reconstituted 
PDC complex with the glutamate mutation was also determined and compared to wild-type 
recombinant PDC using the standard spectrophotometric assay that monitors formation of 
NADH at 340 nm. The activity of mutant PDC was again found to be very low (approx. 
10-15%) as compared to the wild-type.  Chapter 4  
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This loss of activity could not be attributed solely due to loss of lipoylation in the outer 
lipoyl domains of the enzyme and in the core. Although lipoylation of PDC is crucial for 
catalysis, the inner lipoyl domains in the E2 enzyme and E3BP lipoyl domains in the core 
were still lipoylated (data not shown). In studies employing E. coli PDC, where only one 
lipoyl domain was functional out of three lipoyl domains in tandem repeat, the activity of 
the complex was comparable to wild-type complex (Allen et al., 1989). Our own data 
(Chapter  3,  section  3.14)  also  showed  that  the  loss  of  one  lipoylatable  lysine  in  the 
complex caused only a 25-35% decline in complex activity. However, the overall complex 
activity due to the  E35 mutation was found to extremely low, in the range 10-15% of the 
wild-type control. This drastic decline in enzymatic activity can be explained in terms of 
improper E2:E3BP core formation. The loss of core structure in the event of glutamate 
mutation is evident from tryptophan fluorescence and far uv spectrophotometry. However, 
more rigorous evidence comes from analytical ultracentrifugation, where the sedimentation 
coefficient of the  E35 E2:E3BP core is not only lower than the wild-type core, but also 
indicates the presence of several molecular species (Fig. 4.30). The premature aggregation 
of ‘sticky’ lipoyl domains may lead to the formation of mostly abnormal, less compact or 
low molecular weight core with abnormal subunit composition rather than the normal high 
molecular  weight  60:12  meric  E2:E3BP  core.  However,  in  the  sedimentation  velocity 
experiment, it was also found that a small amount of normal sized core was present that 
could account for the 10-20% residual activity and was in agreement with the patient’s 
PDC activity as determined by CO2 release assay.   
The low activity in the patient’s PDC could also be explained partly by E1 and E3 enzyme 
binding to a large population of inactive cores and therefore be catalytically ineffective. E1 
catalysed reductive acetylation of a lipoyl group depends on the 3D structure of lipoyl 
domain (Dardel et al., 1993). Some isoforms of PDC kinase, particularly isoform 4, appear 
to bind more strongly to the outer lipoyl domain of the mammalian enzyme (Tuganova et 
al., 2002; Yeaman et al., 1978). In this study the structure of outer lipoyl domain has also 
found to be lost (Fig. 4.19 & Fig. 4.20) which might impair the attachment of this kinase in 
vivo leading to further dysregulation of the complex.  
These experimental data showed that glutamate 35 mutation is crucial for the structural 
integrity  of  the  complex  and  has  different  consequences  from  the  earlier  mutation 
investigated in Chapter 3 in which the single lipoylatable lysine is replaced by glutamine.  Chapter 4  
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The two mutants (E35D & E35Q), studied simultaneously were not found to be equivalent 
to the deletion mutant. The aspartate substitution was similar in all respects to the wild-
type  in  terms  of  structure  and  function,  whereas  very  slight  structural  and  functional 
changes were shown by the glutamine mutant. Thus, alterations in the size and charge of 
amino  acids  at  this  position  have  only  minor  effects  on  core  assembly  and  function 
whereas  the  omission  of  the  glutamate-35  indicates  its  importance  for  the  folding, 
assembly  and  integrity  of  the  entire  E2:E3BP  core.  These  data  provide  a  detailed 
explanation for the unexpected severity of the effect of the glutamate 35 deletion in the 
outer lipoyl domain of E2, accounting for the unusual nature of the PDC deficiency in this 
patient. Chapter 5  
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Chapter 5 
 
  
A preliminary investigation of the subunit 
organisation of the recombinant 2-
oxoglutarate dehydrogenase (OGDC) 
  
5.1 Introduction  
 
The  2-oxoglutarate  dehydrogenase  (OGDC),  along  with  the  pyruvate  dehydrogenase 
(PDC)  and  branched  chain  2-oxoacid  dehydrogenase
  complex  (BCOADC),  collectively 
constitute  the  family  of  2-oxoacid  dehydrogenase
  multi-enzyme  complexes.  They  are 
important in controlling carbon flux from
 carbohydrate precursors and a select group of 
amino acids into
 and around the tricarboxylic acid cycle. Located in the mitochondrial
 
matrix, the mammalian complexes catalyze the irreversible oxidative
 decarboxylation of 
their respective 2-oxoacid substrates yielding
 the appropriate acyl CoA derivatives, NADH 
and  CO2.  Central  to
  this  catalysis  is  the  consecutive  action  of  their  three  catalytic 
components,
 each present in multiple copies : a substrate-specific 2-oxoacid
 dehydrogenase Chapter 5  
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(E1), a distinct dihydrolipoamide acyltransferase
 (E2) and a common dihydrolipoamide 
dehydrogenase (E3) (Behal et al., 1993; Patel and Harris, 1995).  
The OGDC appears to be much more conserved in evolution than the PDC; both E. coli 
and pig heart complexes exhibit similar quaternary structures (Koike and Koike, 1982; 
Tanaka  et  al.,  1972;  Yeaman  et  al.,  1978),  and  unlike  eukaryotic  PDC  or  BCOADC, 
mammalian OGDC is not regulated by phosphorylation and dephosphorylation (Koike and 
Koike, 1982).  
OGDC  is  an  important
 mitochondrial  multienzyme  complex  that  has  been  increasingly 
associated
 with a number of neurological disorders. It catalyzes a critical step in the Krebs 
cycle  that  is  also  important  in  the  metabolism  of  the  excitotoxic  neurotransmitter, 
glutamate. In human brain, the
 activity of OGDC is lower than that of any other enzyme of
 
energy metabolism, including phosphofructokinase, aconitase
 and the  electron transport 
complexes (Sheu and Blass, 1999). Thus deficiencies of OGDC
 are likely to impair brain 
energy  metabolism  and  therefore  brain
  function,  leading  to  the  manifestation  of 
neurological symptoms. The severity of the neurological symptoms varies according to the 
nature  of  the  deficiency.  Several  disorders  implicating  OGDC  defects  have  been
 
recognized  including  infantile  lactic  acidosis,  psychomotor  retardation
  in  childhood, 
intermittent  neuropsychiatric  disease  with  ataxia
  and  other  motor  manifestations, 
Friedreich's and other spinocerebellar
 ataxias, Parkinson's disease and Alzheimer's disease 
(AD) (Butterworth and Besnard, 1990; Gibson et al., 1988; Mastrogiacomo et al., 1996; 
Terwel et al., 1998).
  
The persistence of abnormalities in the OGDC and particularly in its E2o component in 
familial AD fibroblasts indicates that abnormalities of this complex are an intrinsic part of 
the AD process (Sheu  and Blass, 1999). OGDC is not uniformly distributed in
 human 
brain, and the neurons that appear selectively vulnerable
 in human temporal cortex in AD 
are  enriched  in  OGDC.  A  statistically  significant  negative  correlation  was  observed 
between  OGDC  activity  and  neurofibrillary  tangle  count  in  AD  parietal  cortex 
(Mastrogiacomo et al., 1993). However, reduced levels of OGDC are a feature of some, 
but not all patients with AD (Kish, 1997). Reproducible reductions occur in the PDC, 
OGDC and cytochrome oxidase activities in AD brain and evidence suggests that OGDC 
deficiencies may be genetic in some cases whereas evidence that the other two enzyme 
systems have a genetic component is lacking (Gibson et al., 1998). Chapter 5  
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 In  recent  studies,  OGDC  has  been  found  to  be  a  primary  site  of  ROS  production  in 
normally  functioning
  mitochondria  (Starkov  et  al.,  2004).
  This
  complex  is  also  one  of 
several major autoantigens in primary biliary cirrhosis. Loss of OGDC activity is observed 
in thiamine deficiency and it was recently demonstrated that the response of brain OGDC 
activity,  mRNA  levels  and  immunoreactivity  of  its  E1o,  E2o  and  E3  components  to 
thiamine deficiency is region and time dependent. Loss of OGDC activity in brain cortex is 
probably related to post-translational modification rather than a loss of protein whereas, in 
the sub-medial thalamic nucleus, transcriptional and post-translational modifications may 
account for diminished activity (Shi et al., 2007).  
Less information is available on the subunit organization and the mode of interaction of 
constituent  enzymes  of  OGDC  as  compared  to  PDC  and  BCOADC.  The  constituent 
enzymes of OGDC are assembled in a tight but non-covalent fashion around a 24-meric 
E2o core, exhibiting
 octahedral symmetry. In prokaryotes,
 in combination with its catalytic 
role, the oligomeric E2o core
 is responsible for tethering and orientating both the E1o and 
E3
  enzymes  within  the  complexes  via  compact,  peripheral  subunit-binding
  domains 
(Mande et al., 1996; Mattevi et al., 1992; Yeaman et al., 1978). However, analysis of rat 
and
  human  E2-OGDC  genes  revealed  the  absence  of  any  E1-  or  E3-binding  motifs,
 
although  such  sequences  were  readily  located  in  the  E2-OGDC  genes
  from  other 
organisms, notably E. coli (Spencer et al., 1984) and Azotobacter
 vinelandii (Westphal and 
de Kok, 1990). 
Studies  on  mammalian  OGDC,  employing  subunit-specific  proteolysis  and  N-terminal 
sequence  analysis,  have  identified
  a  proteolytically-sensitive  region  at  the  extreme  N-
terminus of the E1o component
 with significant sequence similarity to the E3BP and E2 
components
 of mammalian PDC (Rice et al., 1992). These similarities suggested that E1o 
might  perform  some  functions  normally  devolved  to  E2  or  E3BP  in
  PDC  and  E2-
BCOADC.  
Selective limited tryptic or arg C degradation
 of OGDC resulted in a single cleavage in 
E1o, producing an N-terminal fragment
 (approx. Mr 10,000), abolition of E3 binding and 
dissociation
  of  an  active  E1'o  species  (Mr  100,000).  Complete  disassembly
  of  OGDC 
following  this  proteolytic  event  indicated  that  this  region  of  E1o  was  critical  for  the 
maintenance  of  complex  stability  and  integrity.
  A  putative  peripheral  subunit-binding 
domain  has  been  identified
  at  the  site  of  tryptic  attack  (Rice  et  al.,  1992).  To  further 
characterise  the  N-terminal  E1o  fragment  and  to  map  the  precise  residues  involved  in Chapter 5  
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maintaining
 critical contact with E2o and E3, N-terminal fragments of human E1o have 
been cloned, overexpressed and purified and their binding potential tested in this Chapter 
in order to obtain a better understanding the subunit organisation of this complex. These 
studies  should  provide  a  more  comprehensive  insight  into  OGDC  subunit  interactions 
contributing to overall complex integrity and enable preliminary mapping of regions of 
E1o/E3  involved  in  generation  of  a  stable  association  with  the  E2o  core.  A  clear 
understanding  of  its  overall  structural  organisation  is  essential  in  view  of  mounting 
evidence  for  a  role  for  OGDC  in  a  range  of  neurodegenerative  disorders  and  its 
involvement in oxidative stress responses. Moreover, this study should provide initial data 
on the feasibility of producing a recombinant OGDC model (equivalent to our PDC model) 
that can be employed for studying its role(s) in disease in future.  
 
5.2 Cloning of full length E1o 
Two putative cDNA clones for human E1o were obtained from GeneService, Cambridge. 
Primers (Materials & Methods section 2.1.4) were designed to amplify the cDNA and to 
introduce Nde 1 and Xho 1 sites at the 5’ and 3’ termini of the amplicon. For PCR, after 
initial denaturation at 94 °C for 5 min, reactions were cycled 30 times through 94 °C (30 
s), 62 °C (30 s) and 72 °C (40 s) with a final incubation at 72 °C for 5 min. PCR products 
were resolved on a 1% (w/v) agarose gel and were found to be amplified in 6 individual 
PCRs from one clone, each yielding a major band of 3 kbp consistent with the predicted 
size  for  E1o  cDNA  (Fig.  5.1  A).  Successful  amplification  confirmed  that  this  plasmid 
contained  a  full  length  copy  of  the  gene.  Amplified  PCR  product  was  extracted  as 
described  in  Methods  section  2.2.3  and  a  sample  of  pET-14b  vector  was  prepared  by 
digestion with Nde1 and Xho1 restriction enzymes. Digested vector was also run on an 
agarose  gel and gel extracted. Then, 100 ng of vector was mixed with a 3-fold molar 
excess of insert. For ligation, a Quick Ligation Kit from New England Biolabs was used. 
Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the bacteria 
plated  onto  LB-amp  agarose  plates.  After  overnight  incubation  at  37  °C,  clones  were 
screened by colony PCR for the presence of insert. In colony PCR, around 5-6 colonies 
were picked, individually suspended in 7  l of sterilized distilled water and streaked onto a 
master plate for future use. Individual bacterial suspensions were heated at 95 °C for 5 
min, chilled on ice and centrifuged to collect 4  l of supernatant as a crude DNA template Chapter 5  
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for PCR. Diagnostic colony PCR was carried out with primers as described earlier. Only 
two clones were found to be positive. Positive clones were further screened by restriction 
digestion  analysis  (Fig.  5.1  B)  and  the  correct  reading  frame  and  E1o  sequence  again 
confirmed by DNA sequencing.  Chapter 5  
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Figure 5.1: Cloning of the E1o cDNA 
 
(A) PCR amplification of the E1o cDNA (lanes 2-7) with Nde1 and Xho1. 10 kb ladder in 
lane 1. (B) Restriction digestion of the two putative E1o clones using Nde1 and Xho1 
releasing pET-14b vector and E1o cDNA insert of the predicted size (lanes 1 & 2). 10 kb 
ladder in lane 3. 
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5.3 Overexpression of E1o 
E1o plasmids were transformed into competent E. coli BL21 (DE3) cells to enable E1o 
expression as His-tagged protein. Overexpression was attempted at 18 °C as well as 30 °C 
with 1 mM IPTG. No expression was detected on SDS-PAGE analysis as well on Western 
blotting with anti-His tag antibody (data not shown). 
Microbial  proteins  are  relatively  easy  to  express  in  the  E.  coli  host  system.  Many 
mammalian  proteins  have  also  been  overexpressed  successfully  although  these  can  be 
more difficult to obtain in active, folded form. E. coli is the quickest and most economical 
expression host of choice, being easy to scale to large volumes and suitable for generation 
of labelled proteins. However, not all large proteins can be successfully overexpressed in 
E. coli. Moreover, it is often not feasible to perform post-translational modifications that 
are required for function. E1o is a homodimer of two 100 kDa subunits and, in this case, it 
proved impossible to achieve detectable expression of this enzyme in the time available. 
To date, there  are no reports in the literature  on successful expression of recombinant 
mammalian E1o. In fact, the native enzyme is also extremely labile and difficult to study 
because of its tight association with E2o.  
 
5.4 Subcloning of E2o 
 
An E2o construct in pET-14b was already available in the laboratory. As the vector is 
ampicillin resistant, it is not suitable for carrying out co-expression with other ampicillin 
resistant  vectors.  Therefore,  E2o  cDNA  was  subcloned  from  pET-14b  into  pET-28b, 
thereby conferring kanamycin resistance as well as incorporating a N-terminal His-tag. 
Minipreps  of  E2o  pET-14b  were  prepared  and  digested  with  Xho1  (Fig.  5.2  A).  The 
digested E2o DNA was gel extracted by the standard protocol (Methods section 2.2.3). 
Minipreps of pET-28b vector were also made and cut with Xho1 in a suitable buffer. The 
linearised DNA was treated with 2.5U of calf alkaline phosphatase for 60 min. Alkaline 
phosphatase removes 5´ phosphates from the DNA and prevents re-circularization of cloning Chapter 5  
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vectors. The treated DNA was run on a 1% (w/v) agarose gel and was gel extracted using 
the Promega kit as per manufacturer’s instructions. The gel extracted E2o and pET-28b 
DNAs  were  ligated  as  described  in  Methods  section  2.2.5.  The  ligation  mixture  was 
transformed into E. coli DH5α cells. A control transformation was also carried out in the 
absence of ligation mixture. Colonies appeared on the test plate and none in the control. 
Single colonies were picked, grown overnight in LB medium and minipreps were prepared. 
The plasmids, thus prepared, were cut with Xho1 and the digested DNA mixture was run 
on  a  1%  (w/v)  agarose  gel.  The  expected  size  of  DNA  insert  was  released  indicating 
successful subcloning (Fig. 5.2 B). The correct orientation of the DNA, subcloned in pET- 
28b vector was checked by overexpression of E2o and subsequent SDS-PAGE analysis 
(Fig. 5.2 C).   
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Figure 5.2: Subcloning of the E2o 
 
(A) E2o was released from the pET-14b vector by digestion with Xho1 (lanes 1, 2 & 3). 
pET-28b vector was linearised by digesting with Xho1 (lanes 5 & 6). 10 kb ladder in lane 
4. (B) Restriction digestion of six E2o clones of pET-28b with Xho1 (lanes 1-6). 10 kb 
ladder in lane 7. (C) Orientation of the  E2o cDNA was checked by overexpressing in E. 
coli BL21 (DE3) cells at 30 ºC for 4-5 h. SDS-PAGE analysis shows overexpression at 
zero time (T0) and 5 h after induction (T5). T0 for the last overexpression is not shown here. 
Four  clones  out  of  five  tested  were  found  to  be  overexpressing  (lanes  5,  7,  9  &  10). 
Molecular weight markers (Mw) are in lane 1. 
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5.5 To investigate a possible interaction between the E2o 
and E3 enzymes of OGDC 
 
To check for any potential interaction between the E2o and E3 enzymes of OGDC, both 
enzymes were overexpressed individually at 30 ºC for 4-5 h. As both enzymes were His-
tagged,  each  was  purified  using  zinc  chelate  chromatography.  Purified  enzymes  were 
dialysed against 150 mM NaCl, 50 mM potassium phosphate, pH 7.5. The two enzymes 
were mixed and passed through a HiPrep 16/60 Sephacryl S-300 High Resolution column 
attached to a BioCAD 700E workstation equilibrated with 50mM potassium phosphate, 
150 mM NaCl, pH 7.5. Two separate peaks of eluted protein were observed. On SDS-
PAGE analysis of the individual peaks, it was found that the first peak eluting at the void 
volume contained only E2o whereas the second peak consisted solely of homodimeric E3 
that eluted at the expected position for a 100,000 Mr species (Fig. 5.3). Thus no stable 
association between E2o and E3 could be detected under these conditions. 
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Figure 5.3: Post–translational mixing of E2o and E3 followed by gel filtration  
 
(A)  E3  and  E2o  were  overexpressed  individually  and  purified  by  zinc  chelate 
chromatography as described in Methods section 2.3.6. Purified fractions of each were 
mixed  post–translationally  and  gel  filtered  through  a  Sephacryl  HiPrep  S-300  High 
Resolution  column  attached  to  a  BioCAD  700E  workstation.  Two  eluted  peaks  were 
observed, one at the void volume and another where the E3 homodimer elutes routinely. 
(B) SDS-PAGE analysis of the two peaks showed E2o (lane 1) eluting at the void volume 
and E3 (lane 2) in the later peak. Molecular weight markers (Mw) are in lane 3.   
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5.6 Overexpression and solubility check of His-tagged N 
and C-terminal truncates of E1o 
 
Constructs of the N-terminal (first 579 bases) and C-terminal (next 2313 bases) region of 
E1o in pET-14b vector were available in the laboratory. The fidelity of the constructs was 
re-checked by DNA sequencing prior to transforming individually into E. coli BL21 (DE3) 
cells. Overexpression was induced at 18 °C overnight with 1 mM IPTG when cultures 
attained an A600 of 0.5. On SDS-PAGE analysis, it was found that the N-terminal fragment 
was overexpressed whereas the C-terminal fragment failed to overexpress (Fig. 5.4 A & B) 
and could not be detected on Western blotting with an anti-His tag antibody (data not 
shown). Again, possibly owing to its large size, the E. coli expression system did not prove 
suitable for overexpression as was the case for full length E1o. A solubility check of the 
overexpressed N-terminal fragment was performed as described in the Methods section 
2.3.3. and the fragment was found to be insoluble (Fig. 5.4 A).  
 
5.7 Co-expression and interaction study on the His-
tagged N-terminal fragment of E1o and E2o 
 
His-tagged N-terminal E1o (comprising the first 193 amino acids) and His-tagged E2o 
were  co-transformed  into  E.  coli  BL21  (DE3)  cells  and  overexpressed  at  22  °C.  Co-
transformation  was  possible  because  the  E2o  construct  was  housed  in  pET-28b,  a 
kanamycin  resistant  vector  whereas  the  other  construct  was  located  in  the  ampicillin 
resistant  plasmid  pET-14b.  The  identities  of  co-expressed  and  His-tagged  E2o  and  N-
terminal E1o present in cell extracts were confirmed by Western blotting using anti-His tag 
antibody (Fig. 5.5 B). This blot also showed that N-terminal E1o overexpression was low Chapter 5  
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when co-expressed with E2o compared to the levels achieved when overexpressed on its 
own. 
The  solubility  of  the  co-expressed  proteins  was  analysed  by  the  standard  protocol 
(Methods section 2.3.3) and resolved by SDS-PAGE. Notably, it was seen that N-terminal 
E1o fragment that was completely insoluble when expressed alone (Fig. 5.4), now became 
partially soluble when co-expressed with E2o as shown by SDS-PAGE (Fig. 5.5 A).  
This indicated the possibility that the N-terminal E1o truncate may be co-integrated with 
E2o in a similar fashion to the way in which E3BP is integrated with E2 in PDC. Both the 
N-termini of E1o as well as E2o were His-tagged and therefore, could be purified on zinc 
chelate chromatography. However, its stable integration could be observed on gel filtration 
when the putative purified complex appeared as a single peak at the void volume on a 
HiPrep  16/60  Sephacryl  S-300  High  Resolution  column  and  both  the  proteins  could 
apparently be visualised by SDS-PAGE (Figs. 5.6, A & B). Owing to lack of availability of 
a suitable E1o antibody for confirming the identity of the putative E1o fragment co-eluting 
with  E2o  at  the  void  volume,  the  binding  between  the  two  could  not  be  determined 
unequivocally as the possibility remained that this band could represent a truncated, His-
tagged N-terminal product of E2o. Therefore, this apparent direct interaction was further 
examined by preparing two glutathione-S-transferase (GST) constructs of N-terminal E1o 
followed by their co-expression with E2o and purification (see sections 5.10 and 5.13) 
using ‘pull down’ assays. Chapter 5  
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Figure 5.4: Overexpression of the His-tagged N-terminal fragment and C-terminal 
region of E1o 
 
(A) The N-terminal fragment of E1o was overexpressed at 18 ºC overnight in E. coli BL21 
(DE3) cells. SDS-PAGE analysis shows expression at zero time (T0) (lane 2) and 15 h after 
induction  (T15)  (lane  3).  Solubility  checking  showed  that  it  was  mostly  insoluble  and 
present in the pellet sample (PS) (lane 5). Supernatant sample (SS) is in lane 4. Molecular 
weight markers (Mw) are in lane 1. (B) The C-terminal region of E1o was overexpressed at 
18  ºC  overnight.  SDS-PAGE  analysis  shows  no  detectable  overexpression  of  protein 
corresponding  to  an  anticipated  86  kDa  species,  15  h  after  induction  (T15)  (lane  3). 
Molecular weight markers (Mw) are in lane 1. 
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Figure 5.5: Detection of co-expression of N-terminal E1o fragment and E2o 
 
(A) E2o and the N-terminal E1o fragment were co-expressed at 22 ºC overnight. SDS-
PAGE analysis on a 4-12% Bis-Tris shows expression at zero time (T0) and 15 h after 
induction (T15). Solubility checking showed that both E2o as well as a band corresponding 
to  the  expected  size  of  the  E1o  fragment  were  soluble  and  present  in  the  supernatant 
sample (SS) (lane 2). Pellet sample (PS) in lane 1. Molecular markers are in lane 5. (B) 
Since the levels of expression were poor, the identities of His-tagged E2o & N-terminal 
E1o fragment were confirmed by Western blotting with anti-His tag antibody. Blotting 
analysis  shows  overexpressed  N-terminal  E1o  (lane  1)  as  a  positive  control  and  co-
expressed E2o and N-terminal E1o (lane 2).   
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 Figure 5.6: Gel filtration of co-expressed and purified E2o and N-terminal E1o  
 
(A)  E2o  and  N-terminal  E1o  were  co-expressed  and  purified  by  zinc  chelate 
chromatography.  Purified  fractions  were  pooled  and  gel  filtered  through  a  Sephacryl 
HiPrep S-300 High Resolution column attached to a BioCAD 700E workstation. (B) On 
SDS-PAGE  analysis  of  the  single  peak  eluting  at  the  void  volume,  E2o  as  well  as  a 
putative  E1o  fragment  were  visualised  indicating  the  possible  formation  of  a  high  Mr 
complex between the two species (lane 2). Molecular weight markers (Mw) are in lane 1. 
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5.8 Subcloning cDNA encoding an N-terminal E1o 
fragment (166 amino acids) into pGEX-2T  
 
The E1o cDNA sequence encoding the first 166 amino acids of mature E1o was subcloned 
into pGEX-2T using the previous N-terminal construct housed in pET-14b as a template. 
This step was carried out in order to facilitate protein-protein interaction studies using ‘pull 
down’ assays with a GST-fused E1o fragment and His-tagged E2o. It was also considered 
that expression of the E1o fragment as a GST fusion may aid solubility when expressed in 
the absence of E2o, thereby enabling investigations on whether any potential binding to 
E2o occurred in a co- or post-translational fashion.   
For cloning, the first 498 nucleotides were amplified by PCR and BamH1 and EcoR1 sites 
were created at the 5’ and 3’ termini of the amplicon by designing and employing suitable 
primers (Materials & Methods section 2.1.4). For PCR, after initial denaturation at 94 °C 
for 5 min, reactions were cycled 30 times through 94 °C (30 s), 56 °C (30 s) and 72 °C (40 
s) with a final incubation at 72 °C for 5 min. PCR products were resolved on a 1% (w/v) 
agarose  gel  and  were  found  to  be  amplified  as  expected.  Amplified  PCR  product  was 
extracted using a gel extraction kit as described in Methods section 2.2.3. A sample of 
pGEX-2T vector was prepared by digestion with BamH1 and EcoR1 then run on a 1% 
(w/v) agarose gel and extracted. Digested vector (100 ng) was mixed with a 3-fold molar 
excess of insert  for ligation using the Quick  Ligation Kit  from New England  Biolabs. 
Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the bacteria 
plated onto LB-amp agarose plates containing ampicillin. After overnight incubation at 37 
°C, colonies appearing on the plate were picked and plasmids prepared. Plasmids were 
screened by restriction digestion with BamH1 and EcoR1 (Fig. 5.7). Positive clones were 
further checked by sequencing.  Chapter 5  
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5.9 Overexpression and purification of the N-terminal E1o 
GST fusion protein (first 166 amino acids) 
 
The pGEX-2T construct containing N-terminal E1o cDNA (corresponding to the first 166 
amino acids) was transformed into E. coli BL21 (DE3) cells. Overexpression was carried 
out at 30 °C for 4-5 h after induction with 1 mM IPTG. Expression was analysed by SDS-
PAGE (Fig. 5.8).  
Frozen  pellet  from  an  overexpressed  culture  (500  ml)  was  disrupted  by  French  press 
treatment  as  described  in  Methods  section  2.3.2  and  the  soluble  supernatant  fraction 
containing  GST-fusion  protein  purified  by  glutathione  Sepharose  4B  chromatography 
(Methods section 2.3.13). Two protease inhibitor tablets (EDTA free) were added before 
French press treatment. 
SDS-PAGE analysis of the purified fractions showed extensive degradation of the GST- 
tagged E1o fragment. However, some intact fusion protein (predicted size 45 kDa; 18 kDa 
E1o  fragment  coupled  to  the  27  kDa  subunit  of  GST)  could  be  isolated.  Lower  Mr 
degradation products of this fusion protein and a band corresponding to the GST protein 
(27 kDa) were also observed (Fig. 5.8). Neither addition of 1 mM EDTA and DTT nor 
expressing  at  lower  temperatures  in  subsequent  experiments  helped  to  limit  this 
degradation.  
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Figure 5.7: Cloning of the N-terminal E1o fragment (corresponding to first 166 amino 
acids) into pGEX-2T  
 
PCR  product  corresponding  to  the  N-terminal  E1o  region  (first  166  amino  acids)  was 
cloned into pGEX-2T. Diagnostic restriction digestion of putative clones was performed 
with  BamH1  and  EcoR1.  One  clone  was  positive  out  of  four  tested  (lane  3)  releasing 
correct-sized insert and vector. Clones in lanes 2 and 4 were discarded as the vector size 
was incorrect although they appeared to contain appropriate inserts. 10 kb ladder in lane 5.   
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Figure 5.8: Overexpression and purification of the E1o fragment (first 166 amino 
acids) fused with GST 
 
(A) N-terminal E1o fragment (166 amino acid) fused with GST was overexpressed at 30 
ºC for 4-5 h. SDS-PAGE analysis on a 4-12% Bis-Tris shows expression at zero time (T0) 
and after 5 h induction (T5). The protein was purified using a glutathione Sepharose 4B 
column (lane 1) and shows extensive degradation. Molecular weight markers (Mw) are in 
lane 4.  
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5.10 Interaction between E2o and the GST fused E1o N-
terminal fragment (first 166 amino acids) 
 
The pGEX-2T construct containing the 5’ region of the open reading frame of mature E1o- 
cDNA (166 amino acids) and E2o cDNA in pET-28b were co-transformed into E. coli 
BL21 (DE3) cells. Overexpression was attempted at 30 °C for 4-5 h after induction with 1 
mM  IPTG.  Protein  expression  was  analysed  by  SDS-PAGE  (Fig.  5.9).  Pellet  (500  ml 
culture) was disrupted using French press treatment as described in Methods section 2.3.2 
and the soluble supernatant fraction containing GST fusion protein purified by glutathione 
Sepharose 4B affinity chromatography as described in the Methods section 2.3.13. Two 
tablets of protease inhibitors (EDTA free) were added before French press treatment. 
SDS-PAGE  analysis  of  the  purified  fractions  showed  the  presence  of  a  band  of  the 
predicted size for E2o and therefore a possible integration of E2o with the E1o fragment 
(Fig. 5.9). In the previous experiment also (section 5.7), the N-terminal E1o fragment was 
found to be integrating with E2o. No Western blotting was attempted at this point in order 
to verify the identities of the constituent polypeptides because of extensive degradation of 
the purified proteins.  
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 Figure 5.9: Co-expression and purification of the E2o and N terminal E1o GST 
fusion protein (first 166 amino acids) 
 
SDS-PAGE analysis shows co-expression of E2o and N terminal E1o GST fusion protein 
at  zero  time  (T0)  and  5  h  (T5)  after  induction.  Soluble  fraction  obtained  from  an 
overexpressed  culture  (500  ml)  after  French  Press  treatment  was  purified  using  a 
glutathione Sepharose 4B column (lane 4) indicating possible E2o co-association with the 
E1o fragment. Molecular weight markers (Mw) are in lane 1.  
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5.11 Subcloning cDNA encoding an N-terminal E1o 
fragment (83 amino acids) into pGEX-2T   
The previous experiment (see section 5.10), again suggested a possible integration of E2o 
with the N-terminal E1o GST fusion protein. However, substantial degradation of the E1o 
fragment was also observed in several attempts to repeat this study, making it difficult to 
draw any definitive conclusions. To determine more precisely the putative E2o binding site 
on  E1o  and  to  possibly  limit  degradation,  the  first  83  amino  acids  of  mature  E1o 
corresponding to the first 249 nucleotides of mature E1o were subcloned into pGEX-2T.  
For this investigation, the first 249 nucleotides were amplified and BamH1 and EcoR1 sites 
created at the 5’ and 3’ termini of the amplicon by designing and employing the primers as 
described in Materials & Methods section 2.1.4. For PCR, after initial denaturation at 94 
°C for 5 min, reactions were cycled 30 times through 94 °C (30 s), 58 °C (30 s) and 72 °C 
(40 s) with a final incubation at 72 °C for 5 min. PCR products were resolved on a 1% 
(w/v) agarose gel and were found to be amplified. Amplified PCR products were extracted 
using a gel extraction kit as described in Methods section 2.2.3. pGEX-2T vector was 
prepared by digestion with BamH1 and EcoR1 restriction enzymes and digested vector  
also run on an agarose gel and gel extracted. Then, 100 ng vector was mixed with 3-fold 
molar excess of insert for ligation employing a Quick Ligation Kit from New England 
Biolabs. Ligation mix (5 ng) was transformed into competent E. coli TOP 10 cells and the 
bacteria were plated onto LB agarose containing ampicillin. After overnight incubation at 
37 °C, clones were prepared and screened by restriction digestion with BamH1 and EcoR1 
for the presence of the correct-sized insert (Fig. 5.10). Positive clones were further checked 
by DNA sequencing.    
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Figure 5.10: Cloning of the E1o cDNA fragment encoding its N-terminal sequence (83 
amino acids) into pGEX-2T  
 
PCR product encoding the N-terminal E1o fragment was cloned into pGEX-2T. Restriction 
digestion of putative recombinant clones treated with BamH1 and EcoR1 is shown. One 
clone was positive, out of three tested (lanes 2-4), containing an insert of the right size 
(lane 3).                                   
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5.12 Overexpression and purification of the N-terminal 
E1o GST fusion protein (first 83 amino acids) 
 
The  N-terminal  E1o  GST  fusion  protein  (containing  the  first  83  amino  acids)  was 
overexpressed and purified in the same manner as the 166 amino acid E1o-GST fusion 
protein described in section 5.9. On SDS-PAGE analysis, this fragment was also found to 
be  sensitive  to  degradation  although  this  was  less  problematic  than  for  the  larger  N-
terminal truncate (Fig. 5.11). However, significant amounts of intact fusion protein of the 
predicted size (36 kDa) were present (9 kDa E1o fragment fused with the 27 kDa GST). 
Free GST (27 kDa) was also observed (Fig. 5.11). The proteolytical degradation did not 
appear  to  occur  during  overexpression  in  vivo,  but  was  apparent  after  French  press 
treatment or at the end of the purification process. Addition of 1% (v/v) rat serum reduced 
but  did  not  completely  eliminate  this  degradation.  Further  addition  of  more  protease 
inhibitors (2 mM PMSF, 0.15 mM leupeptin, 15 mM aprotinin, 1.5 mM pepstatin) and also 
ensuring that the purification process was conducted rapidly and efficiently at 4 °C still did 
not prevent significant degradation.  
 
5.13  Interaction  between  E2o  and  N-terminal  E1o  GST 
fusion protein (first 83 amino acids) 
 
N-terminal  E1o  cDNA  (corresponding  to  first  83  amino  acids)  in  pGEX-2T  and  E2o 
cDNA in pET-28b were co-transformed into E. coli BL21 (DE3) cells. Overexpression was 
carried  out  at  30  °C  for  4-5  h  after  induction  with  1  mM  IPTG.  The  expression  was 
analysed by SDS-PAGE. Pellet from overexpressed culture  (500 ml) was disrupted by 
French press treatment as described in Methods section 2.3.2 and the soluble supernatant 
fraction purified by glutathione Sepharose 4B chromatography (Methods section 2.3.13). Chapter 5  
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Two tablets of protease inhibitors (EDTA free) and 1% (v/v) rat serum were added before 
French press treatment.  
SDS-PAGE analysis of the purified fractions showed the presence of E2o along with E1o 
GST fusion protein (Fig 5.11). The presence of E2o was further confirmed using an anti-
His tag antibody to detect His-tagged E2o (Fig. 5.12 A). 
To ensure that E2o was interacting specifically with the E1o fragment and not with free 
GST, E2o was also co-expressed with free GST in BL21 (DE3) cells at 30 °C for 4-5 h 
after induction with 1 mM IPTG. The supernatant fraction from a disrupted pellet (500ml  
culture) was purified by glutathione Sepharose 4B chromatography. On Western blotting 
of the purified fraction with anti-His tag antibody, His-tagged E2o could not be detected 
(Fig. 5.12 B) indicating that E2o was not binding adventitiously to the GST tag. These 
results demonstrated conclusively for the first time that the first 83 amino acids of N-
terminal E1o were crucial for integrating with E2o. 
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Figure 5.11: Purification of N-terminal E1o GST fusion protein (first 83 amino acids) 
alone and when co-expressed with E2o  
 
E1o fragment (first 83 amino acids) fused with GST was overexpressed alone and with 
His-tagged  E2o  at  30  ºC  for  4-5  h  in  two  individual  experiments.  Soluble  fractions 
obtained  from  both  overexpressed  cultures  (500  ml)  after  French  Press  treatment  were 
purified separately using glutathione Sepharose 4B chromatography. SDS-PAGE analysis 
of purified fractions on a 4-12% Bis-Tris SDS gel shows the N-terminal E1o GST fusion 
protein (83 amino acids) (lane 2) and E2o integrated with N-terminal E1o GST fusion 
protein (lane 3). Molecular weight markers (Mw) are in lane 1. 
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Figure 5.12: Confirming the interaction of E2o with its N-terminal E1o partner  
 
(A1) N-terminal E1o GST fusion protein (83 amino acids) and His-tagged E2o were co-
expressed. SDS-PAGE analysis of the fractions purified using glutathione Sepharose 4B 
chromatography (lane 3) and E2o purified by zinc chelate chromatography as a positive 
control (lane 2). (A2) Western blotting of the above with anti-His tag antibody shows that 
E2o was integrated with E1o GST-fusion protein (lane 3). E2o as positive control is in lane 
2.  (B1)  SDS-PAGE  analysis  of  co-expressed  E2o  and  GST  purified  on  glutathione 
Sepharose 4B (lane 3), E2o as positive control in lane 4 and GST as negative control is in 
lane 2. Molecular weight markers are in lane 1. (B2) Western blotting of the above with 
anti-His tag antibody shows that E2o was absent (lane 3) and therefore does not bind non-
specifically with the GST tag.  
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5.14 Discussion of subunit organisation in the OGDC 
 
The structure and subunit organization of mammalian OGDC has not been analysed in 
depth as compared to other organisms although its E2o core is similarly organised as a 24-
meric cube with octahedral (432) symmetry (Reed and Hackert, 1990). In contrast, the 
structure and catalytic mechanism of the bacterial E2o core, to which the E1o and E3 
components are tethered non-covalently, has been elucidated in some detail (Hackert et al., 
1983). In mammalian OGDC, an early report also suggested that E1o appears to bind more 
tightly to E2o than does E3 (Yeaman et al., 1978).  
Studies  on  mammalian  OGDC,  employing  subunit-specific  proteolysis  and  N-terminal 
sequence analysis, have identified
 a proteolytically sensitive site in the N-terminal region 
of E1o that, on cleavage, leads to rapid inactivation of the complex and dissociation of 
both  a  large,  enzymatically-active,  C-terminal  E1’o  fragment  and  E3.  This  region  also 
displays significant sequence similarity to the E3BP and E2 components
 of mammalian 
PDC (Rice et al., 1992). These similarities suggested that E1-OGDC may perform some 
functions normally devolved to E2:E3BP in
 PDC and E2 in BCOADC. Further indirect 
evidence, in support of additional roles for E1o, came when the genes for rat and
 human 
E2o were cloned (Nakano et al., 1991; Nakano et al., 1994). Analysis of their predicted
 
primary structures failed to locate any E1o or E3-binding motifs,
 although such sequences 
were readily located in E2-OGDC genes
 from other organisms, notably Escherichia coli 
(Spencer et al., 1984) and Azotobacter
 vinelandii (Westphal and de Kok, 1990). Another 
report suggested that single copies of full length bovine E1o and E3 form a stable 1:1 
complex that binds to the E2o core with high affinity via the N-terminal region of E1o 
(McCartney et al., 1998).  
In mammalian OGDC, the E1o enzyme also has high affinity for the E2o core assembly, a 
property it
 shares with the E3BP of PDC (Sanderson et al., 1996a). This affinity is so great 
that attempts
 to use low (non-denaturing) levels of GdmCl to dissociate E1o from the intact 
core also proved futile.
 The successful dissociation of mammalian OGDC into active E2o 
and
  E1o/E3  fractions  was  achieved  by  employing  high  levels  of  MgCl2  and  slightly 
alkaline
 pH to achieve optimal dissociation with minimal denaturation of
 the individual Chapter 5  
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enzymes, yielding functionally active E2o
 and E1o/E3 fractions (McCartney et al., 1998). 
These studies provided the first direct biochemical evidence that
 uniquely, in mammalian 
OGDC, its constituent E1o enzyme is responsible
 for binding the E3 component to the core 
of this multienzyme complex.
  
As indicated previously, selective proteolysis of bovine OGDC with protease arg C has 
shown  that,  with  a  single  cleavage,  a  100  kDa  E1’o  C-terminal  fragment  and  E3  are 
released from E2o (Rice et al., 1992). The cleavage site of E1’o in bovine OGDC is shown 
in Fig. 5.13 and this amino acid sequence shows great similarity with the human E1o. 
However, as the precise arg C cleavage site in bovine E1o is not conserved in human E1o, 
it is not known whether human E1o can be selectively cleaved in a similar fashion. 
Interestingly, there is no direct evidence to show that E3 interacts with E1’o with high 
affinity (Rice et al., 1992). In previous studies, on gel permeation of an isolated, full-length 
E1o/E3  fraction  under  associative  conditions,  the  presence
  of  a  higher  Mr  assembly 
(303,000 kDa) corresponding to an E1:E3
 sub-complex exhibiting 1:1 stoichiometry was 
detected. Moreover, it was observed that
 limited proteolysis of OGDC promotes release of 
both a large C-terminal E1’o fragment and E3, implying that
 sequences critical for their 
tight interaction with the E2o core
 reside in the N-terminal region (McCartney et al., 1998). 
It was not clear, however, from these two previous publications whether E3 was released 
directly as a consequence of its binding to E1o or whether E3 association with the core is 
also  dependent  on  the  integrity  of  the  extreme  N-terminal  region  of  E1o.  A  potential 
interaction between E1’o and E3 could not be evaluated in this study owing to the non-
availability of recombinant E1’o.  
In  this  chapter,  the  main  aim  was  to  map  the  region  of  E1o  that  was  involved  in 
maintaining high affinity contact with E2o. For this, full length E1o was cloned in pET-
14b. Nucleotide sequence corresponding to the first 193, 166 and 83 amino acids of mature 
E1o  were  also  cloned  in  pET-14b  and  pGEX-2T  respectively.  For  studying  the  co-
expression of E1o with E2o, E2o cDNA was subcloned into a kanamycin resistant vector, 
namely  pET-28b.  All  the  cloning  strategies  employed  were  successful;  however,  no 
detectable  expression  of  full  length  E1o  was  achieved  in  E.  coli.  Difficulties  in 
overexpressing and producing soluble E1-PDC were also observed in the past, but finally 
solved  by  cloning  into  pQE-9,  and  overexpressing  in  E.  coli  M15  cells  although  only 
limited amounts of active E1 were produced. The available His-tagged, N-terminal E1o 
fragment (193 amino acids) failed to produce soluble protein (Fig. 5.5). However, when Chapter 5  
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this N-terminal fragment was co-expressed with E2o, a putative soluble N-terminal E1o: 
E2o complex was obtained and the two proteins co-eluted on gel filtration (Fig. 5.6 A, B). 
This  was  the  first indication  that  indeed  the  N-terminal  region  of  E1o  was  capable  of 
forming a stable complex with E2o. However, this was an ambiguous result because the N-
terminal fragment was identified only on the basis of SDS-PAGE analysis and Coomassie 
blue  staining.  The  same  result  was  obtained  subsequently  by  employing  two  different 
pGEX-2T constructs harbouring different lengths of N-terminal E1o. 
To examine whether the first 80-85 amino acids or a longer N-terminal E1o sequence was 
required  to  promote  this  high  affinity  interaction,  two  pGEX-2T  constructs  of  E1o  N-
terminal truncates were employed. Both E1o GST fusion proteins (83 and 166 amino acids 
respectively)  were  relatively  soluble  as  compared  to  the  His-tagged  E1o  fragment  and 
appeared to bind tightly with E2o in GST ‘pull down’ assays using glutathione Sepharose 
4B chromatography (Figs. 5.9 & 5.11). In addition, interaction of E2o with wild-type GST 
was  excluded  in  control  ‘pull  down’  assays  and  Western  blotting  (Fig.  5.12  B).  The 
interaction between E2o and the short (83 amino acid) N-terminal E1o fragment was also 
confirmed by Western blotting (Fig. 5.12 A) showing that the presence of this extreme N-
terminal region was crucial for binding to E2o. These data were consistent with earlier 
selective  proteolysis  data  in  bovine  OGDC  where  a  61  amino  acid  N-terminal  E1o 
fragment remains attached to E2o upon treatment of OGDC with arg C (McCartney et al., 
1998).  
In a parallel study, the affinity of E3 for E2o was examined by purifying the two enzymes 
individually followed by mixing and gel filtration (Fig. 5.3 A, B). The two enzymes did 
not  display  any  affinity  for  each  other,  eluting  as  individual  peaks  at  their  respective 
elution  volumes  on  gel  filtration.  Thus  E3  is  unable  to  enter  into  a  stable  association 
directly with E2o as anticipated. Therefore, E1o involvement appears crucial for mediating 
formation of a stable multienzyme assembly that promotes E3 integration with the E2o 
core.  
Although it is possible that the N-terminal residues of E1o may be involved in interacting 
with  E3  directly,  nevertheless  no  co-  or  post-translational  binding  studies  between  N-
terminal  E1o  and  E3  were  performed  as  a  result  of  time  constraints.  However,  it  was 
shown that the extreme N-terminal region (first 83 amino acids) of E1o co-integrated with 
E2o to form a stable complex and moreover, it was conclusively demonstrated that E2o 
alone does not bind E3 to OGDC.        Chapter 5  
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Most  of  the  earlier  research  investigating  the  morphology  and  subunit  organisation  of 
OGDC have employed native complex purified from various organisms. The isolation of 
individual enzyme components has proved difficult owing to the tight association of the 
E1o  and  E2o  components.  Stringent  conditions  using  chaotrophic  agents  such  as  3  M 
MgCl2  are  required  to  achieve  separation.  In  this  project,  recombinant  enzymes  were 
employed in an attempt to overcome these difficulties. Recently recombinant homodimeric 
E1o from E. coli has been crystallised and its structure elucidated in detail (Frank et al., 
2007). Interestingly, this crystal structure could only be obtained when the first 84 amino 
acid residues were removed by tryptic digestion. It was suggested by the authors that this 
distinctive N-terminal region may extend outwards from the core ‘fold’ and is required to 
mediate interactions with the other components of OGDC. These observations also show 
that the N-terminal E1o region is likely to be  structurally dynamic, consistent with its 
presence preventing the crystallisation process. This N-terminal segment displays a high 
degree of immunogenicity as compared to the large C-terminal E1’o region in mammalian 
OGDC  (McCartney  et  al.,  1998),  also  indicative  of  the  presence  of  a  flexible  and/or 
extended region of polypeptide.  
In our current research, the first 83 and 166 amino acids of human E1o have been cloned, 
overexpressed and purified as GST fusion proteins. These fragments were very prone to 
degradation  and  therefore  any  possible  interactions  of  E3  with  these  N-terminal  E1o 
truncates alone or with an equivalent E1o:E2o subcomplex could not be assessed in the 
time available. Degradation was controlled to some extent by addition of 1% (v/v) rat 
serum containing serine protease inhibitors that are effective against trypsin, chymotrypsin 
and  elastase  (Kuehn  et  al.,  1984).  Another  reason  for  rapid  degradation  could  be  the 
intrinsic susceptibility of the N-terminal E1o region to proteolysis, a property that has been 
noted also with bovine E1o. This again indicates its probable presence as an extended, 
flexible segment of polypeptide as suggested by Frank et al. (2007).  
In this series of experiments, E1o protein production was problematic, in terms of good 
yields of soluble protein and degradation of GST-tagged protein; however, degradation 
was reduced to some extent when E1o fragments were co-expressed with E2o when a 
stable E1o:E2o complex could be purified. It was not possible, however, to determine if a 
stable  interaction  between  E2o  and  this  N-terminal  E1o  region  could  also  occur  post-
translationally owing to the rapid degradation of the various E1o truncates.  Assessing if Chapter 5  
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either these short N-terminal E1o fragments or the large E1’o C-terminal polypeptide can 
enter into a stable association with E3 is clearly a priority for future work.  
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E1 OGDC bovine TAPVA- EPFLSGTSSNYVEEMYYAWLENPKSVHKSWDIFFRNTNAGAPPGT 
E1 OGDC human SAPVAAEPFLSGTSSNYVEEMYYAWLENPKSVHKSWDIFFRNTNAGAPPGT 
 
E1 OGDC bovine AYQSPLPLSPG- LSAVAR    AGPLVEAQPNVDKLV 
E1 OGDC human  AYQSPLPLSRGSLAAVAH  A QSLVEAQPNVDKLV 
                               
Figure 5.13: Alignment of first 83 amino acids of mature N-terminal E1o of bovine 
and human OGDC 
 
The arrow shows the site where E1’o forms as a result of arg C cleavage of bovine heart 
OGDC. The amino acids in magenta match completely showing high degree of homology 
between  human  and  bovine  E1o.  The  E1’o  sequence  in  bovine  starts  from  residue  G, 
probably due to loss of A residue due to the presence non-specific amino peptidases.    
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Chapter 6 
 
Conclusions 
 
In the last 20 years, the 2-oxoacid dehydrogenase complexes have continued to be the 
subject of intensive investigation. Thus the constituent enzymes have now been cloned, 
overexpressed and purified from a variety of different organisms. Most of the research on 
these complexes has so far been based on the analysis of structure, function and interaction 
of the constituent enzymes, regulated by their associated kinases and phosphatases in the 
case of mammalian PDC and BCOADC. 
In this study, for the first time all the constituent catalytic subunits/enzymes of human PDC 
were overexpressed, purified to homogeneity and reconstituted to form a fully functional 
recombinant PDC model. This recombinant multienzyme complex with an overall Mr 9-10 
MDa was found to be fully active in enzymatic assays and displayed a similar specific 
activity (3.5-4  mol NADH min 
–1 mg protein
–1) to PDC extracted from human heart tissue 
(Palmer  et  al.,  1993).  The  recombinant  model  was  prepared  with  a  view  to  studying 
recently  identified  novel  mutations  in  the  E2  enzyme  encountered  in  three  patients 
diagnosed with PDC deficiency symptoms at Oxford Medical School. Before using this 
recombinant  model  to  analyse  the  effect  of  these  mutations  on  structure,  function  and 
assembly, the model was first tested to assess its ability to mimic the effects of combining 
active and inactive lipoyl domains in the E2:E3BP core. For this, eight mutant recombinant 
E2:E3BP  cores  were  constructed,  overexpressed,  purified  and  reconstituted  to  form Chapter 6  
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functional complex by the addition of E1 and E3, in which the lipoyl domains of E2 and 
the  single  lipoyl  domain  of  E3BP  were  mutated  in  various  combinations  to  prevent 
lipoylation and thereby render the domains completely inactive (see section 3.14).  
In this study, as has been previously observed with E. coli PDC, there appears to be a 
considerable degree of functional redundancy in terms of the presence of multiple lipoyl 
domains. Thus loss of lipoylation of either outer or inner lipoyl domains of E2 resulted in 
only a 25-35% decline in overall activity. In addition, the presence of lipoylated or non-
lipoylated E3BP had little apparent effect on PDC activity. Interestingly, mutant PDCs in 
which  E2  lipoyl  domains  were  totally  inactive  still  retained  approx.  10-15%  activity 
mediated  by  the  12  remaining  lipoyl  groups  of  E3BP.  This  latter  observation  is  in 
agreement with a previous study (Sanderson et al., 1996a), in which E2 lipoyl domains 
were removed by collagenase treatment generating a modified complex that still retained 
15% residual activity.  
In previous studies assessing a role for the presence of multiple lipoyl domains, the local 
environment  of  the  remaining  lipoyl  domain(s)  in  mutant  PDCs  was  highly  perturbed, 
potentially reducing steric hindrance effects and allowing the remaining domain(s) greater 
flexibility to visit the active sites of all 3 enzymes during the catalytic cycle. This could 
have led to overestimation of the activity of the modified complex and the versatility of 
individual lipoyl domains in serving as effective substrates for all 3 active sites. In this 
study for the first time, a full complement of correctly folded lipoyl domains was retained, 
either in active or inactive form in the recombinant PDC, without affecting the native 
structure of the complex and their redundancy status re-evaluated. However, results were 
consistent with earlier studies demonstrating the existence of a high degree of functional 
redundancy and showing that all lipoyl domains on E2 and E3BP appeared to interact 
effectively with all three partner enzymes.    
The  validity  of  the  recombinant  PDC  model  for  analysing  natural  mutations  was  also 
assessed  in  another  study  where  the  function  of  the  normal  recombinant  PDC  was 
compared to recombinant PDC without E3BP. PDC devoid of E3BP displayed residual 
activity of 3-8% in the presence of stoichiometric amounts of E3. About 10-20% activity 
has been reported in patients lacking the E3BP subunit (Marsac et al., 1993) where E3 is 
considered to bind weakly to a secondary site on E2. However, the activity of recombinant 
complex lacking E3BP could be significantly raised by adding a 100-200 fold excess of 
E3. This result substantiated an important previous finding by Dr. Susan Richards in this Chapter 6  
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laboratory using surface plasmon resonance (unpublished data) that the E1 binding site on 
E2 retains a residual affinity for E3. When excess amounts of E3 were added to wild-type 
recombinant PDC, its activity declined gradually due to partial displacement of E1 from its 
E2-binding site, again confirming its retention of a residual affinity for E3.   
Further analysis of recombinant PDC lacking E3BP was used to study whether E3BP was 
uniquely involved in the diacetylation reaction i.e. the production of a S
6, S
8 diacetyl-
dihydrolipoamide  intermediate  that  is  known  to  be  exclusive  to  mammalian  and  yeast 
PDC.  The  role  of  diacetylation  is  unknown  but  could  be  of  physiological  importance, 
enabling PDC to act as a reservoir of  acetyl  groups and electrons under conditions of 
excess acetyl CoA and NADH production e.g. in diabetes, high fat diet or in starvation, 
providing a buffer against ketone body production. Diacetylated forms of PDC (produced 
by treatment with AcCoA and NADH or pyruvate in the absence of AcCoA) are protected 
from inactivation by the specific thiol group inhibitor, NEM (Sanderson et al., 1996b). 
Recombinant PDC lacking E3BP, but with a 200-fold excess of E3, was similarly treated 
with AcCoA and NADH. Recombinant PDC in which E3BP was absent, in addition to 
wild-type control was found to be protected from the inhibitory effect of NEM, indicating 
that the E3BP component was not responsible for diacetylation. The recombinant model of 
PDC was found to be an ideal tool to study this phenomenon because it is difficult to 
obtain native PDC complex lacking E3BP which is tightly integrated into the E2 core and 
cannot be readily removed without E2 disassembly. To date no enzymatic function has 
been identified for E3BP and our current analysis also rules out its potential involvement in 
the diacetylation process that is presumably mediated by E2. 
After  checking  the  functional  properties  of  our  recombinant  PDC  model,  it  was 
successfully employed to study three natural mutations observed in patients. Two of these 
mutations were unusual homozygous ‘in-frame’ 3 base pair deletions in E2. One mutation 
was in the outer lipoyl domain of E2 leading to the deletion of glutamate 35 whereas the 
second mutation caused the loss of valine at position 455 that is located in the C-terminal 
domain. The third mutation was the substitution of a leucine for a phenylalanine at position 
490  near  the  active  site  of  E2.  The  main  objective  of  this  study  was  to  analyse  these 
mutations in order to gain detailed information on the molecular basis of these PDC defects 
and also ascertain the validity of this model recombinant PDC system for analysing newly- 
discovered genetic mutations of this type. Chapter 6  
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All these mutations caused symptoms of PDC deficiency in the relevant patients; however, 
the exact mechanism of production of clinical symptoms was unclear. Moreover, in the 
case of the glutamate-35 deletion where the deletion was near to a lipoylatable lysine in the 
outer lipoyl domain, the clinical symptoms were difficult to explain simply in terms of 
possible loss of lipoylation of a single lipoyl domain. Inactivation of a single E2 lipoyl 
domain leads to only about 25-30% reduction in the PDC activity and was not expected to 
elicit any obvious phenotype. Moreover the patient showed about 70% loss of activity as 
measured by CO2 release assay. All mutations were successfully introduced into E2:E3BP 
cores and a series of experiments conducted to determine changes in structure, enzymatic 
function and assembly of the mutant complexes. It was demonstrated that the glutamate 
deletion not only affected lipoylation per se, but led to misfolding of the outer domain or 
domain  instability  rendering  it  ‘sticky’  and  prone  to  aggregation.  In  addition,  it  was 
observed that the proper folding of this N-terminal region is crucial for the correct folding 
and assembly of the C-terminal domain of E2 and its integration with E3BP. It is proposed 
that inappropriate interactions of the N-termini of E2 polypeptide chains disrupt native 
trimer assembly involving the C-terminal regions of E2 and/or E3BP (Fig. 6.1). Indeed the 
AUC data suggested that a proper core was not forming in this case, which could be caused 
by premature and inappropriate aggregation of outer lipoyl domains leading to aberrant 
core  assembly/function.  However,  in  these  experimental  conditions  some  core  of  the 
correct size was present and indeed the extent of native core formation correlates well with 
the residual activity in the patient.    
The  reduced  PDC  function  in  the  case  of  F490L  mutation  appeared  to  be  a  relatively 
straightforward case where no major structural changes were detected, but partial loss of 
acetyltransferase activity was confirmed due to the presence of this mutation in the vicinity 
of the catalytic site. Moreover, this phenylalanine has also been reported to be important 
for the determination of substrate specificity (Mattevi et al., 1993b). It would be of great 
interest to assess the ability of this mutant E2 to use with other substrates to determine if it 
had acquired a broader substrate specificity as a result of this mutation.  
Analysis  of  the  valine-455  deletion  proved  to  be  problematic.  This  mutation  was 
responsible  for  the  deletion  of  a  highly  conserved  valine-455  that  has  the  potential  to 
disrupt the catalytic activity or E2 core assembly. A partial loss of catalytic activity (about 
50%) was demonstrated in the mutant PDC as well as the E2 enzyme and E2:E3BP core 
although  in  all  other  respects  core  formation  and  E3BP  integration  appeared  normal. 
However, in this case the patient appeared to retain no immunologically detectable levels Chapter 6  
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of E3BP. Our initial working hypothesis was that the valine-455 deletion on E2 may be 
responsible for prevention of E3BP integration and that free E3BP was rapidly degraded 
but  no  evidence  was  obtained  to  support  this  prediction.  A  full  clinical,  genetic  and 
biochemical re-evaluation of this patient is currently in progress.  
In this project, a reconstituted model of PDC comprising all three constituent enzymes and 
the accessory structural protein, E3BP has been used for the first time to uniquely evaluate 
these rare mutations. From a clinical viewpoint, the in vitro approaches employed here can 
form  a  basis  for  providing  more  comprehensive  diagnosis  and  possibly  developing 
improved treatment regimes in future. Often diagnosis of such mutations leading to PDC 
deficiency is made from clinical symptoms and CO2 release assays of cultured fibroblasts 
which  are  cumbersome,  time-consuming,  expensive  and  require  considerable  expertise. 
This type of study employing recombinantly-produced complex should provide important 
new information on subunit interactions/organisation and mode of assembly. Moreover, the 
the data obtained will enable clinicians and patients to gain a much clearer picture of the 
precise biochemical lesions associated with a particular genetic defect. Although PDC has 
been  studied  extensively  for  its  structural  and  functional  roles,  nevertheless,  the 
development  of  this  novel  model  system  can  further  provide  new  insights  into  the 
functioning of PDC at a molecular level under normal and disease conditions 
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Figure 6.1: Schematic representation depicting formation of normal and abnormal 
cores of E2:E3BP carrying the D D D DE35 E2 mutation   
The upper part of the diagram (A) shows formation of normal trimers of E2 and E3BP 
polypeptides interacting via their C-terminal domains leading to native core assembly. In 
the case of the DE35 mutation in the outer lipoyl domain (B), abnormal oligomers of E2 
and E3BP have an increased tendency to aggregate due to inappropriate association of the 
N-termini of E2 polypeptide disrupting native trimer assembly that involves the C-terminal 
regions of E2 and/or E3BP. The dotted line indicates that a small amount of native core is 
also being assembled under these conditions.    
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The  last  chapter  describes  our  preliminary  attempts  to  generate  a  recombinant  OGDC 
model. Human OGDC is less widely studied as compared to PDC. Its constituent enzymes 
are equivalent to those in PDC i.e. E1, E2 and E3, but without any homologue of E3BP. 
However, a recombinant model of OGDC on similar lines to PDC is not yet available 
owing  to  difficulties  in  producing  soluble  full  length,  high  Mr,  homodimeric  E1o. 
However, in this study N-terminal fragments of E1o (first 83, 166 and 193 amino acids) 
have  been  cloned,  overexpressed  and  purified.  Analysis  of  nucleotide  sequence  and 
deduced amino acid sequence of E2o has failed to detect any obvious well defined E3/E1o 
binding domains although biochemical evidence suggests that N-terminal of E1o seems to 
carry out some roles assigned to E3BP in PDC.  
E2o and E3 were successfully overexpressed and interaction studies showed that E3 did 
not bind directly to E2o in the OGDC. However, the extreme N-terminal region of E1o 
(first 83 amino acids) did co-integrate with E2o although it was not demonstrated if this 
could occur post-translationally as well as co-translationally. Previous studies have also 
implicated this region of E1o in E3 binding although this was not tested in the current 
study. 
In summary, it has proved feasible to produce a recombinant human PDC that maintained 
its  structural  and  functional  capabilities.  It  was  then  successfully  utilised  to  evaluate 
several  natural  mutations  in  considerable  detail.  For  OGDC,  which  like  PDC  is  also 
implicated in a number of genetic, metabolic, autoimmune and neurodegenerative diseases, 
a recombinant model on similar lines should be fully developed and used in future studies 
to facilitate investigation on its involvement in a number of neurological and degenerative 
disorders linked to oxidative stress.   
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